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ABSTRACT 
 
Liisa Sundberg Smith:  A role for Focal Adhesion Kinase in vascular smooth muscle cell 
proliferation, migration and differentiation 
(Under the direction of Joan M. Taylor, Ph.D.) 
 
 Smooth muscle cells (SMC) are involved various vascular diseases, such as 
atherosclerosis, restenosis following balloon angioplasty and following venous bypass grafts.  
During the development of these vascular diseases and during normal vascular development, 
numerous changes occur within the vessel environment that enables SMC to phenotypically 
modulate between a contractile phenotype and a proliferative phenotype.  The remodeling of 
the extracellular matrix, an increase in growth factors and contractile agonists have all been 
shown to initiate signaling pathways leading to an increase in SMC proliferation, migration, 
and differentiation.  The tyrosine kinase, Focal Adhesion Kinase (FAK) plays a major role in 
the integration of the signals transmitted from these extracellular cues. The aim of this 
dissertation was to determine the SMC functions that are regulated by FAK.  To address this 
goal, I evaluated two prominent signaling pathways; the Ras/Raf/Mek/Erk and Pi3-
kinase/Rac/Pak/JNK cascades, both have been shown to be required for cell growth and 
motility in certain cell types.  The data presented herein shows that FAK activity is required 
for PDGF-, AngII- and adhesion-mediated Rac1 activation.  The p21-activated kinases 
(PAK) are downstream targets of various signaling cascades including PDGF-BB and 
integrins and are effectors for the GTPases Rac1 and Cdc42.  Recently, it was shown that 
PAK activity is required for maximal activation of the canonical Ras/Raf/Mek/ERK 
 iii
MapKinase signaling cascade.  Therefore, I aimed to determine the role of PAK within the 
ERK signaling cascade and found that adhesion-dependent activation of PAK may enhance 
growth factor-stimulated signaling and PAK may serve as a scaffold for the Raf/Mek/Erk 
signaling cascade in SMC.  I also sought to determine if FAK activity plays a role SMC 
phenotypic modulation.  I found that deletion of FAK or inactivation of FAK by FRNK 
(FAK related non-kinase) expression causes a significant increase SMC-specific gene 
expression.  Additionally, the LIM protein, leupaxin, associates with FAK and can 
translocate from focal adhesions to the nucleus leading to increased SMC marker gene 
transcription.  These data indicate that FAK may serve as a necessary regulator of SMC 
phenotypic modulation during vasculogensis, where FAK activation promotes a 
dedifferentiated proliferative phenotype and FAK inactivation induces a switch to a 
differentiated contractile phenotype.    
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CHAPTER I 
INTRODUCTION 
 
 
INTRODUCTION 
 
 
Even though campaigns promoting cancer awareness and prevention are at the 
forefront of public attention, cardiovascular disease is still the leading cause of death in the 
United States.  Recently complied data shows that 36.3% of all deaths in 2004 were due to 
cardiovascular disease [1].  The most common cardiovascular disease is atherosclerosis.  
Atherosclerosis is characterized by plaque formation in the arterial lumen that can eventually 
lead to stenosis and thrombosis formation.  Endothelial damage triggers an inflammatory 
response and subsequent accumulation of several cell types to the injured region including, 
macrophages, mast cells, platelets and smooth muscle cells (SMC) [2].  Damage to the 
endothelial layer is multifactoral with the leading causes being high blood pressure, high 
levels of LDL cholesterol and tobacco use.  According the American Heart Association, over 
72 million people have high blood pressure and 36.6 mil Americans have cholesterol levels 
over 240mg/dL, both of which will contribute to the 1.2 million cardiac events predicted for 
2007 [1].  Several pharmacological agents have been developed to treat high blood pressure 
and high cholesterol levels.  While these drugs are often effective in preventing disease 
progression, invasive therapies including balloon angioplasty and stent insertion are still 
necessary to treat vessels with advanced disease.  Unfortunately, restenosis occurs in 20 to 30 
percent of patients following balloon angioplasty and vein bygrafts.  Restenosis results from 
uncontrolled SMC proliferation and migration, which diminishes the diameter of the newly 
formed lumen requiring further treatment.  Thus, a thorough understanding of the SMC 
biology and the underlying mechanisms regulating SMC proliferation, migration, and 
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differentiation could aid in the development of additional therapeutic targets to treat 
restenosis. 
 
SMC MIGRATION AND PROLIFERATION 
Vasculogenesis is initiated by endothelial cell differentiation from angioblasts and the 
subsequent formation of endothelial tubes comprising the primary capillary plexus.  The 
basal lamina of these tubes, in addition to PDGF secreted from the endothelial cells, attracts 
SMCs that migrate and proliferate encompassing the endothelial tube and forming the medial 
layer of the vasculature.  PDGF-BB stimulated proliferation and migration has been shown to 
be the major regulator of vessel maturation, since PDGF-B-null mice die in utero exhibiting 
vascular hemorrhage due to the absence of mesangial cells within the vessels [3].  While 
SMC migration and proliferation are essential for vessel formation aberrant regulation of 
these processes are involved in various vascular pathologies, such as the development of 
atherosclerosis, restenosis following balloon angioplasty and vascular hypertrophy following 
vein bypass grafts.  The increased SMC accumulation observed in these disease processes 
and during vascular development is likely due to the activation and upregulation of various 
signaling components mediating SMC proliferation and migration [4].  During 
vasculogenesis and vascular injury various cells, including macrophages, platelets, 
endothelial cells and SMC secrete growth factors (PDGF-BB, IGF-1 and bFGF) and 
contractile agonists (Ang II, ET-1 and thrombin) that are known stimulators of the canonical 
MAPKinase and Pi3K/Akt pathways required for cellular growth and migration [5].  
However, numerous studies reviewed by Howe et al showed that growth factor mediated 
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activation of the MAPKinase cascade is an anchorage dependent process requiring additional 
signaling form the surrounding matrix [6].  
Interestingly, in parallel to an increase in secreted agonists, the extracellular matrix 
(fibronectin, laminin, and collagen) within the vessel remodels during vascular development.  
During development and following vascular injury, the basement membrane shifts from a 
quiescent state of low fibronectin and high collagen and laminin levels to an environment 
with increased fibronectin and decreased collagen and laminin levels [7].   Mouse knockout 
models have provided additional evidence for the importance of both growth factor and 
matrix signaling in the developing vasculature.  Thus, like the PDGF-B knockout,  
fibronectin-null mice die in utero due to vascular defects and malformation [3, 8] 
 
Integrins: 
Cell adherence to the extracellular matrix (ECM) activates heterodimeric 
transmembrane receptors, termed integrins.  Integrins are composed of various combinations 
of 18 distinct α and 8 distinct β subunits.  The α and β subunits are comprised of an 
extracellular head, a central transmembrane domain, and a cytoplasmic tail [9].  While 
integrins are necessary purveyors of inside-out and outside-in signaling, they lack catalytic 
activity and are dependent upon the recruitment of various adaptor and kinase proteins, such 
as Syk, Abl, Src family kinases and FAK [10-13].    
Integrins are an essential component of the signaling pathways involved in cell 
migration, proliferation, and differentiation.  Various α and β combinations are expressed 
within the vasculature during different times.  β1-containing integrins are highly expressed in 
vascular smooth muscle cells.  α1β1 and α3β1, the collagen ligand receptors are both highly 
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expressed in contractile SMC and are important for maintaining a differentiated phenotype 
and tensile strength of the vessel [14, 15].  Expression of α5β1, the fibronectin receptor, is 
upregulated following vascular injury and mediates phenotypic modulation of SMCs by 
downregulating SM marker gene expression [16].  Recently, α8β1 integrin expression was 
also shown to induce phenotypic modulation of SMC by decreasing migratory capacity and 
increasing the expression of contractile proteins [17].    
The vitronectin and osteoponin receptor, αvβ3, is an important regulator of SMC 
migration.  However, in vivo injury models have demonstrated that β3 is essential for SMC 
migration but not proliferation.  Carotid injury performed in β3-/- mice exhibited decreased 
neointima formation after carotid injury compared to their wildtype littermates.  This was 
attributed to defective migration signaling, since SMCs of aortic explants from β3-/- null 
mice showed no proliferative defect in response to PDGF-AB [18].  Bendeck et al have 
proposed that overexpression of αvβ3 stimulates SMC migration by increasing MMP-1 
production [19].  
 
FAK: 
Once cells attach to the ECM, integrins cluster and rapidly recruit numerous 
structural and signaling proteins that collectively form a focal adhesion [20, 21].  Focal 
adhesions are multifarious collections of proteins that are important for actin cytoskeleton 
stability and signal transmission leading to various cellular processes [22, 23].  One of the 
essential proteins in this complex is the non-receptor tyrosine kinase, Focal Adhesion Kinase 
(FAK).  FAK is a 125 kDa non-receptor tyrosine kinase, that is comprised of three domains, 
an N-terminal integrin binding domain, a central kinase domain and a C-terminal, proline 
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rich, focal adhesion targeting (FAT) domain (Figure 1.1) [24]. After integrin engagement to 
the ECM, FAK is recruited to sites of adhesion becomes activated and autophosphorylates on 
tyrosine 397.  Tyrosine phosphorylation at this site promotes Src binding [25] which further 
phosphorylation of FAK and leads to activation of the subsequent downstream signaling 
cascades leading to cell proliferation, migration, differentiation and survival [26].   
Tyrosines 576, 577, 861 and 925 are known targets of Src-dependent phosphorylation 
sites of FAK.  Phosphorylation of Y576 and Y577 that are located in within the central 
kinase domain of FAK, increases FAK catalytic activity [27].  Y925 has been shown to be 
important for the association of the Grb2-SOS complex that signals to downstream the 
MAPKinase cascade [28].  While the precise function of Y861 is not clear at present, studies 
performed in endothelial cells have shown that VEGF-stimulated Y861 phosphorylation is 
important for regulating cell migration and anti-apoptotic signaling events [29].  Further 
work from the Cheresh lab determined that this phosphorylation event heightens the 
formation of αvβ5/FAK complex, which is essential for VEGF-mediated EC migration [30].   
Studies from mass spec analysis have revealed additional phosphorylation sites on 
FAK.  Recently work demonstrates a role for Y407 as an inhibitory phosphorylation site.  
Located proximal to Y397 within the central kinase domain, Y407 is phosphorylated during a 
quiescent state and negatively regulates Src-dependent Y397 phosphorylation [31].  These 
studies support previous data showing that VEGF-stimulated Y407 phosphorylation was 
mediated by RhoA signaling and Y407 phosphorylation attenuated paxillin and vinculin 
binding to FAK [32].  The ying yang of Y397 and Y407 activation may aid in our 
understanding of the role of FAK in focal adhesion turnover and engagement. 
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Four serine residues within the C-terminus, S722, 732, 843, 910, have been identified 
as targets of serine/threonine kinases and phosphorylation of these sites may function to 
antagonistically regulate FAK tyrosine phosphorylation.  FAK tyrosine phosphorylation is 
adhesion-dependent, where as most data indicates that serine phosphorylation is adhesion-
independent.  Therefore distinctive signaling pathways regulate serine phosphorylation from 
tyrosine phosphorylation may be involved in how FAK activation is regulated during focal 
adhesion turnover [31, 33].  Additionally, FAK serine phosphorylation has been thought to 
be important for regulating cell mitosis, possibly through inhibition of adhesion-dependent 
signaling complexes [34].   
The C-terminus of FAK has been to shown to bind to several focal adhesion proteins.  
The SH3 domain of p130Cas binds to the first proline rich region designated Site I, while 
Site II binds the SH3 domains of two GAPs, GRAF and ASAP1 [35-37].  Additionally, the 
focal adhesion targeting (FAT) domain is necessary for directing FAK to focal adhesions.  
Numerous other proteins have been identified as FAK C-terminal binding partners, including 
talin, endophilin A2, and paxillin, [38-40].    
 
 
FRNK: 
The C-terminal portion of FAK is also produced as an independent protein termed 
FRNK (focal adhesion related non-kinase).  Like FAK, FRNK is localized within focal 
adhesions where it can bind to the same FAK C-terminal binding proteins (Figure 1.1).  
However, while FAK is ubiquitously expressed, FRNK is selectively expressed in smooth 
muscle.  Taylor et al have previously shown that FRNK protein levels are upregulated during 
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vascular development and are induced following vascular injury [41].  Interestingly, whereas 
FAK protein levels remain relatively constant, FRNK protein levels change dynamically with 
high FRNK expression in the neonatal period and at two to three weeks following balloon 
injury.  The expression pattern correlates with the conversion of SMCs from a synthetic to 
contractile phenotype that takes place during these times, suggesting that FAK activity is 
tightly regulated in vivo.   
The precise mechanism by which FRNK functions in SMCs is unknown.  Very few 
studies have addressed the possibility of FRNK phosphorylation.  Ma et al showed that 
overexpressed FRNK could be serine phosphorylated in vivo [42] however, if endogenous 
FRNK can be serine or tyrosine phosphorylated in an agonist-dependent manner remains to 
be elucidated.  Since FRNK localizes to focal adhesions and inhibits FAK activation, FRNK 
has been a useful tool to show that FAK activity is necessary for SMC proliferation and 
migration (Figure 1.2).  Additionally, FRNK may function to suppress FAK activity enabling 
SMC to differentiate to a contractile state; support for this hypothesis is presented in 
Appendix I. 
 
 
 
 
FAK signaling in vitro: 
 
Several pathological states are correlated with enhanced FAK signaling, including 
uncontrollable cell growth seen in cancers and vascular diseases.  FAK is able to modulate 
these cellular changes associated with these diseases by functioning as an integrator of 
various receptors and as a signaling conduit to the Rho family of small GTPases that regulate 
the cytoskeleton.  Two canonical pathways that have been shown to be to be utilized in 
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adhesion-dependent proliferation and migration:  the Pi3K/Rac/Pak/Jnk and 
Ras/Raf/Mek/Erk pathways.   
The Ras superfamily include H-Ras, R-Ras, and Rho family members (Rac, Rho, and 
Cdc42) are activated by numerous transmembrane receptors such as receptor tyrosine 
kinases, G-protein coupled receptors, and integrins.  Activation leads to a variety of cellular 
processes including proliferation, differentiation, and migration [43].  GTPases are molecular 
switches that cycle between an active GTP-bound state and an inactive GDP-bound state 
[44].  In the GTP-bound form, the Ras-related GTPases interact and activate a number of 
effector molecules that have been implicated in regulating cell cycle progression and/or cell 
migration such as the serine/threonine protein kinases, lipid kinases, and actin 
binding/scaffolding proteins [45, 46].  Progress has been made in identifying the specific 
cellular responses regulated by these effectors, particularly those that are involved in cellular 
migration.  Members of the Rho GTPase family, RhoA, Rac1 and Cdc42, regulate the 
cytoskeleton through actin reorganization.  RhoA activation induces stress fiber formation, 
active Rac1 leads to lamellipodia protrusions and Cdc42 activation stimulates filapodia 
formation [47].  FAK is involved in several signaling pathways regulating these proteins.  
Fibronectin-mediated Rac1 activation was shown to be propagated through either the 
FAK/Pi3K/SOS pathway or the FAK/Cas/Crk/DOCK180 pathway [48].  To address which 
pathway is utilized in SMCs, in Chapter II, I show that integrin-, growth factor- and G-
protein coupled- receptor –stimulated SMC migration and proliferation is dependent on FAK 
activation of the small GTPase Rac1.      
Additional studies have indicated that signaling through the Rho GTPases is FAK-
dependent, which may indicate another mechanism by which FAK regulates cytoskeletal 
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stability and SM phenotype.  Specifically, fibroblast studies have shown that integrin-
mediated FAK Y397 activation is necessary for RhoA inactivation allowing for focal 
adhesion disassembly and cell migration [49).  Interestingly, SMC differentiation is 
dependent on RhoA activity {Mack, 2001 #76] and Taylor et al identified GRAF, a 
RhoGTPase activating protein that binds to FAK [36], indicating that inhibition of RhoA 
may be one mechanism by which FAK may regulate SMC differentiation.  However, in 
striated muscle, SK-alpha actin transcription was shown to require FAK-dependent RhoA 
activation [50], indicating the RhoA may be regulated in a cell-specific fashion.  With all of 
the published evidence showing an intricate signaling network that regulates cell 
differentiation, a SMC-specific in vivo model is needed to detangle the precise function of 
FAK in these cellular responses.   
 
FAK signaling in vivo: 
 
In vivo examination of FAK has shown that FAK is essential for numerous cellular 
pathways, since FAK -/- embryos die in utero between day E8.5 and E10 [51].   It has been 
concluded that cardiovascular abnormalities are the cause of  death, for there is no disparity 
between wildtype and null embryos up until day E7, and post mortum observations showed 
poor or no heart formation and poor vascular network extension [52].  Studies using FAK-/- 
embryoid bodies and endothelial cells derived from these mice showed that FAK was not 
required for endothelial cell differentiation but was necessary for endothelial migration 
needed for sufficient tubulogenesis [53].  Other studies showed that embryonic fibroblasts 
derived from FAK-/- embryos displayed in culture an increase in the number of focal 
adhesions, and an upregulation of the FAK family  
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Figure 1.1.  Structure of FAK and FRNK.  FAK is comprised of an N-terminal 
integrin binding domain, a central kinase domain and a C-terminal focal adhesion 
targeting (FAT) domain.  There are 6 tyrosine and 4 serine phosphorylation sites 
identified within FAK.  Src-dependent phosphorylation of Y397 is the major site of 
FAK activity.  FRNK, a dominant negative of FAK, is comprised of the FAK C-
terminus 
.  
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 member, Pyk2, that allowed for ERK activation [54]. However, this compensation effect 
was not sufficient to overcome the observed attenuation of migration in these cultured cells.  
This lethal phenotype of FAK-/- embryos handicaps any advancement in cell-specific 
understanding of FAK-dependent signaling events, therefore several models have been 
developed using Cre/LoxP technology.  To date, published models include the use of 
endothelial, heart, brain, and keratinocyte specific FAK deletion models [55-59]. 
 As observed in the original FAK knockout, EC-specific FAK deletion resulted 
in decreased cell migration, proliferation, and cell survival contributing to embryonic 
lethality during late embryogenesis [55].  However, EC-specific FAK deletion studies 
performed in another lab showed that FAK ablation had no effect on EC migration or 
proliferation, but did result in increased cell retraction and apoptosis causing embryonic 
lethality during embryogenesis [56].  The disparity observed between the two published EC 
models could be due the time at which FAK was deleted development.  Even though both 
groups used Tie2-Cre animals, there appears to be variation in the effectiveness of the two 
Cre transgenes, which may be due to varying transgene copy number between the two Tie-
Cre strains.  Similar to the FAK-null  MEFs, FAK-null keratinocytes exhibited elevated Rho 
activity and Schober et al found that increased Rho activity resulted in increased MLCK 
phosphorylation and PAK1 activation.  Additionally, these cells exhibited no proliferation 
defects [59].  Additional disparities at the single cell level could highlight cell-specific 
regulation of FAK and further studies are required to determine the intricacies of cell-specific 
FAK signaling.
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Figure 1.2.  FAK activity is required for cell migration and proliferation.  Previous data 
from Taylor et al showed that FAK activity is required for growth factor-, G-protein coupled 
receptor- and integrin-dependent SMC proliferation and migration.  Overexpression of 
FRNK is able to attenuate FAK-dependent SMC processes and it is hypothesized that this 
may help regulate SMC phenotypic modulation. 
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FAK-DEPENDENT SIGNALING PATHWAYS IMPLICATED IN PROLIFERATION 
AND MIGRATION 
 
MapKinases and Small GTPases: 
Ras- and Rac-dependent activation of the MapKinase signaling cascade appears to be 
the dominant mitogenic pathway utilized by a various agonists [60].  Ras is required for the 
activation of the serine/threonine protein kinase Raf and the subsequent activation of MEK 
and ERK kinases [61] whereas Rac is important for the activation of the serine/threonine 
kinase PAK and the subsequent JNK kinase activation [62].  Once activated, ERK and JNK 
both translocate to the nucleus and phosphorylate and activate transcription factors necessary 
for immediate early gene expression and cell growth  [63, 64]. 
Although the Ras-ERK and Rac-JNK pathways were initially thought to be 
independent parallel pathways, recent studies aimed at deconstructing these pathways have 
indicated that there is significant cross talk between these mitogenic signaling cascades.  
Studies using dominant-interfering mutants for Rac showed that activation of Rac was 
necessary for maximal Ras-dependent ERK activation and nuclear translocation [65, 66].  
These data indicated that Ras acts upstream of Rac in the mitogenic signaling cascade.  It 
was later revealed that Ras-dependent activation of Pi3Kinase leads to activation of Rac and 
its downstream effector PAK [67].  Exactly how Rac signaling feeds back into the 
Raf/MEK/ERK signaling cascade is highly studied.  Li et al have published that Raf 
activation by Ras can be partially attenuated by overexpressing a dominant negative Rac1 
construct [68].  Activation of Raf is a complex process known to involve Ras-dependent 
plasma membrane association as well as phosphorylation.  Interestingly, the carboxy-
terminus of activated PAK was recently shown to associate with the catalytic domain of Raf, 
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phosphorylating Raf Ser-338, which is essential for Raf activation [69].  In addition, PAK 
can enhance phosphorylation of MEK on a site (S228) that is necessary for maximal MEK 
activation by Raf.  These studies indicate that Pak and Ras co-activate the serine/threonine 
kinase Raf, and in addition, PAK and Raf co-activate the dual specificity kinase Mek, 
indicating that the convergence in these two well established pathways likely occurs at the 
level of PAK [70].   
 
PAK: 
The family of p21-activated kinases (PAK) is subdivided into two groups, Group I 
consisting of PAKs 1-3 (also known as α,γ,β) and Group II consisting of PAKs 4-6 (77).  
Group I PAKs contain an N-terminal autoinhibitory domain that has been shown to bind and 
inactivate the C-terminal serine/threonine kinase domain.  Originally, autoinhibitory domains 
were identified in Group II PAKs (reviewed by [71]); however, recent data demonstrated that 
PAK5 also contains a functionally related C-terminal  autoinhibitory domain [72].  PAK 
contains several interspersed SH3-binding sites necessary for binding to a number of cellular 
proteins such as the adapter proteins Nck and Grb2, and the chromosomal protein histone H3 
[73-75].  In a variety of cell types, PAK1 (the best characterized family member) affects 
cytoskeleton rearrangement and cell migration through its function as a Rac and Cdc42 
effector [47].  GTP-bound Rac and Cdc42 activate PAK1 by binding to the p21-binding 
domain (PBD) localized within the N-terminal autoinhibitory domain [76].  This interaction 
dissociates the PAK1 trans-homodimer, exposing the C-terminal kinase domain and enabling 
subsequent autophosphorylation [71, 77].  Recent studies have shown that integrins are a 
major upstream activator of PAK.  Notably, plating cells on the ECM fibronectin enhanced 
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the ability of GTP-Rac to activate PAK [78], which mediates β1 integrin-dependent 
activation of JNK [79].  This signaling cascade could also be dependent on adhesion-
activated FAK since Stoletov et al have shown that PAK and FAK are associated within 
focal adhesions.  However, they did not determine whether the observed PAK/FAK 
association was direct or dependent on the adaptor protein, Nck [80].  Additionally, the 
adapter protein Grb2 has been shown to mediate PAK1 signaling.  Data by Puto et al showed 
that Grb2 was required for the PAK1/EGFR association utilized for EGF-stimulated 
migration [74].  Since the binding assays were performed using whole cell lysates, the 
PAK/EGFR complex formation may also be dependent on FAK localization.  FAK can 
directly bind to the EGFR, therefore EGF-dependent tyrosine phosphorylation of FAK may 
regulate Grb2 binding to FAK [81], bringing Grb2 proximal to the EGFR.  Interestingly, 
Howe et al demonstrated that inhibition of PAK attenuated integrin-dependent ERK 
activation, and Eblen et al showed that this was likely due to the ability of PAK to enhance 
the formation of MEK-ERK complexes in an adhesion-dependent fashion [82, 83].  These 
results suggest that there is an overlap of pathways between the Raf/MEK/ERK and 
Pi3K/Rac/PAK cascades.  In Chapter III, my studies provide additional evidence of cross-
talk between the Raf/MEK/ERK and Pi3K/Rac/PAK signaling cascades.  My data shows that 
ERK and PAK directly associate allowing for ERK-dependent phosphorylation of PAK, 
indicating that PAK may function as a scaffold for adhesion- and growth factor-dependent 
activation of the MapKinase cascade. 
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 SMC DIFFERENTIATION 
 Differentiated SMC constitute the medial layer of large arteries and small arterioles 
of the vasculature.  A fully differentiated SMC is characterized by expression of  high levels 
of SM myosin heavy chain (SM MHC), SM α-actin, SM 22α, SM myosin light chain kinase, 
telokin, and calponin, all of which are necessary for regulating SMC contractility (see [4] for 
review).  These contractile genes are commonly referred to as SM marker genes.  
Differentiated SMC maintain tensile strength of the vessel wall in response various 
vasoactive and constrictive agents to regulate blood pressure and proper tissue perfusion.  
However, unlike skeletal and cardiac muscle cells, SMC do not terminally differentiate and 
retain the genetic plasticity that enables them to transition from a highly contractile 
phenotype to synthetic phenotype.  A synthetic phenotype is commonly characterized by low 
levels of SM contractile gene expression and an increased responsiveness to proliferative and 
migratory signals.  The ability to phenotypically modulate to a more proliferative phenotype 
in response to various environmental stimuli [4] is critical for proper vessel development and 
injury repair processes.  However, unfettered SMC phenotypic switching can result in 
various vascular pathologies, such as atherosclerosis and restenosis following balloon 
angioplasty and following vein bypass grafts.   
In addition to vascular pathologies, SMC specification, commitment, and 
differentiation are essential for proper vasculogenesis and organogenesis during embryonic 
development.  Not much is known regarding SMC specification and commitment, although 
SMC precursors have been shown to include both neural crest and mesodermal cells [4].  
Many labs have contributed to our understanding of SMC differentiation, which has recently 
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been extensively reviewed by Owens et al [4].  Differentiation appears to be regulated by 
SRF [84, 85] and myocardin (or myocardin-related) transcription factors [86], which have 
been shown to regulate expression of CArG-box containing promoters found in most SMC 
contractile genes, such as SMα-actin, SM22 and SM-MHC [87, 88].  Almost all SM markers 
are regulated by a SRF DNA binding element termed a CArG box (CC(A/T)6GG).  SRF can 
associate with various cofactors to mediate SRF-dependent gene expression.  Known SRF 
co-factors include the ubiquitously expressed ternary complex factors (TCFs, e.g. Elk-1), 
GATA-4, Nkx2.5, myocardin family members, and various LIM domain proteins [4, 89, 90].  
It is hypothesized that several of these cofactors form a ternary complex with SRF and the 
CArG element, since most lack the ability to directly bind DNA.  Ternary complex formation 
may promote gene specificity, enhance SRF/CArG binding affinity, and/or result in histone 
actelyation or deacetylation regulating the DNA configuration and gene transcription. 
 
Myocardin: 
Myocardin is a cardiac and smooth muscle specific transcription factor (see  [91] for 
review).  Genetic deletion of myocardin results in embryonic lethality at day E11.5 due to the 
absence of proper smooth muscle cell development within the vasculature [92].  The 
resulting phenotype of the myocardin knockout highlighted the role of myocardin as being 
the major regulator of SMC differentiation; however, elaborate studies using myocardin-null 
ES cells to generate chimeric mice demonstrated that myocardin was not essential for SMC 
differentiaiton  [93].  The authors note that this observation does not explain why the 
myocardin knockout exhibits defective SMC development.  The disparity may be due to 
differences in in vivo and ex vivo differentiation models.   
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Myocardin is composed of several domains that mediate its function.  The 
transactivation domain (TAD) within the C-terminus of myocardin is essential for robust SM 
marker gene transcription.  Interestingly, the central DNA binding domain (SAP) of 
myocardin is not required for SM22 transcription, suggesting that myocardin may induce 
transactivation through dimerization with other myocardin family members mediated through 
the LZ domain (for review see [94]). 
The precise mechanism of myocardin transactivation is subject of intense study.  Cao 
et al have demonstrated that myocardin-dependent SM gene transcription is propagated 
through histone actelyation by an SRF/myocardin/p300 coactivation complex.  This complex 
is necessary for chromatin destabilization, since myocardin does not have HAT activity and 
p300 expression alone failed to induce SM genes [95].  In addition, Liu et al have found that 
myocardin stimulated gene transcription is regulated by the forkhead transcription factor 
FOXO4.  They showed that constitutively nuclear myocardin is repressed when bound to 
FOXO4 and that stimulation of the Pi3K/AKT signaling cascade stimulated the nuclear 
export of FOXO4 allowing for myocardin-dependent transcription [96].  The ability of 
myocardin to interact with various transcriptional coactivators and repressors may allow for 
the variegated SM marker gene expression during SMC phenotypic modulation. 
 
TGF-β signaling: 
Selected agonists, including TGF-β and S1P have been shown to induce SMC 
differentiation.  TGF-β, the major activator, has been shown to be sufficient to induce SMC 
differentiation in various cell lineages, including non-committed fibroblast like cells, 
10T1/2’s, adipose-derived stem cells, rat peritoneal exudates macrophages, and totipotent ES 
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cells [97-99].  TGF-β activates a well-characterized signaling cascade initiated by the ligand 
binding to the membrane bound TGF-β-receptor serine/threonine kinase complex.  This 
complex triggers the subsequent binding and phosphorylation of RSmad (Smad 2 and 3) 
family members followed by the RSmad-Smad4 complex formation and its nuclear 
translocation and targeted gene transcription [100].  Several studies aimed to delineate the 
TGF-β signaling pathway in SMCs have shown that both Smad2 and Smad3 play a role in 
TGF-β stimulated SM marker gene transcription [99, 101].  Interestingly, even though both 
Smads are equally expressed in SMC lineages, there is a disparity in which Smad is required 
for selected SM marker gene transcription.  Gene-specificity may be directed through the 
Smad association with various coactivators.  Qiu et al found that Smad3 interacts with the 
coactivators p300 and myocardin to induce SM22 transcription which may serve to regulate 
TGF-β dependent SMC differentiation [102, 103].  Of the two known inhibitory Smads, 
Smad6 and Smad7, Smad7 has been shown to negatively regulate TGF-β signaling in SMC, 
for overexpression of Smad7 blocked TGF-β stimulation SM marker gene transcription 
[104]. 
In contrast to the numerous studies suggesting Smad3 as the main transducer of TGF-
β stimulated differentiation, involvement of other signaling pathways have been conflicting.  
Chen et al determined through the use of pharmacological inhibitors that RhoA, not Pi3K- or 
ERK- mediated signaling was required for TGF-β stimulated neural crest cell 
transdifferentiation [105].  On the other hand, Lien et al, also using pharmacological 
inhibitors, found that TGF-β stimulated SM marker gene transcription in 10T1/2 cells was 
mediated through the Pi3K/Akt pathway [106].  Lastly, Deaton et al found that TGF-β 
stimulated SM marker gene transcription was mediated through RhoA/PKN/pp38 MAPK 
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signaling events in pulmonary aortic SMC [107], although, whether this signaling cascade 
stimulated SM marker genes in a Smad-dependent, or –independent manner was not 
examined.  The various signaling pathways utilized may suggest cell-type specificity and 
further studies are required to determine if differentiation state dictated which signaling 
pathways are activated. 
 
PDGF-BB signaling: 
 Contractile mechanisms need to be repressed as the cell phenotypically modulates to 
a more proliferative state.  PDGF-BB is thought to not only induce proliferative machinery 
but to repress pathways utilized for maintaining a differentiated phenotype.  It was first 
observed that quiescent SMC treated with PDGF-BB displayed reduced mRNA and protein 
levels of SM α−actin [108] and further studies showed that SM22 and SM-MHC were also 
reduced following PDGF-BB treatment [109].  The reduced levels may be attributed to 
PDGF-dependent increase of Sp1 levels and its subsequent binding to the G/C repressor 
element within the SM22 promoter [110].  Another putative mechanism may be through 
PDGF-BB dependent Elk-1 phosphorylation, which Wang et al showed diminished the 
affinity of CArG-SRF-Myocardin complex [111].  Recent data showed a decreased 
association between the myocardin family member, MRTFA and the CArG element 
following PDGF-BB treatment [112].  PDGF-BB has also been shown to affect SRF nuclear 
localization, for prolonged growth factor exposure increased cytostolic SRF levels resulting 
in decreased SM marker gene transcription [113].  Whether SRF nuclear export is the 
limiting factor regulating the complex formation with myocardin and MRTFA to activate 
SMC gene promoters or if there is a PDGF-BB-dependent dissociation of the transcriptional 
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complex that enables SRF nuclear translocation is unknown.  Additionally, the cytostolic 
signaling events regulating SRF return to the nucleus to transactivate CArG containing 
growth genes, such as c-fos, in response to PDGF-BB is also unknown.   
 
LIM domain proteins: 
LIM domain containing proteins have recently been highlighted for their involvement 
in signal transduction from focal adhesions to the nucleus.  These proteins are identified by 
double zinc-finger like structures anchored by cysteine/histidine residues.  These modules 
were termed LIM domains based on homeodomain commonality observed in LIN-11, Isl1 
and MEC-3 proteins and have been shown to facilitate protein-protein interactions [114].  
LIM domains are made up of 55 amino acids that vary between the 58 known LIM 
containing genes [114].  Protein families are segregated by the number of LIM domains, for 
example, the CRP family (crp1, crp2, crp3) has two, the Zyxin family (zyxin, ZRP-1/Trip6, 
LPP, Ajuba) has three domains, and the Paxillin family (paxillin, Hic-5, leupaxin) has four 
domains.  
A role for the CRP family has recently been implicated in SMC differentiation.  
CRP1 is ubiquitously expressed, while CRP2 expression is restricted to arterial SMC and 
CRP3 is expressed in both skeletal and cardiac muscle [115].  In vitro data have implemented 
a role for CRP1 and CRP2 in cardiovascular development however, only CRP3 knockout 
mice die postnatally due to cardiac defects [116].  Due to the high sequence homology 
among the three family members, a compensation mechanism has been proposed in the 
CRP1 and CRP2 genetic deletion models.  Even though CRP2 is not essential for 
cardiovascular development, Chang et al have shown that CRP2 plays a role in SMC 
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differentiation through complex formation with SRF and GATA4 [90].  Additionally, CRP2 
expression may be important for regulating SMC phenotype since SMC isolated from CRP2-
/- mice exhibit increased PDGF-stimulated Rac1 activation and an increased migratory 
capacity compared to littermate controls [117].   
 Compared to the CRP family, the zyxin family is widely expressed.  Overall, the 
zyxin family members are important for cell migration through focal adhesion localization.  
Genetic deletion of zyxin has no effect on viability [118].  Ajuba-null mice were also viable 
with no observable phenotype.  However, cells isolated from Ajuba- null mice displayed 
impaired migration due to reduced FAK-dependent Rac1 activation [119].  Trip6 can bind to 
the LPA2 receptor, which is important for its focal adhesion localization, and when localized 
to focal adhesions Trip6 can associate with FAK [120].  Similar to other family members, 
LPP localizes to focal adhesions and can translocate to the nucleus, which has been 
suggested to be mediated through an interaction with VASP [121].  Inhibition of LPP 
through RNAi decreased SMC migration and LPP expression was reduced in migration-
defective FAK-null fibroblasts [122].  However, if LPP expression was directly related to 
FAK ablation or a due to secondary affect was not studied.  
The paxillin family of LIM proteins consists of paxillin, Hic5, and leupaxin.  This 
subfamily has four C-terminal LIM domains and four/five N-terminal LD motifs (Figure 
1.3).  The focal adhesion protein, paxillin, is a 68 kDa protein that binds numerous other 
actin-binding proteins, kinases and GTPase activating proteins (GAPs) [123].  Through 
identification of various binding partners, paxillin has been implicated in cell migration by 
regulating focal adhesion turnover and matrix adhesion.  Genetic deletion of paxillin resulted 
in embryonic lethality around day E9.5 due to cardiac and somatic defects mimicking those 
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seen in FAK and FN-/- models [124].  In support of adhesion-dependent defects, paxillin-null 
ES cells displayed defective cell spreading and reduced FAK activation compared to wt cells 
[125].  Of interest, several binding assays have mapped LD motifs 2 and 4 of Paxillin to be 
required for FAK binding [126].  Src- dependent FAK activity (Y397 phosphorylation) has 
been shown to regulate Paxillin tyrosine phosphorylation [127].  Paxillin phosphorylation is 
essential for migration since transient expression of a nonphosphorylatable paxillin 
(Y31FY118F) mutant attenuated robust migration observed in vinculin -/- cells [128].  
Vinculin, a focal adhesion adaptor protein, has been mapped to bind to paxillin through LD1, 
LD2, and LD4 [129] and its binding interferes with FAK/paxillin association thereby 
regulates cell migration [128].  Thus, unregulated FAK/paxillin-dependent signaling has been 
attributed to the highly motile phenotypes observed in vinculin knockout models [130].  
Additionally, the paxillin/PKL interaction is dependent upon Src/FAK-dependent paxillin 
tyrosine phosphorylation, which mediates PXL focal adhesion localization [131].  p95PKL 
has been shown to bind to LD4 of paxillin, forming paxillin/PKL/PIX/PAK complex and 
stimulating proper cell migration [132, 133].  Another known binding partner, PTP-PEST, 
negatively regulates paxillin signaling.  PTP-PEST binds to the C-terminal LIM domains and 
dephosphorylates paxillin [134, 135].  This has been proposed to impair cell migration by 
inhibiting paxillin/Rac1 signaling [135].  The PTP-PEST/paxillin complex may be essential 
for focal adhesion turnover required for proper migration, since PTP-PEST-/- cells exhibit 
rapid cell spreading and defective cell migration that has been attributed to increased levels 
of FAK and paxillin activity in comparison to WT cells [136]. 
Another paxillin family member is Hic-5.  Hic-5, a 55 kDa protein, is structurally 
homologous to paxillin and has been shown to have several overlapping binding partners, 
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including, FAK, vinculin, and PTP-PEST [137, 138].  Characteristic of a sub-class of LIM 
domain proteins, Hic-5 is able to translocate from focal adhesions to the nucleus.  Even 
though very similar in structure, paxillin and Hic--5 have been shown to have independent 
functions.  Hic-5 competes with paxillin for FAK binding.  Hic-5 bound to FAK, decreases 
FAK and paxillin activation resulting in a reduction of cell spreading [139].  Since Hic-5 
only shares 57% structure homology with paxillin [140].  Hic-5 may antagonize paxillin-
mediated signaling events by recruiting a different subset of signaling proteins to focal 
adhesions. 
Besides regulating cell migration, Hic5 is most commonly known as a transcriptional 
coactivator.  Hic-5 can regulate several hormone-responsive genes through interactions with 
the glucocorticoid receptor and the androgen receptor [141].  Additionally, Hic5 activates 
several growth genes including p21 and c-fos [142].  Shibanuma et al have shown that Hic-5 
complexes with p300, a gene coactivator, and Smad3 and  binds to Sp1 sites located within 
the p21 gene promoter [143].  Therefore, Hic-5 may function as a transcriptional scaffolding 
protein mediating the association of promoter-specific coactivators required for transcription.  
Leupaxin, the lesser known member of the paxillin family, was first identified by 
Lipsky et al in leukocytes.  Lipsky et al first observed leupaxin expression was highly 
expressed in lymphocytes compared to undifferentiated bone marrow cells [144].  Similar to 
Hic-5, leupaxin has four N-terminal LD motifs and four contiguous C-terminal LIM 
domains.  Emerging evidence has shown that Leupaxin has several common binding 
partners, including Pyk2, FAK, and PTP-PEST, with its paxillin family members [144, 145].  
There is little evidence on the localization and function of leupaxin.  Published herein is the 
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first report of leupaxin’s enrichment in SMC, cytoplasmic to nuclear shuttling, and function 
as a SRF-dependent transcription coactivator (Chapter IV).  
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Figure 1.3.  Paxillin family members.  The Paxillin family consists of paxillin, Hic-5 and 
leupaxin.  Each has four contiguous LIM domain and five (paxillin) or four (Hic-5 and 
leupaxin) N-terminal LD motifs.  *leupaxin NES is putative and addressed in Appendix II. 
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 SUMMARY 
It is becoming increasing clear that there is not one master regulator of SM 
phenotype.  Although SRF is required for CArG-dependent SM gene transcription, it is not 
specific for SM marker genes, and the mechanism regulating SRF-dependent SM marker 
gene transcription versus SRF-dependent growth gene transcription is not yet known.  
Myocardin was initially thought to be the single regulator of SM phenotype through its 
ability to potently active the SM gene promoters, although knockout models dispersed the 
notion it was the one essential coactivator.  However, the myocardin family, including 
myocardin, MRTF-A, and MRTF-B could all function in overlapping roles to mediate SM 
gene expression.  Additional loss of function experiments and chimeric models are required 
to determine precise mechanism of each family member.  SM marker genes have also been 
shown to be regulated by numerous transcriptional coactivators, including LIM domain-
containing proteins.  These proteins may function in a scaffolding capacity, bringing the 
required coactivators within close proximity to the transcriptional machinery.  Since LIM 
domain-containing proteins are able to shuttle from focal adhesions to the nucleus, cellular 
localization of these proteins may be regulated by focal adhesion proteins, such as FAK, in 
response to various external cues.      
 Data published by us and others, have demonstrated that FAK is a point of 
convergence for adhesion-, growth factor- and G-protein coupled receptor- mediated 
signaling.  Since FAK has been shown to activate numerous signaling cascades including the 
canonical Ras/Raf/MEK/ERK and Pi3K/Rac/PAK/JNK cascades, it can be hypothesized that 
the specific pathway activated and subsequent gene transcription can be regulated by the 
activation state of FAK.  Therefore, this dissertation focuses on the signaling pathways that 
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regulate SMC proliferation, migration, and differentiation, highlighting the involvement of 
Focal Adhesion Kinase.  Chapter II demonstrates that FAK is an important point of 
convergence for adhesion-, G-protein coupled receptor-, and growth factor- dependent 
signaling.  The overexpression of FRNK, a dominant negative inhibitor of FAK, showed that 
SMC proliferation and migration requires FAK-dependent Rac1 activation.  Chapter III 
illustrates the cross talk between the Ras/ERK and PAK/Rac signaling cascades.  Various 
binding assays showed a novel direct interaction between PAK and ERK suggesting that 
PAK may function as a scaffold for the Raf/Mek/ERK signaling cascade.  Lastly, Chapter IV 
shows that FAK activity may play role in regulating SMC phenotype.  Promoter assays 
showed that TGF-β-dependent SM marker gene expression is upregulated in FAK-ablated 
primary SMC cultures.  These data also suggest that FAK may regulate SM differentiation 
through interacting with the LIM domain protein leupaxin.  This Chapter is also the first 
report showing leupaxin can translocate from focal adhesions to the nucleus and bind to 
transcriptional complexes inducing SM gene transcription.   
Review of published data detailing the intricate signaling networks that regulate cell 
phenotype, growth, and motility, also show conflicting data depending on the utilized cell 
system.  Therefore, a SMC-specific in vivo model is needed to detangle the precise function 
of FAK in these cellular responses.  My studies described herein, using a SMC-specific FAK 
deletion model to delineate FAK-dependent mechanisms that regulate SMC growth and 
development contribute to our comprehensive understanding of SMC biology and the 
putative involvement of integrin-dependent FAK signaling in vascular pathologies.   
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CHAPTER II 
An endogenous inhibitor of Focal Adhesion Kinase blocks Rac1/JNK but not Ras/ERK- 
dependent signaling in vascular smooth muscle cells.1
                                                 
1 Data published as: Liisa J. Sundberg, Lisa G. Galante, Heather M. Bill, Christopher P. Mack and Joan M. 
Taylor. An endogenous inhibitor of Focal Adhesion Kinase inhibits Rac1/JNK but not Ras/ERK-dependent 
signaling in vascular smooth muscle cells.  J Biol Chem (2003) 278(32) 29783-91. 
ABSTRACT 
Humoral factors and extracellular matrix are critical co-regulators of smooth muscle 
cell (SMC) migration and proliferation.  We previously reported that FRNK (FAK Related 
Non Kinase) is expressed selectively in SMC and can inhibit PDGF-BB- induced 
proliferation and migration of SMC by attenuating FAK activity.  The goal of the current 
studies was to identify the mechanism by which FAK/FRNK regulates SMC growth and 
migration in response to diverse mitogenic signals.  Transient overexpression of FRNK in 
SMC attenuated autophosphorylation of FAK at Tyr-397, reduced Src-family dependent 
tyrosine phosphorylation of FAK at Y576, Y577, and Y881, and reduced phosphorylation of 
the FAK/Src substrates Cas and paxillin.  However, FRNK expression did not alter the 
magnitude or dynamics of ERK activation induced by PDGF-BB or AngII.  Instead, FRNK 
expression markedly attenuated PDGF-BB-, AngII- and integrin-stimulated Rac1 activity and 
attenuates downstream signaling to JNK.  Importantly, constitutively active Rac1 rescued the 
proliferation defects in FRNK-expressing cells.  Based on these observations, we hypothesize 
that FAK activation is required to integrate integrin signals with those from receptor tyrosine 
kinases and G protein-coupled receptors through downstream activation of Rac1, and that in 
SMC, FRNK may control proliferation and migration by “buffering” FAK-dependent Rac1 
activation.   
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INTRODUCTION 
Smooth muscle cell (SMC) proliferation is certainly important during vascular 
development, but it is clear that increased SMC proliferation and migration are important 
contributors to the pathogenesis of several important cardiovascular disease states including 
atherosclerosis, restenosis, and hypertension.  A large number of extrinsic cues (growth 
factors, extracellular matrix, cell-cell interactions, etc.) have been identified that regulate 
SMC growth and migration (1,2).  However, the precise cellular signaling mechanisms 
involved are not completely understood, and very little is known about how (or if) these 
signaling pathways are integrated. 
The majority of soluble SMC mitogens can be broadly divided into two groups, 
activators of receptor tyrosine kinases (i.e. platelet-derived growth factor BB homodimer 
(PDGF-BB), basic fibroblast growth factor, insulin-like growth factor-1 (IGF-1) and 
activators of G protein-coupled receptors (i.e. angiotensin II (AngII), thrombin, endothelin-1 
(ET-1); ref. 2).  A large body of evidence indicates that members of both groups activate (to 
varying degrees) the Ras/Raf/MEK/ERK and Pi3 kinase/Rac/PAK/JNK kinase cascades, 
PLC, and PKC signaling pathways among others (1).  Interestingly, it is becoming clear that 
the mitogenic responses elicited by many of these factors are dependent upon extracellular 
matrix (ECM)/integrin interactions.  For example, when cultured fibroblasts are held in 
suspension, PDGF-, EGF- and lysophosphatidic acid-stimulated ERK activity is markedly 
reduced compared to cells plated on fibronectin (3,4). 
Integrin-mediated activation of the non-receptor tyrosine kinase, focal adhesion 
kinase (FAK) is a critical step in integrin signaling and may be important for growth factor 
signaling as well.  In support of this idea, several mitogens (including PDGF-BB, AngII, 
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IGF-1, and ET-1) stimulate FAK tyrosine phosphorylation in an adhesion-dependent manner 
(5-8).  In addition, Renshaw et. al. have shown that integrin augmentation of growth factor 
mediated signaling to ERK2 appears to be dependent upon FAK activation, because the 
inhibition of MAP kinase activation observed in suspended cells can be rescued by over-
expression of activated FAK (9).  Furthermore, integrin-mediated autophosphorylation of 
FAK on Tyr397 leads to recruitment and activation of Src and PI3K and subsequent 
downstream activation of Ras/ERK or Rac/JNK cascades (10,11).  
 Interestingly, our lab recently showed that FAK appears to be regulated in a unique 
fashion in SMC.  We reported that the noncatalytic carboxy-terminal domain of FAK, termed 
FAK related non-kinase (FRNK), is selectively expressed in SMC with very high levels 
found in the large arterioles.  FRNK transcription results from the utilization of an alternative 
start site within the FAK gene and FRNK expression is independently regulated by a distinct 
promoter embedded within FAK intronic sequences (12,13).  Interestingly, whereas FAK 
protein levels remain relatively constant, FRNK protein levels in vivo are dynamically 
regulated with increased FRNK expression in the neonatal period and from two to three 
weeks following balloon injury.  This pattern of expression correlates with the attenuation of 
SMC proliferation that is known to occur under these circumstances, suggesting that FRNK 
may be an important regulator of SMC growth (2).  In support of this idea, we have shown 
that overexpression of GFP-FRNK in rat aortic SMC completely prevented the PDGF-BB-
induced increase in [3H]-thymidine incorporation and significantly inhibited the mitogenic 
effects of serum.  In addition, GFP-FRNK also significantly inhibited fibronectin-dependent 
SMC migration toward PDGF-BB (12).  Taken together these data suggest that FRNK acts as 
 33
an endogenous inhibitor of FAK activity and that its expression in vivo may act to buffer 
FAK dependent proliferative and migratory signals. 
In this report, we sought to identify the mechanism by which FRNK attenuates 
growth factor and adhesion signaling in SMC.  Our data indicate that in contrast to other cell 
types, FAK/FRNK signaling does not modify agonist-stimulated ERK activity in SMC.  
Instead, our data reveal that in SMC, Rac1 activation may be a key convergence point in 
growth factor and FAK-dependent integrin regulated cell proliferation.   
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MATERIALS AND METHODS 
Antibodies and Reagents 
The 4G10 phosphotyrosine- specific antibody, an anti-human FAK antibody, and the Rac1 
antibody were purchased from Upstate Biotechnology, Inc. The phosphotyrosine specific 
anti-FAK antibodies (Y397, Y576, Y577, Y861) were purchased from BioSource 
International.  Texas-Red conjugated phalloidin was purchased from Molecular Probes.  The 
phospho-specific and immobilized phospho p44/42 MAP kinase antibody was purchased 
from Cell Signaling along with the phospho-SAPK/JNK (Thr183/Tyr185) and phospho-
ELK-1 antibodies.  CAS was detected using a mixture of two polyclonal antibodies generated 
against the C-terminal domain of CAS (CAS-F and CAS-P; provided by Dr. Amy Bouton, 
University of Virginia, (14).  The monoclonal, Erk1/2 antibody (1B3B9) was generously 
provided by Dr. Michael Weber (University of Virginia).  The anti-flag (M5) antibody, Ang 
II and fibronectin were purchased from Sigma and PDBF-BB was purchased from 
Calbiochem.   
 
Adenovirus Production and Expression Constructs    
The GFP and GFP-tagged FRNK viruses (replication-defective ψ5 adenovirus) were plaque-
purified by cesium-chloride gradients as described previously (12).  The cDNA construct 
encoding an aminoterminal DsRed conjugated L61Rac1 was generated by cloning L61Rac1 
into the 5’ BamHI and 3’ EcoRI restriction sites in the pDsRed2-CI vector (Clonetech).    
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Cell Culture, Infection, Transfection, and Agonist Treatment   
Rat aortic SMC were obtained from 8week rat thoracic aortas by enzymatic digestion as 
previously described (15).  Cells were used from passages 7-21 and were maintained in 
Dulbecco’s modified Eagles medium (DMEM)- F12 (1:1) plus 10% fetal bovine serum and 
1% pencillin-streptomyocin.  For adenoviral infection, cells were incubated in serum 
containing media with either GFP or GFP-FRNK (MOI 10) for 12-15 hours prior to 
treatment.  In some experiments, cells were serum starved for 4 hours followed by treatments 
with PDGF-BB or Ang II for the times indicated.  For the adhesion suspension experiments, 
cells were trypsinized, neutralized in soybean trypsin inhibitor (1mg/ml in PBS), collected by 
centrifugation and resuspended in serum-free DMEM:F12.  Cells were held in suspension or 
plated on fibronectin-coated (40μg/ml) dishes for the times indicated.  In some experiments, 
SMC were transfected using Gene Jammer transfection reagent (Strategene) following the 
manufacturers instructions. 
 
Immunocytochemistry.   
SMC were plated on Lab Tek II chamber slides (Nalgene; 5,000 cells/cm2) and infected with 
virus, as described above.  Cells were serum starved for 4 hours (DMEM-F12, 1% pencillin-
streptomycin) and then dosed with 20ng/ml PDGF-BB for 45min.  Slides were then washed 
three times with phosphate buffered saline (PBS; calcium and magnesium free) and fixed in 
4% paraformaldehyde in PBS for 20 min.  Following an additional three washes in PBS, 
slides were permeabilized for 3 minutes with 4% Triton X-100 in PBS.  Detergent was 
removed by washing three times with PBS and then slides were blocked with blocking 
solution (5% goat serum, 2% BSA in PBS) for 30 minutes.  Cells were incubated for 1 hour 
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with Texas-Red phalloidin in PBS (1:1000) to visualize filamentous actin.  All steps were 
performed at room temperature. 
 
BrdU and WST-1 proliferation assays   
To detect BrdU incorporation, SMC plated on Lab Tek II chamber slides, as described above, 
were transfected with 0.7 μg pDsRedC1 vector (DsV) or pDsRedC1 tagged RacL61 
(DsRacL61) using Gene Jammer transfection reagent.  48 hours following transfection, cells 
were infected with GFP or GFRNK adenoviruses for 15 hr.  Cells were serum starved as 
described above, then treated with either 10% fetal bovine serum or PDGF-BB (30ng/ml) 
overnight. Cells were then incubated with 1/1000 dilution of BrdU labeling reagent (Roche) 
for 1hour at 37o C.  Slides were washed 3 times for 5 min with PBS and then fixed with 
ethanol (50mM glycine, 70%ethananol, pH 2.0) in the dark at –20oC for 20 min.  BrdU 
detection reagent was used following the manufacturers instructions, followed by a 30 min 
incubation at 37oC with a cascade blue-conjugated secondary antibody (1:1000, Molecular 
Probes).  Slides were washed, mounted with coverslips, and BrdU positive nuclei were 
visualized by indirect fluorescence microscopy.  For the WST-1 experiments, SMC were 
plated in 96 well culture dishes (2,000 cells/well) and treated as described above, with the 
exception that the WST-1 tetrazolium salt (Roche) was added to the culture for 2 hrs to 
monitor cell proliferation as per the manufacturer’s instructions.  After this incubation period 
the production of formazan dye was quantitated using a spectrophotometer (450 nm).   
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Immunoprecipitation and Western Blotting 
SMC were lysed in modified RIPA buffer (50mM Hepes, 0.15M NaCl, 2mM EDTA, 0.1% 
NP-40, 0.05% sodium deoxycholate, pH 7.2 ) containing 1mM Na3VO4, 40mM NaF, 10mM 
Na2 pyrophosphate 100μM Leupeptin, 1mM AEBSF, 0.02 mg/ml soybean trypsin inhibitor, 
and 0.05 TIU/ml aprotinin.  CAS and paxillin were immunoprecipitated by incubation of 1 
mg of cell extract with 5μg of the appropriate antibody for 2 hours at 4oC, followed by a 1 
hour incubation with protein A-Sepharose conjugated beads (Amersham).  For paxillin 
immunoprecipitations, the beads were pre-coupled rabbit anti-mouse Ab (10μg/ml, Jackson 
Labs).  The immune complexes were collected by centrifugation and washed 3 times with 
RIPA buffer and 2 times with Tris-buffered saline (TBS; 0.2M NaCl, 50mM Tris-HCl, pH 
7.4).  Proteins were boiled in sample buffer and resolved on a 10% sodium dodecyl sulfate 
(SDS)-polyacrylamide gel (PAGE) and transferred to nitrocellulose.  Western blots were 
performed using the appropriate antibodies at a 1/1000 dilution (except anti-ERK, 1B3B9, 
which was used at 1:10,000).  Blots were washed in TBS-T (TBS plus 0.05% Triton-X), 
followed by incubation with either horse-radish peroxidase conjugated Protein A sepharose 
(Amersham) or horse-radish peroxidase conjugated rabbit anti-mouse antibody (Amersham) 
at a 1/2000 dilution.  Blots were visualized after incubation with chemiluminescence reagents 
(ECL, Amersham). 
 
Kinase Activity   
Kinase activity was measured by using a p44/p42 MapKinase Assay Kit (Cell Signaling), 
following the manufacturers protocol.  In brief, 250 μg of lysate from PDGF-BB SMC lysate 
was incubated with 15μg of provided immobilized phospho-p44/p42 MapK antibody and 
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complexes were rotated overnight at 4oC. Immune complexes were collected by 
centrifugation and washed 3 times with provided 1X lysis buffer and resuspended in 
provided 1X kinase buffer containing 200μΜ ATP and 2μg Elk-1 fusion protein.  The 
reaction was incubated at 30oC for 30 min, and terminated by the addition of 3X SDS sample 
buffer.  Sample proteins were electrophoresed on an 11% SDS-PAGE gel, transferred to a 
nitrocellulose membrane, incubated with phophos-Elk-1 antibody and processed as described 
above. 
 
GST-Pull Down Assay   
GST-Pak (aa 1-290 of Pak1) was purified from bacterial lysates using glutathione- agarose 
beads (Pharmacia) as described previously (16).  GFP- or GFRNK-infected SMC were serum 
starved and treated with PDGF-BB or AngII as described above. Cells were lysed in Buffer 
A (50mM Tris pH 7.6, 500mM NaCl, 0.1% SDS, 0.5% DOC, 1% Triton X-100, 0.5mM 
MgCl2, plus 100μM Leupeptin, 1mM AEBSF, and 0.05 TIU/ml Aprotinin) and cleared by 
centrifugation for 10 min at 14000 rpm at 4oC (17).  500μg of lysate was combined with 
30μg of GST-PBD and samples were rotated at 4oC for 30 minutes.  The complexes were 
pelleted by centrifugation, and washed 2x times in Buffer B (50mM Tris pH 7.6, 150mM 
NaCl, 1%Triton X-100, 0.5 mM MgCl2, plus 100μM Leupeptin, 1mM AEBSF, and 0.05 
TIU/ml).  Samples were boiled in SDS-PAGE buffer, electrophoresed (15% SDS-PAGE gel) 
and transferred to PVDF (Biorad).  Western blotting was performed using an anti-Rac1 
primary antibody as described above.  
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RESULTS 
 We previously reported that overexpression of GFP-FRNK in cultured aortic SMCs 
by adenoviral gene transfer resulted in a modest increase in FRNK protein effectively 
inducing an exogenous FRNK to endogenous FAK ratio of around 3:1.  This FRNK:FAK 
ratio compares favorably with endogenous ratios observed in neonatal vessels and is 
sufficient to inhibit both FAK activity and PDGF-BB-stimulated proliferation and migration.  
To begin to dissect the signaling pathways altered by FRNK expression in SMC, we first 
examined the affect of FRNK overexpression on total cellular phosphotyrosine levels.  In 
adherent cultures of SMC, three major tyrosine phosphorylated bands were attenuated in 
cells expressing GFP-FRNK (GFRNK) in comparison to GFP-infected or un-infected control 
cells (Figure 2.1A).  The 125 kDa protein is probably FAK since FAK co-migrates with this 
band, and FRNK overexpression in SMC inhibits auto-phosphorylation of Y397 as 
previously reported (12).  The use of additional phospho-specific antibodies demonstrated 
that FRNK over-expression in SMC also inhibited phosphorylation of the major Src-
dependent phosphorylation sites in FAK namely pY556, pY557 and pY861 (Figure 2.1B).  
The tyrosine phosphorylated proteins migrating at approximately 130 kDa and 70 kDa likely 
represent the FAK binding partners p130Cas and paxillin (Figure 2.1C).    
 Since proliferation and migration of SMC in response to PDGF-BB are at least 
partially dependent on ERK activation (18-20), and since ERK activation has been reported 
to be dependent on FAK/p130Cas interactions (21), we tested whether overexpression of 
GFP-FRNK could attenuate mitogen-stimulated ERK activity.  Surprisingly, dose-dependent 
stimulation of ERK by PDGF-BB was not altered by overexpression of GFP-FRNK (Fig. 
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2.2A, top panel) even though PDGF-BB-stimulated FAK activation (in the same lysates) was 
clearly attenuated (Figure.2.2A, middle panel). 
 Since the time-course of ERK1/2 activation may also regulate cell cycle progression, 
(22,23) we examined whether FRNK might alter the kinetics of PDGF-BB stimulated ERK 
activity.  As shown in Fig.2.2B and 2.2C, FRNK expression did not alter the kinetics of 
PDGF-BB-induced ERK activation at time points ranging from 1 min to 3 hr.  In addition, 
we observed no significant difference in the ability of ERK to phosphorylate ELK-1 as 
assessed by an immune-complex kinase assay that measures direct phosphorylation of a 
GST-ELK fusion protein (Figure 2.2C).  These data likely indicate that in SMC, FRNK 
inhibits PDGF-BB-stimulated migration and proliferation in an ERK- independent fashion.   
Other major signaling pathways known to regulate both proliferation and migration 
include activation of the small GTPases of the Rho family.  Interestingly, Rac1 has been 
previously shown to be activated by both PDGF receptors and following engagement of 
certain integrins (24,25).  We used a well-defined assay to examine Rac1 activation in SMC 
using a GST-PAK1 fusion protein to precipitate active (GTP-bound) but not inactive (GDP-
bound) Rac1.  As shown in Figure 2.3A, this GST-fusion protein effectively precipitated 
activated L61Rac, but not inactive N17Rac when these constructs were overexpressed in 
COS-7 cells.  Using this assay, we have shown that PDGF-BB induced a rapid transient 
activation of Rac1 in SMC.  PDGF stimulated an approximate 2-3 fold increase in Rac1 
activity which peaked between 1 and 3min following stimulation (Figure 2.3B, left panel).  
As shown in Figure 2.3B (right panel), overexpression of GFP-FRNK slightly inhibited basal 
activity and markedly attenuated PDGF-stimulated Rac1 activity in SMC.  In addition, 
activation of JNK (a kinase known to be downstream of Rac1 activation) was also attenuated  
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Figure 2.1.  FRNK inhibits FAK autophosphorylation and co-localizes with FAK 
in SMC.  Rat aortic SMC were infected with GFP or GFP-FRNK (GFRNK) 
adenovirus for 12 h.  A.  Extracts (100 μg) were analyzed by SDS-PAGE and 
immunoblotting using a generic phosphotyrosine antibody (4G10), an antibody to total 
FAK, or phosphorylation specific antibodies to Y397, Y576, Y577, Y861 of FAK.  B. 
Paxillin (Pax) or p130Cas (Cas) were immunoprecipitated (IP) from the GFP or GFP-
FRNK infected cell extracts as described under “Experimental Procedures” followed by 
immunoblotting with anti-phosphotyrosine antibody (4G10) and the appropriate 
antibody for loading controls.   
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Figure 2.2.  FRNK expression does not alter dose- or time-dependent activation of 
ERK by PDGF-BB in SMC.  Rat aortic SMC were infected with GFP or GFP-FRNK 
adenovirus (10 M.O.I.) for 12 h.  Cells were transferred to serum free media and incubated 
for 4 hr.  Cells were treated with PDGF-BB (0-30 ng/ml) for 10 min (panel A) or with 
PDGF-BB (20 ng/ml) for various times as indicated (panel B).   Lysates were 
electrophoresed and Western analysis was performed using an anti- ERK or anti- phospho-
specific ERK Ab.  Panel C.  ERK was immunoprecipitated from cell lysates with an anti-
ERK1/2 antibody, immune complexes were washed and incubated with 2 mg of purified 
GST-ELK immobilized on glutathione beads in a kinase buffer containing 10 mM MgCl2 
and 200 mM ATP for 30 min at 30 o C.   Immune complexes were then electrophoresed and 
Western analysis was performed using a phosphorylation-specific Elk-1 antibody.  Control 
blots indicated that FRNK expression significantly attenuated FAK pTyr as assessed by 
Western blotting with an anti pTyr397 antibody in each experiment.  Data are representative 
of at least 3 separate experiments.  
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Figure 2.3.  FRNK expression inhibits PDGF-BB- stimulated Rac1 activation and 
membrane ruffling in SMC.  A.  COS cells were transfected with Flag-tagged active 
(L61)- or dominant-negative (N17)-Rac1 for 48 hr.  Lysates were prepared and incubated 
with 30 μg of purified GST-PAK1 immobilized on glutathione beads for 30 min.  Beads 
were washed, boiled in sample buffer, electrophoresed and Western blotted using an anti- 
Flag Ab.  “PD” indicates the Rac1 precipitated with GST-PAK and “L” indicates a 10% 
loading control.  B.  Rat aortic SMC were infected with GFP or GFP-FRNK adenovirus (10 
M.O.I.) for 12 h.  Cells were transferred to serum free media and incubated for 4 hr.  Cells 
were treated with 20 ng/ml PDGF-BB for the indicated times.  Lysates were incubated with 
30 μg of purified GST-PAK for 30 min, complexes were washed and Western blotting was 
performed using an anti- Rac1 Ab.  The bottom panels represent a 10% loading control of 
total Rac1 in the lysates.  C.   Rat aortic SMC were infected and treated with PDGF-BB (20 
ng/ml) as described above for times indicated.   Lysates were electrophoresed and Western 
analysis was performed using phosphorylation-specific anti-JNK, anti- ERK or anti-FAK 
(pY397) antibodies.   The blot was stripped and re-probed using an anti-ERK Ab to serve as 
a loading control.  D.  Rat aortic SMC were infected with GFP or GFP-FRNK adenovirus 
and serum starved as described above.  Cells were treated with 20 ng/ml PDGF-BB for 45 
minutes.  Cells were fixed and stained with Texas-Red conjugated phalloidin to visualize 
filamentous actin as described in “Experimental Procedures”.  The ruffled phenotype was 
observed in 87% of GFP infected cells compared to 22% of FRNK infected cells (187/215 
and 46/205 cells respectively).  Data shown are representative of at least 3 separate 
experiments. 
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in the GFP-FRNK expressing cells (Figure 2.3C).  Since Rac1 activation stimulates the 
formation of distinct actin-rich lamellipodia, an important event during cell motility 
(24,26,27), we examined whether FRNK expression in SMC might alter this process in 
PDGF-BB-stimulated SMC.  Indeed, in GFP-infected cells, PDGF-BB stimulated a 
reorganization of actin filaments and a resultant ruffled morphology (note the dissolution of 
stress fibers and formation of actin bundles around the periphery of the PDGF-BB-stimulated 
cells; Figure 2.3D, top panels).  In contrast, PDGF treatment of GFP-FRNK infected cells did 
not result in noticeable changes in actin rearrangements (Figure 2.3D, bottom panels).  Taken 
together, these data indicate that FRNK expression attenuates the activation of Rac1 and 
Rac1-dependent signals in SMC. 
To determine whether inhibition of Rac1 was the sole determinant for the 
proliferative defects induced by FRNK, we examined the ability of activated Rac1 to rescue 
PDGF-BB-stimulated proliferation in FRNK over-expressing cells.  To this end, SMC were 
transfected with either pDsRedC1 vector (DsV) or pDsRedC1 tagged RacL61 (DsRacL61) 
prior to infection with GFP and GFP-FRNK adenoviruses.  Following serum starvation, cells 
were treated with PDGF and analyzed for their capacity to incorporate BrdU.  Consistent 
with our previous report, FRNK over-expression attenuated PDGF-stimulated BrdU 
incorporation by approximately 40% to a level comparable to cells in serum free media 
(p<0.05 compared to GFP infected cells; Figure 2.4).  Importantly, while Rac1 alone had 
little effect on BrdU incorporation in GFP expressing cells, over-expression of constitutively 
active L61Rac1 efficiently rescued the effects of FRNK on cell proliferation (p<0.01 
compared to FRNK+ DsV).  Control experiments indicated that similar amounts of FRNK 
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were expressed under both conditions (Figure 2.4, upper panel).  These data indicate that 
Rac1 acts downstream of FAK/FRNK to control SMC proliferation. 
To determine whether inhibition of Rac1 activity might be a general mechanism by 
which FRNK attenuates SMC growth, we examined the capacity of FRNK to inhibit Ang II-
mediated signal transduction.  We found that overexpression of FRNK also inhibits Ang II- 
stimulated cell growth reducing the proliferative index by 77 +/- 12% after a 24 hour 
treatment as assessed colorimetrically by monitoring cleavage of the tetrazolium salt, WST-
1.  These data corroborate studies reported elsewhere (28) and suggest that FRNK can inhibit 
proliferative signals induced by G protein-coupled receptors as well as receptor tyrosine 
kinases.  Since Ang II has also been shown to stimulate Rac1 activity in SMC (29) and other 
cell types, we examined whether this affect might also be altered by FRNK.  Indeed, as 
shown in Figure 2.5A, Ang II stimulated a rapid transient increase in Rac1 activity in SMC 
and this effect was attenuated by ectopic expression of GFP-FRNK.  As shown in Figure 
2.5B and 2.5C, neither the kinetics of Ang II-stimulated ERK activation nor the 
concentrations of AngII required for maximal ERK activation were significantly altered by 
overexpression of GFP-FRNK in SMC.  Control experiments indicated that Ang II does 
stimulate FAK activity and that this activity is blocked by overexpression of FRNK.  Thus, 
FRNK appears to attenuate both AngII and PDGF-BB-dependent mitogenic signaling 
without effects on ERK activity. 
 As noted above signaling through many SMC mitogens is dependent on ECM but the 
precise mechanisms involved in this regulation have not been clearly defined.  In certain cell 
types, fibronectin-binding integrins have been shown to contribute to the activation of Rac1 
(30).  Thus, we examined we examined whether plating SMC on fibronectin would stimulate 
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the activation of Rac1 in SMC and if so, whether expression of FRNK might alter integrin-
dependent Rac1 activation.  As shown in Figure 2.6, plating SMC on fibronectin stimulated a 
transient activation of Rac1 that peaked at 1 hr and overexpression of FRNK attenuated this 
response at each time point (Figure 2.6).  In contrast, overexpression of FRNK had little 
effect on fibronectin-stimulated ERK activity.  These data indicate that FRNK attenuates 
FAK-dependent activation of Rac1 in response to PDGF-BB, Ang II, and integrins.  Based 
on these observations, we hypothesize that Rac1 activation may be a key convergence point 
in growth factor and integrin regulated cell proliferation and migration in SMC, and that 
FRNK may act to regulate signaling through diverse pathways at this level (see Figure 2.7).    
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Figure 2.4.  L61Rac1 expression overcomes inhibitory effect of FRNK on 
proliferation.  SMC were transfected with pDsRedC1 vector (DsV) or a DsRed fusion 
protein containing the constitutively active form of Rac1, (DsRacL61).  48 hours after 
transfection, cells were infected with GFP or GFP-FRNK virus as described above.  
Cells were serum starved for 4 hours and then dosed overnight with either 30ng/mL 
PDGF-BB or vehicle control.   Cells were labeled with BrdU, fixed and stained for 
BrdU using a cascade blue-conjugated secondary antibody as described in 
“Experimental Procedures”.  The BrdU labeling index for cells positive for GFP and 
DsRed was determined and data are presented as the percentage of cells labeled 
positive in the PDGF-BB-stimulated versus un-stimulated wells.   The graph represents 
means +/- SE of three independent experiments in which a total of 180-350 cells were 
counted for each condition.  The percentage of BrdU positive cells in the un-stimulated 
GFP-FRNK control group was 18.2 +/- 1.9%.   Levels of GFP-FRNK were comparable 
in DsV and DsRacL61 expressing cells (see upper panel).   
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Figure 2.5.  FRNK expression attenuates Ang II- stimulated Rac1 but not ERK 
activity in SMC.  Rat aortic SMC were infected with GFP or GFP-FRNK adenovirus 
(10 M.O.I.) for 12 h.  Cells were transferred to serum free media and incubated for 4 hr.  
Cells were treated with Ang II for various times (panels A and B) or with various 
concentrations (panel C).  A.  Lysates were incubated with 30 μg of purified GST-PAK 
as described above.   Western blotting was performed using an anti- Rac1 Ab.  The 
bottom panels represent a 10% loading control of total Rac1 in the lysate.  B and C.  
Lysates were electrophoresed and Western analysis was performed using an anti- ERK 
or anti- phospho-specific ERK Ab.  Control blots indicated that FRNK expression 
significantly attenuated FAK pY397 in each experiment.  Data in panel A are 
representative of 3 separate experiments and data in panels B and C are representative of 
at least 4 separate experiments. 
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Figure 2.6.  FRNK expression blocks FN-stimulated Rac1 activity in SMC.  SMC 
were infected with GFP or GFP-FRNK as described above.  Cells were trypsinized, 
neutralized in soybean trypsin inhibitor, pooled and either held in suspension (S) or 
plated on fibronectin (FN) for the times indicated.  Cells were lysed and incubated with 
30 μg of purified GST-PAK as described above.   Western blotting was performed using 
an anti- Rac1 Ab.  The bottom panels represent a 10% loading control of total Rac1 in 
the lysate.  Levels of active ERK in lysates were assessed using an anti- phospho-
specific ERK Ab.  Data are representative of 3 separate experiments.  
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 Figure 2.7.  Schematic summarizing mitogenic signaling pathways that regulate 
SMC growth and migration.  A variety of agonists that regulate SMC growth and 
migration are known to regulate Rac/JNK and Ras/ERK signaling.  We hypothesize that 
FAK activation is required to integrate signals from integrins, receptor tyrosine kinases 
and G protein coupled receptors leading to the downstream activation of Rac1.   In 
SMC, FRNK may control proliferation and migration by “buffering” this FAK-
dependent response. 
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DISCUSSION 
 
Numerous studies have implicated a role for the non-receptor tyrosine kinase, FAK in 
the regulation of migration and proliferation. FAK is strongly activated by integrin-, growth 
factor receptor-, and G protein coupled receptor- engagement and thus may serve to integrate 
downstream signals from a variety of agonists; however the precise mechanisms by which 
FAK regulates signaling from these diverse pathways have not been clearly defined (11).  In 
this report, we studied the convergence of growth factor and integrin signaling through FAK 
in the regulation of vascular SMC proliferation.  As we previously reported, FAK activity 
appears to be regulated in a unique fashion in SMC whereby autonomous expression of the 
carboxyterminal domain of FAK (termed FRNK) can act as an endogenous inhibitor of FAK 
signaling (12,31,32).  In recent studies, we have shown that: 1) FRNK is expressed 
selectively in SMC with high levels observed in the vasculature; 2) FRNK expression is 
regulated during development and following vascular injury; and 3) ectopic expression of 
FRNK in cultured SMC blocked PDGF-BB stimulated migration and proliferation (12).  
These data indicate that FRNK expression may impart tight regulation on FAK-dependent 
ECM-mediated signaling events in SMC.  Here we report that expression of FRNK in SMC 
blocks mitogenic signaling from diverse factors by attenuating FAK-dependent co-activation 
of the Rac/JNK but not the Ras/ERK pathway. 
Ras/ERK and Rac/JNK are two of the main pathways known to be key regulators of 
cell proliferation and migration.  Cell adhesion to extracellular matrix regulates Ras/ERK 
signaling in many cell types and studies have clearly shown that maximal growth factor 
signaling to ERK is anchorage-dependent (33).  Several pieces of evidence highlight a 
possible role for FAK activation in ERK-dependent growth regulation.  First, several 
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mitogens (including PDGF-BB, AngII, PE, IGF-1, and ET-1) stimulate FAK tyrosine 
phosphorylation in an adhesion-dependent manner (5-8).  Second, at least two pathways have 
been defined by which FAK can activate ERK activity.  One pathway involves adhesion-
dependent tyrosine phosphorylation of FAK at residue 925 which directs SH2-mediated 
binding to the adapter protein GRB2, and recruitment of the GTP exchange factor SOS 
followed by subsequent activation of the Ras/Raf/MEK/ERK pathway (34,35); and a separate 
pathway involves the adhesion dependent association of the adapter protein CAS with FAK 
which can facilitate ERK signaling through the adapter proteins NCK and SOS and 
subsequent activation of the Ras/Raf/MEK/ERK pathway (21).  Finally, overexpression of 
FAK can rescue growth factor induced ERK activation in non-adherent cells whereas 
inhibition of FAK function can attenuate activation of ERK in adherent cells (9,36).  Indeed, 
we previously reported that adenoviral infection of GFP-FRNK inhibits PE-stimulated ERK 
activation in isolated cardiomyocytes (37).   
In contrast, we have clearly shown in this report that FRNK expression attenuates 
FAK signaling in primary cultured SMC (in which FRNK is expressed endogenously) 
without affect on the time or dose-dependent activation of ERK by both strong (PDGF-BB) 
or weak agonists (Ang II).  Instead, the effects of FRNK on mitogen and ECM-induced 
proliferation were mediated by inhibition of Rac1/JNK, a conclusion strongly supported by 
our results demonstrating that L61 Rac1 was sufficient to rescue the FRNK inhibitable 
component of PDGF-BB-stimulated cell proliferation.  Our results do differ somewhat from 
a previous report in which stable transfection of FRNK into smooth muscle-like cells reduced 
PDGF-stimulated ERK activity at low but not high concentrations of PDGF (38).  The 
apparent discrepancies between these results may be due to their use of smooth muscle cell  
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lines immortalized by large T antigen as opposed to primary SMC cultures.  Thus, we 
propose that the mechanisms by which FAK regulates adhesion-dependent growth factor 
signaling may be cell type specific.  Indeed, previous work has shown that in keratinocytes, 
integrin-dependent ERK activation appears to proceed through SHC- but not FAK- 
dependent signals (39).  Perhaps similar FAK-independent ERK signaling pathways are 
utilized in SMC.  Although most of our data indicates that the effects of FRNK are mediated 
by inhibition of FAK, we cannot rule out the possibility that FRNK might regulate signaling 
in a FAK-independent fashion in SMC.   
Our results do not completely exclude the possibility that FAK/FRNK may play a 
role in regulating ERK signaling in SMC in vivo.  It is still possible that weak ERK 
activation induced by limiting amounts of mitogens in the vessel wall may be more 
susceptible to the effects of FRNK.  It is also possible that examination of total ERK activity 
may not be representative of the relevant functional activity of this enzyme in the cell.  For 
instance, active ERK localizes to focal adhesions as well as the nucleus, suggesting that 
targeting of this kinase may direct specificity towards downstream targets (40,41).  Thus, 
FRNK may attenuate localization of active ERK, which could be masked in experiments 
designed to measure total activity in cell lysates.  Interestingly, adhesion to the ECM is 
required for efficient accumulation of active ERK in the nucleus and recent studies point to a 
role for Rac1 in mediating this process (40,42).  Therefore, although FRNK might not affect 
ERK activation per se, it could affect downstream ERK signaling secondary to its affect on 
Rac1 activation.  Studies to examine this possibility are currently underway.   
             Our data suggest that in SMC, Rac1 activation may be a key convergence point in 
growth factor- and integrin-regulated cell proliferation, since FRNK expression attenuated 
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integrin-, Ang II- and PDGF-BB stimulated Rac1 activation and downstream signaling.  
Activation of the small GTPase Rac1 elicits membrane ruffling and lamellipodia formation 
upon growth factor stimulation and this modification of cell morphology is required for cell 
spreading and migration (24,26,27).  In addition, activation of Rac1 is required for cyclin D1 
expression and concomitant cell cycle progression (43,44).  Rac1, like other low molecular 
GTPases, is a molecular switch that cycles between the active GTP- and inactive GDP- 
bound states and is regulated by numerous proteins that facilitate this process.  The exchange 
of GDP for GTP is accelerated by guanosine nucleotide exchange factors (GEFs), while 
GTPase-activating proteins (GAPs) increase the intrinsic rate of GTP hydrolysis.  In the 
GTP-bound form, Rac1 interacts with and activates a number of effector molecules that have 
been implicated in regulating proliferation and migration including serine/threonine protein 
kinases, lipid kinases, and actin binding/scaffolding proteins (45,46).  We have shown that 
FRNK expression attenuates PDGF-BB mediated activation of JNK, a stress-activated 
protein kinase downstream of Rac1 signaling known to control cell proliferation.  In addition, 
we showed that the proliferative defect in FRNK expressing cells was completely rescued by 
active RacL61.  Taken together, these data provide strong evidence that Rac1 is co-regulated 
by FAK-dependent integrin and growth factor signaling.   
Recent studies corroborate the suggestion that activation of the Rac1 GTPase may be 
the critical convergence point for mitogen- and integrin-dependent growth and migration in 
certain cell types.  In endothelial cells, mitogens stimulate robust ERK activity when cells are 
attached to either fibronectin or laminin, but only stimulate proliferation when the cells are 
plated on fibronectin.  This effect was correlated to the ability of fibronectin (but not laminin) 
to support mitogen-stimulated Rac1 activity, indicating a role for Rac1 in adhesion-
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dependent growth responses (30).  Two other reports show that β integrins are both necessary 
and sufficient for adhesion dependent Rac1 activation.  Hirsch et. al. showed that fibroblasts 
derived from mice that express a mutated β1 integrin display defective activation of FAK, 
Rac1 and JNK but not ERK and are impaired in G1-S cell cycle progression (47).  In 
addition, Berrier et al showed that clustering β1 and β3 integrin tails on the surface of non-
adherent cells activates Rac1 activity (48). 
FAK activates a number of signaling molecules that might contribute to integrin-
dependent Rac1 (and downstream JNK) activation.  Evidence suggests that FAK-dependent 
signaling through CAS, paxillin, or PI-3Kinase can lead to activation of Rac1 by several 
different mechanisms.  Integrin-mediated activation of Rac1 could proceed through a 
FAK/(CAS or paxillin)/Crk/DOCK 180 pathway.  Indeed, dominant interfering mutants of 
the SH2/SH3 adapter protein Crk, the adapter/exchange factor DOCK 180 or Rac1 each 
attenuate Cas- or paxillin- stimulated cell migration (49-52).  Recently, a more direct 
paradigm has been suggested whereby FAK-dependent activation of paxillin could lead to 
focal adhesion recruitment and activation of the putative Cdc42/Rac guanine nucleotide 
exchange proteins PIX/COOL (3,30,53).  Alternatively, activation of Rac1 could proceed 
through a FAK/PI3K/SOS pathway.  Pi3kinase associates with Tyr397 of FAK upon integrin 
ligation and one of its catalytic products, phosphatidylinositol-tris-phosphate, binds to and 
activates the PH-domain containing guanine nucleotide exchange factor, SOS which can 
activate both Rac1 and Ras (53,54).  In endothelial cells fibronectin-stimulated Rac1 activity 
is dependent on FAK/PI3Kinase/SOS signaling (30); however recent data using Src 
transformed fibroblasts suggests that a FAK/CAS/DOCK180 pathway might be utilized (55).   
 56
Whether the pathways leading from FAK to Rac/JNK are redundant or differentially 
regulated in a cell-type specific fashion are important questions that remain to be addressed. 
ECM is a critical component of the medial layers of the vessel wall which serves to 
both maintain vascular integrity and to regulate vascular development and remodeling.  
Results from genetic deletion of various ECM components, integrin receptors, and FAK each 
result in extraembryonic and embryonic vessel defects leading to lethality at approximately 
day 8.5-10 of mouse development supporting a role for adhesion signaling in the regulation 
of growth and migration of vascular SMC (56-59).  FAK is co-activated by integrins and 
autocrine factors and its activation is necessary for proliferation and migration in a number of 
cell types (11).  We have shown that FAK activity may be regulated in a unique fashion in 
SMC, because FRNK, a dominant-inhibitory form of FAK is selectively expressed in these 
cells.  FRNK overexpression inhibits both AngII and PDGF-BB stimulated migration and 
proliferation, effects likely due to the ability of FRNK to block Rac1 activation.  
Interestingly, several SMC mitogens have been linked to Rac1 activation either in SMC (i.e. 
AngII) or other cell types (i.e. PDGF, ET-1, IGF-1, fibroblast growth factor) and proliferative 
signals induced by these agonists are attenuated by overexpression of a dominant-interfering 
mutant for Rac1 (29,60-64).  Thus, it is tempting to speculate that enhanced signaling 
through FAK to Rac1 is permissive for SMC growth during development and for the 
phenotypic reversion of SMC to a more proliferative state following vascular injury and that 
expression of FRNK might hold these processes in check.  
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CHAPTER III 
Adhesion stimulates direct PAK1/ERK2 association and leads to ERK-dependent PAK1 
Thr212 phosphorylation2
 
 
                                                 
2 Data published as:  Liisa J. Sundberg-Smith, Jason T.Doherty, Christopher P. Mack and Joan M. Taylor.  
Adhesion stimulates direct PAK1/ERK association and leads to ERK-dependent PAK1 Thr212 
phosphorylation.  J Biol Chem (2005) 280(3):2055-64. 
ABSTRACT 
The Rac1/Cdc42 effector p21-activated kinase (PAK) is activated by various signaling 
cascades including receptor tyrosine kinases and integrins, and regulates a number of 
processes such as cell proliferation and motility.  PAK activity has been shown to be required 
for maximal activation of the canonical Ras/Raf/MEK/ERK Map Kinase signaling cascade, 
likely due to PAK co-activation of Raf and MEK.  Herein, we found that adhesion signaling 
also stimulates an association between PAK1 and ERK1/2.  PAK1 and ERK1/2 co-
immunoprecipitated from SMC plated on fibronectin and the two proteins co-localized in 
membrane ruffles and adhesion complexes following PDGF-BB or sphingosine 1-phosphate 
treatment respectively.  Far Western analysis demonstrated a direct association between the 
two proteins, and peptide mapping identified an ERK2 binding site within the auto-inhibitory 
domain of PAK1.  Interestingly, deletion of a major ERK binding site in PAK attenuates 
activation of an ERK-dependent serum-responsive element (SRE)- luciferase reporter gene, 
indicating that association between PAK and ERK is required to facilitate ERK signaling.  
We also show that ERK2 phosphorylates PAK1 on Thr212 in vitro and that Thr212 is 
phosphorylated in smooth muscle cells following PDGF-BB treatment in an adhesion and 
MEK/ERK-dependent fashion.  Expression of a phosphomimic variant, PAK T212E, does 
not alter ERK association, but markedly attenuates downstream ERK signaling.  Taken 
together, these data suggest that PAK1 may facilitate ERK signaling by serving as a scaffold 
to recruit Raf, MEK, and ERK to adhesion complexes, and that subsequent growth-factor 
stimulated phosphorylation of PAKT212 by ERK may serve to provide a negative feedback 
signal to control coordinate activation of ERK by growth factor- and matrix-induced signals. 
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INTRODUCTION 
The Ras superfamily of small GTPases including H-Ras, R-Ras, and Rho family 
members (Rac, Rho, and Cdc42) among others are activated by numerous transmembrane 
receptors such as receptor tyrosine kinases, G-protein coupled receptors, and integrins and 
regulate a variety of cellular processes including proliferation, differentiation, and migration 
(1).  These GTPases are molecular switches that cycle between an active GTP-bound state 
and an inactive GDP-bound state (2,3).  In the GTP-bound form, the Ras-related GTPases 
interact with and activate a number of effector molecules that have been implicated in 
regulating cell cycle progression and/or cell migration such as the serine/threonine protein 
kinases, lipid kinases, and actin binding/scaffolding proteins (3,4). 
Ras and Rac regulate MAPKinase signaling, and a variety of agonists use Ras-
dependent activation of ERK and/or Rac-dependent activation of JNK as dominant mitogenic 
signaling pathways (5).  MAPK activation typically occurs by highly conserved multi-level 
kinase cascades (i.e. Ste20/Ste11/Ste7/Fus3 in yeast and Raf/MEK/ERK in mammalian cells) 
eventually leading to MAPK nuclear translocation and transcription factor activation (6,7).  
Although the mammalian MAPK signaling pathways were initially thought to be 
independent and parallel, recent studies indicate that there is significant cross-talk between 
them. 
Several lines of evidence indicate that integrins and growth factors promote 
coordinated activation of the ERK signaling cascade.  Integrin-signaling has been shown to 
be required for maximal activation of either growth factor-stimulated Raf or MEK activation 
an event likely dependent on the specific integrin receptors engaged in the particular cell type 
used (8-10).  Studies indicate that the Rac effector, p21-activated protein kinase (PAK), a 
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homologue to the yeast MAP4K, Ste20, may serve as a convergence point between growth 
factor- and integrin-mediated Ras/ERK signaling.  GTP-bound Rac and Cdc42 activate 
PAK1 in an adhesion-dependent fashion by binding to the p21-binding domain (PBD or 
CRIB) localized within the N-terminal autoinhibitory domain of PAKs 1-3 (11,12).  This 
interaction exposes the PAK C-terminal kinase domain permitting activation, 
autophosphorylation, and downstream signaling (13,14).  Notably, plating cells on the ECM 
fibronectin enhances the ability of Rac to activate PAK, and β1 integrins have been shown to 
transmit signals downstream to JNK through the Pi3kinase/Rac/PAK cascade (15,16).   
Interestingly, Howe et al demonstrated that inhibition of PAK attenuated integrin-
dependent ERK activation and subsequent studies showed that this was likely due to the 
ability of PAK to enhance adhesion-dependent Raf and/or MEK activation (17).  Activated 
PAK associates with Raf, and phosphorylates ser-338 and ser-339 within the catalytic 
domain.  Although several phosphorylation sites have been reported to be necessary for Raf 
activation, phosphorylation of these serines has been shown to be essential for maximal Raf 
activation by Ras in response to integrin-mediated Pak1 activation (14,18).  However, the 
convergence of integrin signaling at the level of Raf is controversial, and at least one study 
refutes the necessity of Pak3 for ser-338 phosphorylation in response to EGF (19).  Recent 
studies indicate that PAK also phosphorylates MEK on a site (S298) that is necessary for 
maximal MEK activation by Raf and that adhesion-dependent PAK signaling enhances 
association between MEK and ERK (5,20-22).  Thus, convergence of these two well-
established pathways likely occurs at the level of PAK, which can affect ERK signaling at 
multiple levels including co-activation of Raf and MEK.  Whether the pathways leading from 
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PAK to ERK are differentially regulated in an integrin-dependent cell-type specific fashion 
are important questions that remain to be addressed. 
Herein, we report that adhesion signaling induces a direct association between ERK 
and PAK1.  Taken together with previous data, our results indicate that PAK may coordinate 
signaling between Raf, MEK and ERK by acting as a scaffold for these proteins.  We also 
present evidence that ERK2 phosphorylates PAK1 on Thr212, a site just downstream of the 
ERK binding site on PAK, and that this event may provide negative feedback inhibition of 
ERK signaling.  These data highlight yet another level whereby adhesion signaling may 
regulate synergy between Ras and Rho family proteins to dynamically regulate the activation 
state of ERK at distinct regions within the cell. 
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MATERIALS AND METHODS 
Antibodies and Reagents 
The phospho-specific ERK1/2 antibody and the anti-PAK1 antibody were purchased from 
Cell Signaling.  The phospho-Tyr15 Cdc2 antibody was purchased from Santa Cruz. The 
phospho-specific PakT212 antibody, anti-Flag (M5), anti-acetylated tubulin and anti-vinculin 
antibodies, alsterpaullone and fibronectin were purchased from Sigma.  PDGF-BB and 
UO126 were purchased from Calbiochem.  The purified active ERK2 and anti-ERK2 
antibody were purchased from UBI.  The anti-paxillin antibody was purchased from 
Transduction Laboratories, and Texas-Red phalloidin was purchased from Molecular Probes. 
Expression Constructs 
Rat His-PAK1 and His-ERK2 (wild type and kinase defective) constructs were generous gifts 
from Leslie Parise (UNC) and Melanie Cobb (UTSW) respectively.  GFP-PAK1 was made 
by inserting full length wild type human PAK1 (generous gift from Alan Howe, UVT) into 
EGFP-C1 vector (Clonetech) cut with Bgl1 +EcoR1, GST-PAK1 (aa 1-290) was constructed 
as previously described (23).  S212E or A and S223A variants were generated by PCR site-
directed mutagenesis of GST- or GFP-tagged PAK1 constructs. Forward and reverse 
complimentary primers corresponding to the following sequence were used:  for PAK1 
S212A, 5’:GAACCACTTCCTGTCGCTCCAACTCGGGACGTGG, for S212E, 5’: 
GTGATTGAACCACTTCCTGTCGAACCAACTCGGGACGTGGC, for PAK1 S223A, 5’: 
GGCTACATCTCCCATTGCACCTACTGAAAATAACACC.  Mutations were confirmed 
by direct sequencing. 
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Cell Culture and Agonist Treatment  
Rat aortic smooth muscle cells (SMC) were obtained from rat thoracic aortas by enzymatic 
digestion as previously described (24).  Cells were used from passages 7-21 and were 
maintained in Dulbecco’s Modified Eagles medium (DMEM)-F12 plus 10% fetal bovine 
serum and 1% penicillin-streptomycin.  In some experiments, cells were serum starved for 4 
hours before treatment with PDGF-BB (20 ng/ml) for the times indicated.  For adhesion 
suspension experiments, cells were trypsinized, neutralized in soybean trypsin inhibitor 
(1mg/ml in PBS), collected by centrifugation and resuspended in serum-free DMEM:F12 
plus 1% penicillin-streptomycin.  Cells were held in suspension or plated on fibronectin-
coated (40μg/ml) dishes for the indicated times.  A7r5 (ATCC) smooth muscle cells, were 
maintained in DMEM plus 10% fetal bovine serum and 1% penicillin-streptomycin. 
 
Protein Purification 
His-ERK2 (wild type and kinase defective) and His-PAK1 were purified from bacterial 
lysates using Qiagen Nickel-NTA (nickel-nitriloacetic acid) agarose according to the 
manufacturers protocol (The QIAexpressionisttm  5th Ed.). Briefly, cleared lysates in a buffer 
containing 50mM NaH2PO4, 300mM NaCl, 20mM Imidazole, pH 8.0 plus 1mg/ml 
lysozyme,1 mM Na3VO4, 40 mM NaF, 100μM Leupeptin, 1mM AEBSF, and 0.05 TIU/ml 
aprotinin were combined with 1 ml Nickel NTA-agarose, rotated for 1 hr at 4oC, and then 
transferred to a chromatography column.  The His-ERK Nickel NTA agarose complexes 
were washed 3x with 50mM Imidazole wash buffer (50mM NaH2PO4, 300mM NaCl, 50mM 
Imidazole, pH 8.0) and eluted with 250mM Imidazole elution buffer (50mM NaH2PO4, 
300mM NaCl, 250mM Imidazole, pH 8.0). The His-PAK1 Nickel NTA agarose complex 
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was washed 3x with 30mM Imidazole wash buffer (50mM NaH2PO4, 300mM NaCl, 30mM 
Imidazole, pH 8.0) and 1x with 40mM Imidazole wash buffer (50mM NaH2PO4, 300mM 
NaCl, 40mM Imidazole, pH 8.0). 25μl of each elution fraction was analyzed by SDS-PAGE 
to determine the appropriate fractions to pool.  Proteins were dialyzed (50mM Hepes, 
150mM NaCl and 10% glycerol) overnight at 4 oC and then aliquoted and stored at –80oC for 
subsequent experiments. 
 
GST-Pulldown Assay 
GST-PAK (aa 1-290 of PAK1, J.Chernoff) was purified from bacterial lysates using 
gluathione-agarose beads (Pharmacia) as described previously (23).  SMC were incubated in 
serum-free media (DMEM:F12 plus 1% penicillin-streptomycin) and treated with PDGF-BB 
(20ng/ml) as described above.  Cells were lysed in Buffer A (50mM Tris, pH 7.6, 500mM 
NaCl, 0.1% SDS, 0.5% DOC, 1% Triton X-100, 0.5mM MgCl2, plus protease inhibitors) and 
500μg of protein was combined with 30μg GST-PAK1 fusion protein and rotated for 30-60 
min at 4oC. The beads were then washed twice with Buffer B (50mM Tris pH 7.6, 150mM 
NaCl, 1% Triton X-100, 0.5mM MgCl2, plus protease inhibitors) and once with Tris-buffered 
saline (TBS, 0.2 M NaCl, 50 mM Tris-HCL, pH 7.4).    The beads were resuspended in SDS-
PAGE sample buffer, boiled for 5 min, electrophoresed on a 12% SDS-polyacrylamide gel, 
and analysed by Western blotting using either an anti-pERK1/2 or anti-ERK2 antibodies 
(1:1,000). 
In Vitro Kinase Assay 
To detect ERK phosphorylation, purified His-ERK2 (kinase dead, 0.1-1μg), and His-PAK1 
(0.1-0.5 μg) were incubated with 10μCi of γP-32 ATP in Kinase Buffer (50mM Hepes pH 
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7.3, 10mM MgCl2, 1mM MnCl2, 5mM NaF, 0.25% Triton 100-X) for 10min at 30 oC.  To 
detect phosphorylation of PAK1, freshly purified GST, GST-PAK1(1-290)or GST-PAK1 
variants (5μg) were incubated with 10ng of active ERK2 (UBI) in Kinase Buffer in the 
presence of 50μM ATP with or without [γPP32]-ATP (10μCi) ) for 10min at 30 oC.  Samples 
were resolved by SDS-PAGE.  The radioactive gels were fixed in 50% methanol, 10% acetic 
acid and 20% glycerol for 20min and then rehydrated for 90min in 7% acetic acid 5% 
methanol and 20% glycerol.  The gel was dried for 2 hours at 80 oC and then exposed to 
Kodak XAR autoradiograph film.  The gel was then rehydrated in ddH O and then stained 
with 1% Coomassie Blue.  For non-radioactive kinase assays, the gel was transferred to 
nitrocellulose, and analyzed by Western blotting using the phospho-Thr212 antibody. 
2
 
Western Blotting.   
Western blots were performed using the appropriate antibodies at a 1/1000 dilution. Blots 
were washed in TBST (TBS plus 0.05% Triton-X), followed by incubation with either horse-
radish peroxidase conjugated- rabbit anti-mouse antibody or - Protein A sepharose 
(Amersham) at a 1/2000 dilution.  Blots were visualized after incubation with 
chemiluminscence reagents (ECL, Amersham). 
 
Far Western 
Purified GST and GST-PAK1 beads were electrophoresed by SDS-PAGE (12%) and 
transferred to nitrocellulose. The blot was incubated in 5% powdered milk/TBST + 0.2% 
sodium azide for 48 hr at 4oC (to block the membrane and re-nature proteins) the blot was 
then incubated with purified His-ERK2 (8g/ml in 5% powdered milk/TBST) overnight at 
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4oC.  The blot was washed 3 times (10min) with TBST and then incubated with India 
HisProbe-HRP (1:5,000 Pierce) for 1hr at room temperature.  The blot was washed with 
TBST overnight at 4oC before detection with SuperSignal West Pico (Pierce) 
chemiluminscence substrate.  
PAK1 Spot Blot 
A membrane containing 12 mer overlapping peptides derived from PAK1 sequence was 
prepared by SPOT synthesis (ABIMED, generously provided by Leslie Parise).  The PAK1 
spot blot was blocked with 10% powdered milk in TBS-T, followed by incubation with 
2g/ml purified His-ERK2 in Binding Buffer (20mM Hepes pH 7.4, 150mM NaCl, 1% 
glycerol, 5% BSA and 0.05% Tween-20), overnight at 4 oC.  The blot was washed 3 times 
(10min) with TBST.  The blot was then incubated with anti-ERK2 antibody, followed by 
incubation with horse-radish peroxidase conjugated Protein A sepharose at a 1/2000 dilution, 
and visualized by chemiluminscence (ECL, Amersham). 
Luciferase Assay  
A7r5 cells were transfected with 0.75 μg of SRE-luciferase reporter construct and 0.25μg of 
the GFP construct variant per well using Superfect (Stratagene) following the manufacturer’s 
protocol. All transfections were done in quadruplicate.  Luciferase assays were performed 48 
hours post-transfection using Steady-Glo Luciferase Assay Kit (Promega) following the 
manufacturer’s protocol. Relative promoter activity is expressed as the mean +/- standard 
error relative to total protein.    
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Immunocytochemistry 
A7r5 cells were transfected with the desired GFP-tagged construct using Superfect (Qiagen).  
After 48 hours, the cells were trypsinized, rinsed in soybean trypsin inhibitor (1mg/ml), 
centrifuged, washed twice in PBS and resuspended in serum-free DMEM plus 1% penicillin-
streptomycin.  Cells were counted and plated on fibronectin coated (10μg/ml) slides (Lab-
Tek) for 20-90 min.  Staining procedure was followed as previously published (25). In brief, 
cells were fixed with 4% paraformaldehyde, permeabilized with 4% Triton X-100 in PBS, 
incubated with specified primary antibody for 1 hour at the following concentrations: anti 
pErk 1:200, anti-vinculin 1:50, anti-paxillin 1:250, anti-acetylated tubulin (1:1000).  After 
washing with PBS, slides were incubated for 1 hour with either Texas Red-conjugated 
donkey anti-rabbit or donkey anti-mouse antibodies (2μg/ml) or Texas Red-conjugated 
phalloidin to detect filamentous actin. 
Mass-Spectral Analysis 
GST-PAK1 (aa 1-290, 10 μg) was electrophoresed on a 14% Pre-Cast Tris/glycine SDS-
PAGE gel (Invitrogen). The gel was fixed by soaking in 25% isopropanol/10% acetic acid 
for 20 min, stained with 0.01% Coomassie in 10% acetic acid overnight, followed by de-
staining in 10% acetic acid.  Appropriate bands were excised, trypsinized, peptides were 
eluted and subjected to MALDI-TOF/TOF (ABI 4700 Proteomics Analyzer) and LC-MS 
(Micromass Q/TOF API-US LC/MS/MS) to define the cleavage site as previously described 
(26). 
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RESULTS 
We reported previously that inhibition of FAK in SMC by ectopic overexpression of 
its dominant-interfering form FAK-related non-kinase (FRNK) did not attenuate the 
magnitude or duration of total cellular ERK activity induced by PDGF-BB, angiotensin II, or 
fibronectin.  However, recent studies indicate that active ERK is localized in several different 
compartments within the cell including focal adhesions (21,27-29).  To determine whether 
adhesion-dependent FAK signaling might regulate activation of ERK at distinct sites within 
the cell, we plated GFP-FRNK-transfected SMC on fibronectin for 60 min and stained cells 
with an antibody that recognizes active (phosphorylated) ERK1/2.  As shown in Figure 3.1, 
ectopic expression of FRNK does dramatically reduce adhesion-stimulated ERK activation in 
focal adhesions.   
In light of our previous data revealing that FRNK expression markedly attenuated 
integrin-stimulated Rac1 activity, and mounting evidence that the Rac1 effector, PAK 
regulates ERK activity in vivo in an adhesion-dependent fashion, we examined whether PAK 
might be involved in regulating ERK activation in focal adhesions.  As shown in Figure 
2.2A, ectopically expressed GFP-PAK and phospho-ERK1/2 co-localize in membrane ruffles 
following PDGF-BB stimulation and co-localize within nascent focal adhesions following 
sphingosine 1- phosphate treatment when SMC are plated on fibronectin.  In addition, 
immunoprecipitation experiments revealed an adhesion-dependent association of endogenous 
ERK1/2 and PAK1 in SMC.  SMC were either continuously grown in serum (denoted A, for 
attached) or trypsinized and held in suspension (S) in serum free medium and/or plated on 
fibronectin (FN)-coated plates for the times indicated.  As shown in Figure 3.2B, association 
between PAK and ERK appears to peak after 60 min and surpasses the amount co-
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immunoprecipitated in stably adherent cells.  Very little of the PAK1-ERK complex was 
formed in non-adherent cells, as might be expected since activation of PAK is dependent on 
adhesion signaling (30).  Taken together, these data support the hypothesis that PAK1 and 
ERK1/2 associate in intact cells.   
Interestingly, we showed that a GST-PAK1 fusion protein containing the N-terminal 
290 amino acids of PAK1 could efficiently precipitate phosphorylated ERK1/2 from SMC 
lysates, indicating that the N-terminus of PAK is sufficient for ERK binding (Figure 3.3A).  
Subsequent experiments, in which ERK2 was precipitated from serum starved SMC or SMC 
treated with 20 ng/ml PDGF-BB for 10 min (to maximally activate ERK), revealed that 
phosphorylated (active) and un-phosphorylated (inactive) ERK2 are precipitated equally well 
with the PAK1 fusion protein (Figure 3.3B), indicating that pre-activation of ERK was not 
required for PAK1 binding. 
Previous studies have shown that Raf also binds to PAK, however the binding site for 
Raf is located within the C-terminus of PAK (in a region not included in our GST-PAK1 
construct), thus it was unlikely that ERK was precipitated by an indirect association with Raf 
and its binding partner MEK.  Nonetheless, a number of proteins have been shown to 
associate with the N-terminus of PAK, including the small GTPases Rac and Cdc42 and the 
adapter proteins NCK, GRB2, and PKL (31-33).  Therefore, to further rule out the possibility 
of an indirect ERK-PAK1 association, we used a Far Western approach.  We probed a 
membrane containing increasing amounts of GST-PAK1 fusion protein with purified His-
ERK2 protein and processed the membrane by Western blotting with an anti-His antibody.  
As shown in Figure 3.4A, purified His-ERK2 binds directly to GST-PAK1 in a 
concentration-dependent fashion.  In separate experiments, the binding of His-ERK2 to GST-
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PAK1 was also detected using ERK-specific antibodies (data not shown).  It should be noted 
that in most preparations of GST-PAK1-290, we observe the full-length product as well as 
one major putative cleavage product (Figure 3.4B).  Interestingly, His-ERK2 also readily 
associated with the presumptive cleavage product, but did not associate with GST alone 
(Figure 3.4C).  In order to identify the nature of the breakdown product, we isolated the full-
length band (denoted P1) and the cleavage product (denoted P2) from a Coomassie Blue-
stained polyacrylamide gel and submitted the bands for mass spectral analysis.  A 
combination of MALDI-TOF/TOF and LC-MS data revealed that P1 corresponded to GST 
fused to N-terminal amino acids 1-290 of PAK1 (as expected) while P2 corresponded to GST 
fused to PAK1 amino acids 1-55.  The PAK sequence from 1-55 of appeared to be sufficient 
for ERK2 binding, but the observation that ERK2 bound the larger 1-290 fragment slightly 
better (compare amounts precipitated with 0.5 μg fusion protein in 4A versus 4C) indicates 
that additional sites within the 56-290 region may also be important. 
 In order to further map the interaction site on PAK1 for ERK2, a membrane 
containing immobilized 12mer peptides derived from the amino acid sequence of PAK1 was 
incubated with purified His-ERK2 and subsequently probed with an anti-ERK2 antibody.  As 
shown in Figure 4D, interactions were detected in three distinct regions corresponding to 
amino acids 40-54 (site A), 86-94 (site B), and 124-138 (site C) of PAK1.  All three binding 
sites are within the autoinhibitory domain of PAK.  Site B is within the CRIB domain that is 
responsible for binding to Cdc42 and Rac while sites A and C flank this region.  Coupled 
with the result from the previous experiment, these data indicate that amino residues 40-54 
within PAK1 are sufficient for ERK2 binding, but that additional interactions within the 
CRIB domain and autoinhibitory domain may be required for a high affinity interaction.  
 71
Figure 3.1.  GFP-FRNK expression attenuates ERK activity in focal adhesions.  
SMC were transfected with GFP-FRNK and plated on fibronectin-coated chamber slides 
(10 μg/ml) for 90 min in the presence of serum.  Cells were fixed as described in 
Experimental Procedures and stained with an anti-phosphoErk antibody (Cell Signaling 
1:200) followed by a Texas Red-conjugated donkey anti-rabbit antibody (2μg/ml).  
GFP-FRNK was visualized by direct fluorescence.   
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Figure 3.2.  ERK1/2 and GFP-PAK1 co-localize and endogenous ERK1/2 and PAK1 
associate in SMC plated on fibronectin.  A. A7R5 cells were transfected with GFP-
PAK1 and plated on fibronectin-coated slides in serum free media.  After 45 min, cells 
were treated with PDGF-BB (20ng/ml) or sphingosine 1-phosphate (S1P; 1 μM) for and 
additional 45 min.  Endogenous pErk and ectopically expressed GFP-PAK1 co-localize in 
membrane ruffles and focal adhesions respectively as indicated by arrowheads.  B. Rat 
aortic SMC were either left attached (A), or trypsinized and held in suspension for 90 min 
(S) or plated on 40μg/ml fibronectin (FN) for indicated times.  Cells were lysed and 
endogenous ERK was immunoprecipitated (IP) using an anti-pERK1/2 antibody as 
outlined in Experimental Procedures.  Western blotting (IB) was performed with anti-
PAK1 and anti-ERK antibodies.  Bottom panels show a 5% lysate loading control for 
PAK1 and ERK1/2.  Data in Figure 3.2 are representative of three separate experiments.   
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Figure 3.3.  ERK precipitates from SMC cell lysate with GST-PAK1 fusion protein.  
SMC were serum starved for 4 hours before treatment with PDGF-BB (20ng/ml) for the 
times indicated.   Lysates were incubated with 30μg of purified GST-PAK1 (aa 1-290) for 
30 min and complexes were precipitated and analyzed by SDS-PAGE as described in 
Experimental Procedures.  A.  Western blotting was performed using an anti-
phosphoERK1/2 antibody (perk, top panel).  Middle and bottom panels represent a 10% 
lysate loading control for phospho-ERK1/2 and total ERK2, respectively.  B.  Pull downs 
were performed in triplicate for each time point. Western blotting was performed with an 
antibody recognizing total ERK1/2.  Data are representative of three to five separate 
experiments. 
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Figure 3.4.  ERK2 binds directly to N-terminus of PAK1.  A.  Indicated 
concentrations of immobilized GST-PAK1 (aa1-290) was electrophoresed, transferred to 
nitrocellulose, incubated with purified His-ERK2 protein, then probed with anti-His 
antibody as described in Experimental Procedures (Top).  Western blot was striped and 
reprobed with an anti-GST antibody to reveal the amount of GST-PAK1 loaded at the 
indicated concentrations (bottom).  B.  His-ERK2 (left), GST, and GST-PAK1 (right) 
proteins were purified as described in Experimental Procedures.  Proteins (5μg) were 
analyzed on a 12% SDS-acrylamide gel and stained with Coomassie Blue. Mass spectral 
analysis revealed that the higher molecular weight band in the GST-PAK1 lane (denoted 
P1) contains GST and aa 1-290 of PAK1 and the lower molecular weight band (denoted 
P2) contains GST and aa 1-55 of PAK1. C.  Far Western was performed as described 
above using GST or GST-PAK1 1-55 as bait and His-ERK2 as a probe.  The membrane 
was probed with anti-His antibody (Top) and then striped and reprobed with an anti-GST 
antibody to reveal the amount of GST and GST-PAK1 (aa 1-55) loaded at the indicated 
concentrations (bottom).  D.  PAK1 SPOT peptide membrane was blocked and incubated 
with purified His-ERK2 protein as described in Experimental Procedures. The membrane 
was probed with an anti-ERK antibody and binding was detected by chemiluminescence.  
Three binding sites were identified by chemiluminescence and labeled site A: aa 40-54, 
B: aa 86-94 and C: aa 124-138.  The first row of the grid contains 12 mar random control 
peptides and the remaining squares contain overlapping 12 mars derived from PAK1 
sequence.  Data in panels A-C are representative of at least three separate experiments.   
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Figure 3.5  PAK crystal structure.  The three identified binding sites are near (A) and 
within (B and C) the CRIB domain in the PAK N-terminus.  The crystal reveals that 
three binding sites (yellow box) form a docking site for ERK binding. 
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Interestingly, crystal structure analysis of the autoinhibitory domain of PAK1 (aa 70-149) 
revealed that sites B and C, which form a β-sheet and α-helix respectively, are in close 
proximity indicating that this region may provide a single docking site for ERK (34, Fig 3.5). 
Consistent with the idea that ERK makes multiple contacts within the PAK1 N-
terminus, a GST-PAK fusion protein with a deletion of aa 40-54 (GST-PAKdA) greatly 
reduces, but does not completely block PAK-ERK association (Figure 3.6A).  GST-PAKdA 
and GST-PAK(1-290) did however precipitate comparable amounts of Rac1 from SMC 
lysates, indicating that the tertiary structure of the CRIB domain in this deletion construct is 
likely intact (Figure 3.6A, bottom panel).  To determine the effect of the PAK-ERK 
interaction on ERK signaling, we generated a similar deletion (delta aa 40-54) in the context 
of full length GFP-PAK (GFP-PAKdA).  This mutation did not affect PAK localization to 
focal adhesions (data not shown).  We then co-transfected either GFP-PAK or GFP-PAKdA 
along with a serum-responsive element (SRE)- luciferase reporter construct and measured the 
activity of this ERK-dependent transgene.  In the presence of serum, GFP-PAK expression 
significantly enhanced SRE-LUC activity, whereas GFP-PAKdA expression did not (Figure 
3.6B).  These results indicate that PAK/ERK association is important for PAK-dependent 
ERK signaling.   
Since we mapped the binding site of ERK2 to the auto-inhibitory domain of PAK1, 
we reasoned that ERK binding to PAK might relieve auto-inhibition and activate PAK by a 
mechanism similar to that observed for Rac or Cdc42.  To address this question, we 
incubated purified kinase-defective ERK2 (KD-ERK2) with purified His-PAK1 and 
performed an in vitro kinase assay.  As shown in Figure 3.7, purified His-PAK1  
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 Figure 3.6.  PAK/ERK association is required for PAK-dependent ERK signaling.  
A. Equal amounts of pooled SMC lysate (500 μg) was incubated with either GST-PAK 
(25μg) or a GST-PAK variant lacking aa 40-54 (GST-DA, 25μg) and complexes were 
precipitated and analyzed by SDS-PAGE and Western blotting as described above (top 
panel).   A7r5 cells were transfected with Flag-L61 Rac, cells were lysed 48 hours post-
transfection, lysates were pooled and 500μg of protein was incubated with 25μg of GST-
PAK or GST-DA as described above.  Western blotting was performed with an anti-Flag 
antibody (bottom panel).  B. A7r5 cells were transfected 0.75μg SRE-luciferase reporter 
plasmid along with 0.25μg of either GFP-C1, GFP-Pak or GFP-PakDA. 48 hours post-
transfection, cells were lysed and analyzed for luciferase activity.  The inset shows 
equivalent expression levels of the GFP-PAK1 and GFP-PAKDA constructs.   Data was 
normalized to total cellular protein.  The graph represents means +/- S.E. of four separate 
experiments.  The single asterisk indicates significant increases from control GFP-
transfected cells (p<0.05). 
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Figure 3.7.  PAK1 does not phosphorylate ERK2 in vitro.  An in vitro kinase assay was 
performed with purified His-PAK1 (lanes 1-4), kinase-defective ERK2  (KD-ERK; lanes 
9-12) or both (lanes 5-8) in the presence of [γ32P]-ATP for 10min at 30 oC as described in 
Experimental Procedures.  Samples were examined by SDS-PAGE, and the gel was either 
dried and exposed to Kodak XAR imaging film for 2hr (top), or re-hydrated and stained 
with Coomassie Blue R-250 to reveal KD-ERK loading (bottom).  Data are representative 
of two separate experiments. 
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Figure 3.8.  ERK2 phosphorylates PAK1 on Thr212 in vitro.  A. Equal amounts of GST 
and GST-PAK1 (5μg) were incubated with purified active ERK2 (10 ng) and γ32P-ATP for 
10 minutes at 30 oC as described in Experimental Procedures.  Samples were analyzed by 
SDS-PAGE, the gel was either stained with Coomassie Blue R-250 (left) or dried and 
exposed to Kodak XAR film for 20 min (right).  B.  An in vitro kinase assay was performed 
as described above with equal amounts of GST, GST-PAK1 (WT), GST-PAK1 T212A 
(212A), GST-PAK1 S223A (223A) or GST-PAK1 T212A/S223A (212A/223A).  
Coomassie stained gel shows equal loading for each variant (left) and the autoradiograph 
reveals level of ERK2-stimulated phosphorylation (right). C. 0.3 μg of GST-PAK1 was 
incubated with (+) or without (-) active ERK2 (10 ng) and cold ATP (50μM) for 10 minutes 
at 30 oC as described in Experimental Procedures.  Samples were analyzed by SDS-PAGE, 
the gel was transferred to nitrocellulose and a Western blot was performed using an anti-
pT212 PAK1 antibody (top).  The membrane was stripped and re-probed using an anti-GST 
antibody (bottom) to reveal equal loading.  Data are representative of at least three separate 
experiments. 
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Figure 3.9.  PDGF-mediated Thr212 PAK1 phosphorylation in SMC is dependent on 
both ERK and adhesion signaling. A. SMC were serum starved and treated with PDGF-
BB (20ng/ml) for times indicated with or without a prior 30 min pretreatment with U0126 
(10 μΜ).  Cell extracts were prepared and samples were examined by Western blotting 
using anti-pT212 PAK1, anti-PAK1, anti-pERK1/2 and anti-ERK2 antibodies.  B.  SMC 
were either held in suspension (S) or plated on fibronectin for the indicated times or 
treated with 20ng PDGF-BB for 10 min after plating (+).  Western blotting was performed 
using anti-pT212 PAK1 and anti-PAK1 antibodies.  C. SMC were either held in 
suspension or plated on fibronectin for 90 min.  Cells were treated with PDGF-BB 
(20ng/ml) for the times indicated.  Western blotting was performed using anti-pT212 
PAK1 and anti-PAK1 antibodies. 
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Figure 3.10.  PDGF-BB-stimulated Thr212 PAK1 phosphorylation in SMC is not 
dependent on Cdc2/Cdk5 activity.  A. Serum starved SMC were pretreated for 3 hours 
with alsterpaullone (10μΜ) prior to PDGF-BB (20ng/ml) treatment for the indicated 
times. Samples were electrophoresed and Western blotting was performed with anti-
pT212 PAK1 (top panel) or anti-PAK1 antibodies (bottom panel).  B. Serum starved 
SMC were treated with PDGF-BB (20ng/ml) for times indicated.  Cell extracts were 
prepared and samples were examined by Western blotting using an anti-pTyrCdc2 
antibody.  Data are representative of at least three separate experiments. 
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Figure 3.11.  PAK1 Thr212 phosphorylation does not alter focal adhesion 
localization, formation or cell spreading.  A7r5 cells transfected with GFP-PAK, GFP-
PAKT212A or GFP-PAKT212E were trypsinized and plated on fibronectin-coated 
chamber slides (10μg/ml) for 1 hour as described in Experimental Procedures.  Cells were 
fixed, permeabilized and either observed by direct fluorescence (GFP, top panel) or 
stained with anti-vinculin or anti-paxillin antibodies to examine mature and nascent focal 
adhesions respectively, or phalloidin or anti-acetylated tubulin antibody to examine actin 
or tubulin polymerization.  Arrows indicate GFP-PAK1, GFP-PAK1 T212A or GFP-
PAK1 T212E expressing cells identified by direct fluorescence.  Data are representative of 
at least three separate experiments scoring 100-150 transfected cells for each treatment. 
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autophosphorylates in a concentration-dependent fashion, however titration of KD- ERK2 
(up to a 15-fold molar excess over PAK) into the reaction does not enhance PAK1  
autophosphorylation.  Actually, KD-ERK2 appeared to attenuate PAK activity at the higher 
concentrations (0.25-1 μg), but the significance of this inhibition is unclear.  This experiment 
also revealed that PAK1 does not phosphorylate ERK2 in vitro as evident by the lack of 
radioactivity incorporated into KD-ERK2. 
In terms of the reciprocal phosphorylation event, PAK1 contains two consensus sites 
for ERK phosphorylation, PVTP (T212) and PISP (S223) just downstream of the defined 
ERK2 binding site.  To determine whether ERK2 phosphorylates PAK1 directly, we 
performed an in vitro kinase assay in which a GST-PAK1 fusion protein containing the two 
putative phosphorylation sites (aa 1-290) was incubated with purified active ERK2 and γ32P-
ATP.  Figure 3.8A shows that the N-terminal GST-PAK1 fusion protein, but not GST alone, 
was efficiently phosphorylated by ERK2 in vitro.  Based on this observation, we mutated 
each of the consensus amino acids to alanine individually and in combination to determine if 
these sites were phosphorylated by ERK2 in vitro.  As shown in Figure 3.8B, the T212A 
mutation dramatically reduced ERK-mediated phosphorylation.  The S223A mutation had 
only a slight effect on its own or in combination with T212A.  To confirm these data, ERK2-
mediated phosphorylation of Thr212 was measured using a phospho-threonine 212-specific 
antibody.  Results shown in Fig 3.7C provide further evidence that PAK Thr212 is a major 
target for ERK phosphorylation. 
To determine whether Thr212 is phosphorylated by ERK in cells, we treated SMC 
with PDGF-BB for various times and examined the phosphorylation of PAK1 Thr212 
(pThr212) by Western Analysis.  As shown in Figure 3.9A, PDGF-BB stimulated a time-
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dependent increase in pThr212 that lagged slightly behind activation of ERK, with an 
observed peak in phosphorylation around 10 minutes (Figure 3.9A).  Pretreatment of SMC 
with the MEK inhibitor, UO126, almost completely blocked PDGF-BB-stimulated PAK1 
phosphorylation, indicating that this response is mediated by ERK signaling.  Interestingly, 
although adhesion signaling can stimulate association between ERK and PAK, plating on 
fibronectin alone for 30-90 min is not sufficient to induce pThr212 (Figure 3.8B).  
Nonetheless, adhesion is required for PDGF-BB stimulated pThr212, since PDGF-BB 
treatment of SMC held in suspension did not alter pThr212 levels (Fig 9C). 
Recent reports demonstrated that Cdc2/Cdk5 can phosphorylate PAK1 Thr212 in a 
cell cycle-dependent manner (35-38).  To rule out the possibility that these cyclin-dependent 
kinases are involved in PDGF-BB-stimulated Thr212 phosphorylation, we exposed SMC to 
the Cdk1 inhibitor alsterpaullone prior to PDGF-BB stimulation and examined the level of 
Thr212 phosphorylation.  As shown in Figure 3.10A, the cyclin-dependent kinase inhibitor 
did not diminish Thr212 phosphorylation.  Interestingly, PDGF-BB inhibited Cdc2/Cdk5 
activity in SMC as measured by the inhibitory phosphorylation of Cdc2-Tyr15 (Figure 
3.10B) further suggesting that adhesion-dependent agonist-stimulated phosphorylation of 
PAK1 Thr212 in SMC is dependent upon ERK and not Cdc2/Cdk5.    
Irrespective of the kinases involved, phosphorylation of PAK1 Thr212 has been 
implicated in the regulation of post-mitotic cell spreading and microtubule organization (35-
37).  In addition, phospho-ERK1/2 and PAK1 co-localize in focal adhesion structures in 
SMC, so we hypothesized that PAKT212 phosphorylation might regulate focal adhesion 
formation.  To this end, we transfected GFP-tagged variants of PAK1 including a non-
phosphorylatable Thr212 (T212A) and one that mimics phosphorylation, T212E, into A7R5 
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SMC that were then plated onto fibronectin for 20-90 minutes.  No change in the rate of cell 
spreading was observed between GFP-PAK1, GFPPAKT212A, or GFP-PAKT212E 
expressing cells (data not shown).  Furthermore, each of the variants localized in focal 
adhesions and had no effect on the organization of nascent or mature focal adhesions as 
assessed by paxillin and vinculin staining, respectively.  Organization of actin microfilaments 
and acetylated tubulin were also indistinguishable between wild type GFP-PAK1 and the 
phosphorylation variants (Figure 3.11).   
Because PAK potentiates ERK activation, we sought to determine whether 
PAKThr212 phosphorylation might regulate ERK-PAK association and/or ERK-dependent 
signaling.  GST-PAK, GST-PAK pre-treated with purified active ERK2 and γ32P-ATP, and 
GST-PAKT212E each precipitated similar amounts of ERK from SMC lysates, indicating 
that pT212 does not attenuate ERK-PAK association (data not shown).  To determine the 
possible effects of T212 phosphorylation on downstream signaling, we examined the effect 
of GFP-PAK and GFP-PAK T2312E expression on transactivation of the ERK-dependent 
SRE- luciferase reporter gene.  As shown in Figure 3.12, in contrast to GFP-PAK which 
stimulated serum-induced luciferase activity, GFP-PAK T212E expression markedly 
attenuated this response.  Based on the observations presented in this report, we hypothesize 
that Rac-dependent adhesion signaling activates PAK and induces an association between 
PAK and components of the ERK signaling cascade to facilitate ERK signaling, and that 
subsequent growth-factor stimulated phosphorylation of PAKT212 by ERK may serve to 
provide a negative feedback signal to control coordinate activation of ERK by growth factor- 
and matrix-induced signals (see Figure 3.13).   
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Figure 3.12.  Thr 212 phosphorylation suppresses SRE activation.  A7r5 cells were 
transfected with an SRE-luciferase reporter plasmid along with either GFP-C1 vector 
control, GFP-PAK1, or GFP-PAK212E.  48 hours following transfection, cells were lysed 
and analyzed for luciferase activity as described in Experimental Procedures.  The inset 
shows equivalent expression levels of the GFP-PAK1 and GFP-PAK212E constructs.   
Data was normalized to total cellular protein.  The graph represents means +/- S.E. of four 
separate experiments.  The single and double asterisks indicate significant increases or 
decreases from control GFP-transfected cells respectively (p<0.05). 
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Figure 3.13.  Adhesion-dependent PAK-ERK association facilitates ERK-signaling.  
Numerous extrinsic factors stimulate Ras activity and thereby initiate activation of the 
canonical Raf/Mek/Erk cascade wherein Raf phosphorylates Mek on serines 218 and 222, 
then Mek phosphorylates Erk on Thr202 and Tyr204 (green arrows).  Adhesion signaling 
through Focal Adhesion Kinase (FAK) activates the smGTPase Rac1, which binds to CRIB 
domain of Pak1, enabling Pak1 activation.  Our studies reveal that activated PAK associates 
with ERK through N-terminal sequences and past studies reveal that C-terminal sequences 
of Pak direct an interaction with Raf and mediate phosphorylation of Raf on serines 338 and 
339 (yellow arrow).  Although Mek has not been demonstrated to interact in a direct fashion 
with Pak, PAK can phosphorylate Mek on Ser282 (yellow arrow) and enhance association 
between Mek and ERK.  Each of these events facilitates ERK-dependent signal 
transduction.  Following growth factor stimulation, ERK phosphorylates PAK on Thr 212 
resulting in a negative feedback loop to depress downstream signaling (red arrow). 
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DISCUSSION 
PAK kinases regulate various cellular processes such as proliferation, migration, 
contraction, and apoptosis.  PAK1 is a Rac/Cdc42 effector that coordinates actin-based 
cellular protrusions, an important step in persistent directional migration (39,40).  Recent 
studies reveal that PAK1 activity is also essential for maximal activation of the mitogenic 
Raf/MEK/ERK cascade (40).  Indeed, PAK can synergize with Ras to activate Raf and can 
synergize with MEK to activate ERK (5,14,17,18,20-22).  Herein we report that ERK2 
associates with PAK1 in an adhesion-dependent manner through sites mapped within the N-
terminal auto-inhibitory domain of PAK.  In addition, we show that a PAK deletion variant 
that does not readily associate with ERK has a reduced capacity to enhance ERK-dependent 
transactivation of an SRE-reporter construct.  These data are consistent with previous 
findings that adhesion-dependent Rac activation is required for efficient accumulation of 
active ERK in the nucleus (41,42).  The ability of PAK to bind (and phosphorylate) Raf, 
phosphorylate MEK and, as demonstrated in this study, bind to ERK, indicates that PAK 
may serve as a scaffold to recruit members of the Raf/MEK/ERK complex to focal adhesions 
and subsequently facilitate signaling through the ERK pathway.    
In yeast, Ste5, which regulates activation of the Fus3 MAP Kinase mating pathway is 
a classic example of a high fidelity signaling scaffold, because it interacts with each member 
of the cascade (Ste20, Ste11, Ste7, and Fus3) (43,44).  To date, a protein that acts in an 
analogous fashion to Fus3 in the ERK cascade has not been identified.  However, Kinase 
Suppressor of Ras (KSR) and MEK- binding partner 1 (MP-1) are putative ERK scaffolding 
molecules because they bind directly to both MEK and ERK (specifically MEK1 and ERK1 
in the case of MP-1) (45,46).  Herein, we have shown that PAK (the Ste 20 homologue or 
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MAP4K of the ERK pathway) interacts with ERK2 through a region within the N-terminal 
auto-inhibitory domain.  Because PAK has also been shown to interact with Raf within 
sequences in the C-terminus, it may serve as an additional potential scaffold for the ERK 
cascade.  Even though there is no evidence of a direct PAK-MEK interaction, it has been 
shown that upon Raf binding to the C-terminus of PAK, MEK becomes phosphorylated at 
S298, a site required for maximal MEK activation (14,18).  Furthermore, Slack-Davis et. al. 
showed that adhesion induces PAK-dependent phosphorylation of MEKS298, and Elben et. 
al. have shown that PAK activation was required for adhesion dependent association of 
MEK1 with ERK (21,22).  Based on these reports, is possible that PAK1 could function to 
target Raf, MEK and ERK to nascent focal adhesions to impart restricted activation of the 
ERK cascade at the leading edge of the cell during migration.   
We identified three distinct ERK2 binding sites that mapped within the N-terminal 
autoinhibitory domain of PAK1: aa40-54, aa86-94 and aa124-138 (denoted A, B and C 
respectively).  Although the reported crystal structure of the complex between the N-terminal 
autoregulatory fragment (aa 70-149) and the C-terminal kinase domain (aa 249-545) of 
PAK1 does not contain the most proximal A binding site, the structure reveals that the β-
sheet comprising the “B” binding site packs tightly against the α-helix comprising the “C” 
binding site, indicating that the binding sites for ERK2 that we defined may indeed constitute 
a single binding pocket within PAK1.  Interestingly, the “A” binding site in PAK1 which we 
have shown is sufficient for ERK binding does contain a cluster of basic residues similar to 
the “D-domain” found in other ERK binding partners including MEK, MAPK phosphatase, 
and ribosomal S6 kinase (47,48).  This motif has been shown to function independently 
(47,48), corroborating our Far Western data revealing that PAK aa 1-55 was sufficient for 
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directing the ERK2-PAK1 interaction and our findings that a GST-PAK fusion protein with a 
deletion of aa 40-54 had a markedly reduced capacity to precipitate ERK from SMC lysates 
compared to the full N-terminal construct.  Future mutagenesis experiments will aid in 
determining the relative contribution of the defined sites to direct high affinity binding to 
ERK.  Notably, the 12 amino acid core of each of the defined binding sites in PAK1 are 
highly conserved across the Group I PAK family members (100%, 100%, and 75% identical 
for A, B and C respectively) thus it is likely that ERK may interact with PAK2 and PAK3 as 
well as PAK1.  In fact, a recent report by Shin et. al. highlights the possibility that ERK1 and 
PAK2 may indeed associate in cells in a FGF-dependent fashion as determined by co-
immunoprecipitation (49).  In addition, the authors reported that a GST-ERK1 fusion protein 
could precipitate exogenously expressed PAK2 from cell lysates, although a direct 
association between the two proteins has yet to be demonstrated (49). 
The location of the ERK2 binding site indicates the likelihood that ERK association 
with full-length PAK in vivo may require pre-activation of PAK by Rac and/or Cdc42.  
Recent structural studies have indicated that the inactive autoinhibited conformation of 
PAK1 is an asymmetric dimer whereby the auto-inhibitory domain of one molecule 
associates tightly with the kinase domain of another (34).  Binding of GTP-loaded Cdc42 or 
Rac with the CRIB domain disrupts the dimer, unfolds the protein, and exposes the auto-
inhibitory domain allowing for subsequent protein-protein interactions (34).  Indeed, the 
association of PAK1 and ERK following cell adhesion mimicked the time course we 
observed for Rac activation following plating cells on fibronectin (23).  Thus, it is possible 
that recruitment of ERK to PAK may be dependent on integrin-dependent Rac activation.   
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We also show that adhesion-dependent association of PAK and ERK can provide an 
additional means of regulation by driving phosphorylation of PAK by ERK.  The time course 
of PAK1 phosphorylation, inhibition of phosphorylation by UO126 and the fact that ERK2 
directly phosphorylated PAK1 in vitro on the same site that is also phosphorylated after 
PDGF-BB treatment of SMC all support the possibility that PAK1 is an in vivo substrate for 
ERK.  Interestingly, although the data presented in this report are consistent with T212PAK 
being an in vivo target for ERK in SMC, other reports have clearly shown that Thr212 is also 
a target for Cdc2/Cdk5 in cells undergoing mitosis (35-38).  Two lines of evidence rule out 
the possibility that PAK1 is a target for Cdc2/Cdk5 following PDGF-BB-treatment of SMC.  
First, pre-treatment of SMC with alsterpaullone (a potent pharmacological inhibitor of 
Cdc2/Cdk5) had no effect on PDGF-BB-stimulated Thr212 phosphorylation, whereas 
treatment with the MEK inhibitor U0126 almost completely inhibited the response.  Second, 
PDGF-BB-treatment of SMC caused a phosphorylation-dependent inactivation of Cdc2, 
similar to what has been reported following ERK activation in Xenopus extracts (50).  Thus, 
at least in the context of adhesion-dependent growth factor signaling, phosphorylation of 
PAK1 in SMC appears to be directed by ERK and not Cdc2/Cdk5. 
Unlike the ERK2 binding sites that are conserved in PAK1-3, Thr212 is unique to 
PAK1.  This consensus site is however conserved in all mammalian forms of PAK1, 
indicating that phosphorylation of the site may regulate an important function.  Notably, a 
previous detailed temporal analysis of pThr212 in vivo revealed that high levels were 
observed in the embryonic forebrain, lung, kidney, intestine, and skin, but that pThr212 was 
virtually undetectable in adult tissues (51).  In terms of function, previous studies indicate 
that the kinase activity of the PAK1 variants T212A and T212E were indistinguishable from 
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wild type PAK1 (36).  Previous reports also indicate that Cdc2-mediated pT212 altered the 
rate and extent of postmitotic spreading of murine fibroblasts (37) and regulated microtubule 
dynamics and overall morphology in neurons (35,36).  We show herein that ectopic 
expression of PAKT212A or PAKT212E in SMC did not alter focal adhesion formation, 
microtubule formation, or the rate of cell spreading, although the consequence of PAK1 
phosphorylation on focal adhesion turnover or directed cell migration has yet to be 
determined.  However, PAKT212E did attenuate serum-stimulated ERK-dependent 
transcription, indicating that phosphorylation of this site might provide a negative feedback 
inhibition to limit adhesion and growth factor-stimulated ERK signaling.  The precise 
mechanism of this inhibitory response is not yet clear.  We have determined that pThr212 
within the context of GST-PAK1 (1-290) does not alter the association of ERK and PAK in 
vitro, indicating that ERK can still bind pT212PAK.  However, Thr212 is located within the 
core of a canonical SH3-binding motif, thus it is feasible that phosphorylation of this site 
could modulate association with a binding partner that could in turn regulate ERK 
phosphorylation or nuclear translocation.  Experiments to address this question are presently 
underway. 
In summary, we have shown that ERK2 binds within the N-terminus of PAK1 and 
when activated by adhesion-dependent growth factor signaling, phosphorylates PAK1 on Thr 
212.  Our present data, together with previous reports that illustrate a role for PAK in the 
regulation of the ERK cascade, indicate that PAK1 may function as a scaffold for this 
canonical pathway.  Why would the ERK pathway require so many scaffolds?  One possible 
explanation may be that scaffolding controls local activation of this seemingly promiscuous 
pathway.  For example, KSR has been shown to shuttle from the cytoplasmic membrane to 
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the plasma membrane following growth factor treatment, and p14, a partner of the putative 
scaffold, MP1, targets MP1-MEK1 and ERK1 to late endosomes/lysosomes (52-54).  In the 
case of PAK, association of the complex could lead to the targeting of active ERK to focal 
adhesions.  Since association of ERK with PAK may be dependent on adhesion-induced 
activation of Rac, one might speculate that adhesion-stimulated PAK-dependent targeting of 
ERK to these dynamic sites might regulate directional lamellipodial extension during cell 
migration.  Notably, studies have shown that ERK activation enhances focal adhesion 
turnover by enhancing the rate of focal adhesion disassembly (55).  This effect could be due 
to the ability of ERK to phosphorylate and regulate several focal adhesion proteins such as 
paxillin, MLCK, and calpain II (56-58).  We have also shown that coordinate signaling 
through adhesion and growth factors regulates phosphorylation of PAK on Thr212, and 
provide evidence that this event may decrease subsequent ERK-dependent signaling.  It is 
likely that ERK signaling would have to be tightly regulated in a temporal fashion in order 
for directed cell migration to occur, thus negative feedback phosphorylations such as Thr 212 
may prove important in controlling this dynamic cellular process.   
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Chapter IV 
Inactivation of focal adhesion kinase promotes smooth muscle cell differentiation:  A role for 
the nuclear shuttling of the LIM protein, leupaxin.3
                                                 
3 To be submitted as: Liisa J. Sundberg-Smith, Lee E. Mangiante, Hilary E. Beggs, Louis F. Reichardt4, 
Christopher P. Mack, and Joan M. Taylor.  Inactivation of focal adhesion kinase promotes smooth muscle cell 
differentiation:  A role for the nuclear shuttling of the LIM protein, leupaxin.  Mol Cell Biol 
 
 
ABSTRACT 
Smooth muscle cell (SMC) differentiation is a dynamic process that must be tightly regulated 
for proper vascular development and to control the onset of vascular disease.  Extensive 
studies indicate that autocrine factors and extracellular matrix (ECM) are critical co-
regulators of vascular SMC growth and differentiation during development and following 
vessel injury.  The non-receptor tyrosine kinase, Focal Adhesion Kinase (FAK) is strongly 
activated by integrin/matrix interactions and growth factor receptor engagement, and the 
observation that fak-/-, fibronectin-/-, and α5-/- mice die between E8.5-10 with notable defects 
in vessel integrity suggests that FAK plays an important role in vascular maturation.  Herein, 
we found that deletion of FAK in SMC enhanced TGF-β-stimulated SM marker gene 
expression, but did not affect PDGF-BB or EGF-stimulated proliferation.  These data suggest 
that enhanced FAK activity limits SM differentiation and that tight regulation of FAK 
activity is likely important for proper SMC phenotypic modulation during development and 
following vascular injury.  We identified leupaxin as a binding partner for FAK in SMC and 
show that leupaxin is enriched in SMC, leupaxin associates with SRF, and that leupaxin 
enhances SRF-dependent expression of SM marker genes.  In addition, we show that 
leupaxin undergoes focal adhesion-nuclear shuttling and that FAK activity attenuates the 
nuclear accumulation of this LIM domain containing SRF co-factor.  Our data indicate that 
sequestration of leupaxin to focal adhesion plaques is one mechanism by which activated 
FAK might limit SMC marker gene expression and we suggest the possibility that extrinsic 
signals may regulate the SMC gene profile by modulating the activation state of FAK.   
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INTRODUCTION 
The investment of newly formed endothelial cell tubes with differentiated SMC is a 
very important process during vascular development and requires intricate regulation of SMC 
motility, growth, and differentiation. Mature medial SMC express high levels of the SMC 
differentiation marker genes (ie. myosin heavy chain (SM-MHC), SM α-actin, SM22α 
among others) that contribute to the regulation of SMC contractility (see [4] for review). 
SMC never terminally differentiate and can transition to synthetic phenotype characterized 
by low levels of SMC contractile gene expression and responsiveness to pro-growth and 
migratory signals.  This unique plasticity is critical for proper vessel development, blood 
pressure homeostasis, and injury repair (1), but can also contribute to the development of 
various vascular pathologies, including atherosclerosis, restenosis, and vascular hypertrophy 
following vein bypass grafts (2).  Thus, defining the signaling mechanisms that regulate 
SMC growth and differentiation will be important for understanding the processes that 
modulate vascular development and is critical for the design of agents that might regulate 
aberrant SMC responses in diseased vessels. 
The transcription mechanisms that regulate SMC differentiation are starting to 
become clear.  Serum response factor (SRF) binding to conserved CArG (CC(A/T)6GG) 
promoter elements is required for the expression of most SMC differentiation marker genes.  
It is well known that SRF activity is regulated through interactions with additional cell-type-
selective and ubiquitous transcription factors, and the potent SRF co-factors of the myocardin 
family are particularly important activators of SMC-specific gene expression. Interestingly, 
several LIM domain proteins including CRP1, CRP2, and FHL2 interact with SRF to 
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regulate SMC differentiation marker gene expression [4, 89, 90, 114] most likely by altering 
SRFs interactions with additional transcription factors. 
 The identification of the signaling pathways that regulate SMC-specific transcription 
mechanisms will be very important for our understanding of the control of SMC phenotype. 
TGF-β, which promotes SMC differentiation [97-99], and PDGF-BB, which promotes 
phenotypic modulation, are important regulators of SMC phenotype and genetic ablation of 
these genes resulted in defective vasculogenesis (12, 13). TGF-β-mediated nuclear 
localization of SMAD2 and SMAD3 can stimulate SMC-specific transcription [99, 101, 
104], and a TGF-β control element (TCE) has been identified in a number of SMC-specific 
promoters. Several studies have also shown that SMADs interact with SRF, myocardin, and 
p300 to enhance SMC-specific transcription [102, 103]. PDGF-BB stimulates SMC 
proliferation by activating Ras/ERK signaling, and this pathway can also limit SMC 
differentiation by competitive inhibition of myocardin-SRF binding by the ERK-activated 
TCFs. 
Extensive evidence indicates that extracellular matrix signaling is also an important 
regulator of SMC growth and differentiation. Enhanced levels of medial fibronectin (FN) 
(which supports proliferation) are produced early in the developing vasculature, whereas the 
basement membrane components collagen type IV and laminin (which promote 
differentiation) are more prominent in the mature vessel 13,14.  In addition, deletion of either 
FN, the α5 integrin FN receptor, or focal adhesion kinase (FAK) (the kinase that mediates 
α5-dependent signaling) each results in extraembryonic and embryonic vessel defects 
leading to lethality in the mouse from E8.5 to E10 18,19 [53]). 
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Although a direct role for FAK in vascular smooth muscle growth and development 
has yet to be examined, FAK is known to play critical role in matrix signaling by supporting 
the formation of multi-protein signaling complexes that lead to downstream activation of a 
number of signaling molecules that been previously implicated in the regulation of SMC 
phenotype including ERK, JNK, and the small GTPases, Rac and Rho [146].  Importantly, 
our lab has recently showed that FAK activity is regulated by the SMC-specific expression of 
FRNK (FAK-Related Non Kinase), a carboxyterminal variant of FAK that acts as an 
endogenously expressed dominant negative. While FAK protein levels remained relatively 
constant during vascular development, FRNK expression in SMC is significantly increased in 
the post-natal period and two to three weeks following vessel injury [147].  These results 
suggest that FAK activity is tightly controlled in SMC especially during the transition from 
the synthetic to contractile phenotype.  
The aim of the present study was to determine whether FAK activation plays a direct 
role in the phenotypic modulation of SMC. We present evidence that FAK deletion (by 
homologous recombination) in SMC enhances TGF-β stimulated differentiation but does not 
effect cell survival or PDGF-mediated SMC growth.  Our data also indicate that the effects of 
FAK on SMC phenotype are mediated, at least in part, by regulating the cytoplasmic-nuclear 
shuttling of the LIM protein leupaxin, which interacts with SRF to enhance SMC 
differentiation marker gene expression.  These data highlight the possibility that extrinsic 
signals can regulate the SMC gene profile by modulating the activation state of FAK.  
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MATERIALS AND METHODS 
Antibodies and Reagents: 
The phospho-specific ERK1/2 antibody was purchased from Cell Signaling.   The anti-Flag 
(M2), anti-vinculin and SMα-actin antibodies, and leptomycin B were purchased from 
Sigma.  PP2, PDGF-BB and TGF-β were purchased from Calbiochem.  The N-term specific 
anti-FAK antibody, C-term specific anti-FAK antibody, and anti-ERK2 antibody were 
purchased from Upstate.  The anti-phospho Y397FAK antibody was purchased from 
BioSource and the Texas-Red phalloidin was purchased from Molecular Probes.  The anti-
GFP antibody was purchased from Clontech. The anti-leupaxin antibody was a generous gift 
from Dr. Don Staunton, ICOS. Ad5CMV Cre Adenovirus was purchased from the University 
of Iowa Gene Transfer Vector Core, and Ad5CMV LacZ adenovirus was purchased the 
University of North Carolina-Chapel Hill Viral Core.  Both viruses were expanded using 
Puresyn’s Adenopure adenovirus purification kit according to manufacturer’s protocol.   The 
Pyk2 antibody  was purchased from Cell Signaling.  
 
Constructs: 
Leupaxin and Hic5 human cDNA clones were purchased from Open Biosystems. Leupaxin 
was directionally cloned into the Flag vector using EcoRI and Xho1.  To generate GFP-
leupaxin, Flag-leupaxin was cut with EcoRI and XbaI and directionally cloned into the GFP-
C1 vector (Clonetech).  Murine Flag-Trip6 was a generous gift from Mary Beckerle 
(University of Utah).  The promoter reporter constructs: SM α-actin (from -2560 to +2784), 
SM22 (from -450 to +88) and SM-MHC (from -4200 to +11600) and SM α-actin mutant 
luciferase constructs used have been previously described [148 1568].  Flag-FAK, Flag- 
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FAKY397F and Flag-FRNK were a generous gift from Dr. Tom Parsons (University of 
Virginia) and were previously described [149]. PBSK-SuperFAK was a generous gift from 
Dr. Michael Schaller (University of North Carolina, [150]).  To generate Flag-SuperFAK, 
PBSK-SuperFAK was cut with BamHI and Xho1 and directionally cloned into the Flag 
vector. GST-FAK variant constructs were generated as previously described [151].   
 
Cell Culture and Agonist Treatment  
Aortic smooth muscle cells were isolated from either Wistar Rats or fakflox/flox mice, a 
generous gift from Dr. Louis Reichardt and Dr. Hilary Beggs, UCSF.  In brief, thoracic 
aortas were stripped of the endothelial and adventitial layers by microdissection.  The SMC 
in the media were isolated by enzymatic digestion in buffer containing trypsin and 
collagenase as previously described [152].  Each of our preparations are routinely tested for 
expression of smooth muscle-specific markers (by immunohistochemistry) and the ability to 
drive smooth muscle specific expression of reporter constructs.  Only the cell lines that are 
deemed at least 85% pure by these measurements are utilized for further experimentation.  
Cells are grown in DMEM: F12 (1:1) supplemented with 10% FBS and 1% penicillin-
streptomycin and are used between passages 5 and 18.   10T1/2 cells (ATCC) were 
maintained in DMEM plus 10% fetal bovine serum and 1% penicillin-streptomycin. Human 
coronary SMC (Cambrex) were maintained in Clonectics SmGM media containing 5% FBS, 
insulin, hEGF, hFGF and gentamicin.   
 
 
 
 101
 Promoter Assays: 
Cells were transfected using either Superfect (Qiagen) or Trans-IT (Mirus) transfection 
reagents according to manufacturer’s protocol.  Luciferase activity was detected by the 
Steady-Glo luciferase assay reagent (Promega). 
 
Western Blotting: 
Western blots were performed using the appropriate antibodies at a 1/1000 dilution. Blots 
were washed in TBST (TBS plus 0.05% Triton-X), followed by incubation with either horse-
radish peroxidase conjugated- rabbit anti-mouse antibody or - Protein A sepharose 
(Amersham) at a 1/2000 dilution.  Blots were visualized after incubation with 
chemiluminscence reagents (ECL, Amersham). 
 
GST-Pulldown Assays: 
GST-FRNK was purified from bacterial lysates using gluathione-agarose beads (Pharmacia) 
as described previously [153].  hCSMC were lysed in RIPA (50 mM Hepes, 0.15 M NaCl, 2 
mM EDTA, 0.1% Nonidet P-40, 0.05% sodium deoxycholate, pH 7.2) containing 1 mM 
Na3VO4, 40 mM NaF, 10 mM Na2 pyrophosphate, 100 µM leupeptin, 1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride hydrochloride, 0.02 mg/ml soybean trypsin inhibitor, 
and 0.05 trypsin inhibitory units/ml aprotinin  and 500μg of protein was combined with 10μg 
of GST, GST-CTII, GST-CTI or GST-CTIm fusion protein and rotated for 60 min at 4oC. 
The beads were then washed twice with the lysis buffer and once with Tris-buffered saline 
(TBS, 0.2 M NaCl, 50 mM Tris-HCL, pH 7.4).    The beads were resuspended in SDS-PAGE 
sample buffer, boiled for 5 min, electrophoresed on an 11% SDS-polyacrylamide gel, and 
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analysed by Western blotting using either an anti-leupaxin (1:1000) or anti-GST antibodies 
(1:10,000).  To generate GST-leupaxin, a 3’ Sma1 site was inserted into GFP-leupaxin by 
PCR and was then cut with EcoR1 and Sma1 and was directionally cloned in the PGEX 
vector (clontech).  Flag-SRF was in vitro translated with S-35 using TNT T7 translational kit 
(Promega) according the manufacturer’s directions.  Translation reaction was diluted 1:10 in 
lysis buffer and rotated with 30ug of either GST or GST-leupaxin beads for 1 hr, washed 4 
times with lysis buffer and then boiled for 5 minutes.  Samples were electrophoresed on a 
10% SDS-polyacrylamide gel and exposed to film. 
 
Immunoprecipitation Assays 
Cos-7 cells were transfected with FL-SRF and GFP-Leupaxin DNA (7.5μg each) for 48 hrs. 
using Mirus Transfection Reagent according to manufacturer’s protocol. Cells were then 
lysed in RIPA plus inhibitors.  5μg of antibody (Flag:M2 or GFP) was incubated with 500μg 
of protein for 2 hrs and then rotated overnight with either Protein-A Sepharose (PAS) beads 
(Sigma) or precoupled Rabbit anti-Mouse PAS beads.  Beads were washed three times with 
RIPA plus inhibitors and once with 1x TBS and then Complexes were electrophoresed on an 
11% SDS-polyacrylamide gel and western blotting was performed with either anti-Flag or 
anti-GFP (both 1:1000) antibodies. 
Immunocytochemistry: 
Cells were processed for immunocychemistry using previously published methods [147]. In 
brief, cells were fixed with 4% paraformaldehyde, permeabilized with 4% Triton X-100 in 
PBS, incubated with specified primary antibodies for 1 hour at the following concentrations: 
anti-vinculin (1:1000), anti-FAK (N-term 1:250), or anti-leupaxin (1:300) Abs.  After 
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washing with PBS, slides were incubated for 1 hour with Texas Red-conjugated donkey anti-
mouse antibodies (2μg/ml) or Texas Red-conjugated phalloidin to detect filamentous actin. 
 
Chromatin immunoprecipitation Assays: 
HCSMC were cross-linked for 20 min with 37% formaldehyde.  Cells were was once with 
cold PBS and then lysed in PBS and spun for 5 min at 1500rpm. Pellets were lysed in Chip 
lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-HCL plus aprotinin, leupeptin and 
pepstatin) on ice for 10 min. DNA was sheared by sonication (10 pulses 20 times). 100μg of 
DNA was immuprecipitated with 5μg Leupaxin Ab along HS-RαM-PAS beads (precoupled) 
overnight.  Beads were washed twice with Abcam CHIP wash buffer (.1% SDS, 1% triton X-
100, 2mM EDTA pH 8.0, 150mM NaCl, 20mM Tris-HCl), once with  Promega LiCl 
Immune Complex Wash Buffer (.25M LiCL, 1% NP-40, 1% deoxycholate, 1mM EDTA  pH 
8.0) and one time with Abcam Final Wash buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA 
pH 8.0, 500 mM NaCl, 20mM Tris-HCl).  Complexes were eluted with Elution buffer (1% 
SDS, 100mM NaHCO3 ) for 15min at RT and then reverse-crosslinked overnight with 16μl 
5M NaCl and 5μl Proteinase K (20mg/ml) at 65oC.  DNA was purified using 
Phenol:Chloroform.  PCRs were performed with the following primers: SMA 5’ 
CAGTGGATGCAGTGGAAGAGACCAGGC, 3’ 
CCTCCCACTTGCTTCCCAAACAAGGAG, SM-MHC 5’ 
CCACTCGGCACCATATTTAGTCAGGGGAGA, 3’ 
CGGGCGGGAGACAACCCAAAAAGGGCAGG. c-fos specific primers were used 
according to previous published reports (owens, jci) PCR products were separated on a 2% 
agarose gel.  
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RESULTS 
To examine the role of FAK in SMC, aortic SMC were isolated from fakflox/flox mice 
[57] using standard procedures and were infected with either a Cre-expressing virus (FAK 
null) or a Lac-Z expressing adenovirus (control).  Incubation of fakflox/flox SMC with Cre 
adenovirus for 72 hr resulted in a significant depletion of FAK protein, while levels of 
FRNK, and the FAK homologue, Pyk2 were not significantly affected (Fig 4.1A).  
Importantly, the FAK-null SMC maintained a well spread phenotype and exhibited similar 
organization of vinculin-containing focal adhesions and actin filament distribution when 
compared to FAK-containing control SMC (Fig 4.1B).   
Since FAK has been shown to be a major regulator of mitogenesis in a variety of cell 
types, we first tested its effects on SMC proliferation.  As shown in Figure 4.2A, FAK was 
not required for SMC growth with control and FAK-null cells demonstrating similar growth 
rates under serum-free conditions and in cells stimulated with PDGF-BB and EGF.  
Accordingly, mitogen-stimulated ERK activity and cyclin D protein levels were similar in 
Cre- and LacZ- treated cells (Fig 4.2B, 4.2C), indicating that FAK was not required for 
activation of the major mitogenic Ras/ERK signaling pathway.  Consistent with our findings 
that deletion of FAK was well tolerated, we observed no significant difference in cell 
survival as measured by caspase 3/7 activity (Fig 4.2D). FAK-null SMC did exhibit a marked 
decrease in PDGF-BB-stimulated chemotaxis, an event likely due to impaired lamellipodial 
stability in these cells (manuscript in preparation).    
To determine whether FAK deletion had a deleterious effect on other focal adhesion 
components, we examined the expression levels of paxillin and vinculin in LacZ- and Cre-
treated SMC maintained in 10% serum. While paxillin levels were similar between FAK-null 
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and control SMC, we observed a consistent increase in vinculin levels in FAK-null SMC (Fig 
4.3A), a finding that supports previous studies in FAK-null mouse embryo fibroblasts (31).  
Since vinculin is a well-known SRF-target gene, we hypothesized that other SRF-dependent 
SMC differentiation marker genes would also be up-regulated in the FAK-null SMC.  
Indeed, SM-MHC levels were also significantly enhanced in FAK-null SMC (Fig 4.3A).  We 
next serum starved the SMC and asked whether TGF-β-induced SM marker gene expression 
was altered in FAK-null SMC.  As shown in Fig 4.3B, TGF-β induced a more marked up-
regulation of SM α-actin protein levels in the Cre-treated compared to LacZ treated SMC.  
To test whether this effect was due to enhanced SMC-specific transcription, we also 
examined the responsiveness of an SM22 promoter/luciferase reporter. As shown in Figure 
4.3C, SM22 activity in control SMC was induced 2-fold by TGF-β, but by 10-fold in FAK-
null cells.  A similar enhancement in TGF-β induced expression of the SM α-actin and SM-
MHC promoters was also observed in FAK-null SMC (Fig 4.3C middle, bottom panels).  To 
test the possibility that FAK inactivation enhanced TGF-β-mediated SMAD activation, we 
measured the phosphorylation of Smad 2 and Smad 3 in control and FAK-null SMC using 
phospho-specific antibodies. Results shown in Figure 4.3D indicate that FAK deletion did 
not significantly affect this parameter.  Taken together, our findings provide evidence that 
FAK activity does not directly regulate SMC growth but does limit TGF-β-stimulated SMC 
differentiation by a mechanism downstream or parallel to SMAD activation.    
Since FAK is a multifunctional protein that associates with a number of adapter 
molecules, we reasoned that the effects of FAK deletion on SM differentiation may be 
secondary to effects on additional focal adhesion proteins. To identify SMC proteins that 
might mediate the effects of FAK on SMC transcription, we performed a yeast two-hybrid 
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screen in a mouse aortic SMC library using the C-terminal protein-binding module of FAK 
as bait.  Interestingly, the vast majority of the clones identified from this screen were LIM-
domain containing proteins including Hic5, zyxin related protein 1 (zrp-1/TRIP6) and 
leupaxin.  Since the LIM domain proteins CRP-1 and CRP-2, and FHL2 have recently been 
shown to play a role in the regulation of SMC marker gene transcription [89, 90], we 
examined whether expression of any of the aforementioned FAK binding partners would 
alter SMC differentiation marker gene transcription in pluripotent 10T1/2 cells. Expression 
of leupaxin but not Hic5, or zrp-1(TRIP6) induced a significant increase in SM22 and SM α-
actin (Fig 4.4A) promoter activity in control and TGF-β treated 10T1/2 cells, and further 
experiments showed that leupaxin enhanced SMC reporter activity in a dose-dependent 
fashion (Fig 4.4B).  Importantly, transient overexpression of leupaxin in 10T1/2 cells 
markedly enhanced endogenous SM α-actin protein levels (Fig 4.4C) and also enhanced 
SMC reporter activity in primary SMC cultures (Fig 4.4D).  Collectively, these data strongly 
support a role for this LIM containing protein in the regulation of SMC differentiation. 
Leupaxin is a member of the paxillin family (along with Hic5) that was previously 
reported to be preferentially expressed in spleen, thymus, and other lymphoid tissues as well 
as several cultured hematopoetic cell lines [144]. Our identification of leupaxin in the aortic 
SMC yeast two-hybrid library suggested that it was also expressed in SMC. To our 
knowledge, an antibody that recognizes murine leupaxin has not been developed. Thus, we 
used an antibody specific for human leupaxin to demonstrate [144], that leupaxin was also 
strongly expressed in SMC isolated from human coronary vessels (HCSMC) (Fig 4.5A). 
Importantly, this antibody does not recognize the leupaxin family members paxillin or Hic 5 
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(Fig 4.5B).  We also used semiquantitative RT-PCR to confirm that leupaxin message was 
expressed in mouse aorta and in our isolated aortic SMC preparations (data not shown). 
Leupaxin was previously shown to interact with the FAK homologue, Pyk2, and we 
used GST pull-down assays to confirm that it interacted with the C-terminus of FAK. 
Somewhat surprisingly, we found that leupaxin did not utilize the same binding site on FAK 
as paxillin and Hic5.  As shown in the top panel of Figure 4.5C, GST fusion proteins 
containing the entire FAK C-terminus (GST-CTII) or the more C-terminal FAT domain 
(GST-CTI) efficiently precipitated paxillin from HCSMC lysates, while a FAT construct 
containing a mutation in the paxillin/Hic5 binding site (GST-CTIm) did not.  In contrast, 
leupaxin was efficiently precipitated from the same cell lysates by the GST-CTII, but not by 
either of the GST-CTI fusion proteins indicating that leupaxin association with FAK requires 
sequences N-terminal to the FAT domain. In addition, the finding that paxillin was equally 
precipitated with fusion proteins that do or do not bind leupaxin (from lysates containing 
leupaxin) may imply that leupaxin and paxillin may not compete for FAK binding.  
Several LIM domain proteins have been shown to reside in both the cytoplasm 
(within focal adhesions) and the nucleus where they can act as transcriptional co-factors 
[114].  Thus, we sought to determine whether leupaxin was present in both of these 
compartments and whether FAK activity regulated leupaxin localization. We first examined 
endogenous leupaxin localization by immunofluorescence in HCSMC and found that 
leupaxin was predominantly localized within focal adhesions (Fig 4.5; top panel).  In order to 
determine whether leupaxin can undergo regulated cytoplasmic/nuclear shuttling, we treated 
HCSMC with the CRM1-dependent nuclear export inhibitor, leptomycin B (LMB) for 30min 
(Fig 4. 6; bottom panel).  LMB treatment induced a dramatic redistribution of leupaxin to the  
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Figure 4.1.  Characterization of FAK-null SMCs. A.  fakflox/flox SMC were infected 
with either LacZ or Cre adenovirus for 72 hours, cells were lysed and Western blotting 
was performed using either anti-C-terminal FAK (that recognizes both FAK and 
FRNK), or anti-Pyk2, specific antibodies. B.  fakflox/flox  SMC were infected with either 
LacZ or Cre adenovirus for 72 hrs prior to fixation. Cells were permeablized, blocked, 
and stained with phalloidin and either anti-FAK (N-terminal specific) or anti-vinculin 
specific antibodies and processed as described in the Experimental Procedures section.   
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Figure 4.2.  FAK depletion does affect SMC growth or growth factor-stimulated 
ERK activation  A.  fakflox/flox  SMC were infected with either Cre or LacZ adenovirus 
for 72 hrs.  Cells were then serum starved for 24 hrs prior to treatment with either 
PDGF-BB (20ng/ml) or EGF (100 ng/ml) for 48 hrs prior to determining WST-1 
activity B. Cre or LacZ infected  fakflox/flox  SMC were serum starved for 24 hrs prior to 
treatment with either PDGF-BB (20ng/ml) or EGF (100 ng/ml) for the times indicated.  
Cells were lysed, electrophoresed and Western blotting was performed with anti- FAK, 
anti- active pERK1/2 and anti-ERK antibodies.  C. fakflox/flox  SMC were infected with 
either Cre or LacZ adenovirus for 72 hr.  Cells were then serum starved for 4 hrs prior to 
treatment with either 10% serum (SM) or PDGF-BB (20ng/ml) for 24 hrs.  Cells were 
lysed, electrophoresed and western blotting was performed with anti- FAK, anti- Cyclin 
D1 and anti-ERK antibodies.  D. Caspase 3/7 Activity was measured in serum starved 
Cre or LacZ infected  fakflox/flox  SMC.  Data are representative of at least three individual 
experiments. 
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Figure 4.3.  FAK depletion enhances TGF-β dependent SM differentiation.  A.  
fakflox/flox SMC were infected with either LacZ or Cre adenovirus for 72 hours, cells were 
lysed and Western blotting was performed using either anti-paxillin, anti-vinculin, anti-
SM-MHC, or anti-ERK specific antibodies. B. fakflox/flox  SMC were infected as mentioned 
above.  Cells were serum starved for 24hrs prior to TGF-β treatment for times indicated.  
Western blotting was performed with anti-SMα-actin and anti-Pyk2  (loading control) 
antibodies.  C. fakflox/flox  SMC were transfected with SM22- SM α-actin, or SM-MHC 
luciferase reporter constructs.  6 hrs post transfection cells were infected with Cre or LacZ 
adenoviruses.  24 hrs following infection, cells were serum starved for 24 hrs prior to 
treatment with TGF-β  (1ng/ml) overnight.  Cells were lysed and luciferase activity was 
measured.  D.  fakflox/flox  SMC were infected as mentioned above.  Cells were serum 
starved for 24hrs prior to TGF-β treatment for times indicated.  Western blotting was 
performed with anti-phosphoSmad2, anti-phosphoSmad3, anti-FAK and anti-ERK 
antibodies.   
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Figure 4.4  Expression of the FAK binding partner leupaxin stimulates SM 
marker gene transcription.  A. 10T1/2 cells were co-transfected with either SM22 or 
SMα-actin-luciferase construct (0.5μg) and 0.5μg of either vector control (C), Flag-
Trip6 (Tr6), Flag-leupaxin (Leu) or Flag-Hic5.  24 hrs following infection, cells were 
serum starved for 24 hrs prior to treatment with vehicle or TGF-β  (1ng/ml) overnight.  
Cells were lysed and luciferase activity was measured.  B. 10T1/2 cells were co-
transfected with the SM22-luciferase construct with either 0, 0.25 or 0.5μg of 
leupaxin.  Total DNA was normalized with empty vector.  Cells were serum starved 
24 hrs prior to treatment with vehicle or TGF-β overnight.  Cells were lysed and 
luciferase activity was measured.  C. 10T1/2 cells were untransfected (-) or transfected 
with Flag-leupaxin (+) and serum starved for 48hrs before Western blotting was 
performed with either anti-SMα-actin, anti- leupaxin or anti-ERK antibodies.  D. Rat 
aortic SMC were co-transfected with the SM22-luciferase construct with along either 
empty vector (C) or leupaxin (leu; 0.3 μg). Luciferase activity was measured 48 hrs 
following transfection. All promoter measurements are presented as fold over a 
minimal TK promoter and all data represent three separate experiments. 
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Figure 4.5.  Leupaxin is enriched in SMC and endogenous leupaxin interacts with 
FAK in HCSMC.  A.  Expression of leupaxin protein in spleen (positive control: 
human spleen lysate from Clontech; 25 μg) and human coronary smooth muscle cells 
(HCSMC; 25 μg) was determined by Western blotting using an anti-leupaxin specific 
antibody.  B. Equal concentrations of HCSMC lysate (25 μg ) was electrophoresed 
and Western blotting was performed with anti-paxillin, anti-leupaxin and anti-hic5 
antibodies.  C. HCSMC lysates were incubated with 30μg of purified GST,  GST-
CTII, GST-CTI, or GST-CTIm for 1 hr, complexes were precipitated and analyzed by 
SDS-PAGE as described in Experimental Procedures and Western blotting was 
performed using anti-leupaxin, anti-paxillin and anti-GST specific Abs. 
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nuclear compartment.  These data indicate that leupaxin can undergo nuclear-cytoplasmic 
shuttling and that leupaxin likely contains a functional CRM-1-dependent nuclear export 
sequence.   
 Since the available leupaxin antibody reacts with human, but not mouse leupaxin, we 
generated a GFP-tagged leupaxin construct to track leupaxin shuttling in real time in our 
mouse SMC lines and to determine the consequence of FAK deletion on leupaxin 
translocation.  Results from co-transfection experiments demonstrated that GFP-leupaxin 
activated the SM22 promoter to a similar extent as Flag-tagged leupaxin, indicating that 
fusion to GFP did not significantly disrupt leupaxin function (data not shown).  We found 
that GFP-leupaxin localized almost exclusively to focal adhesions in control cells maintained 
in 10% serum (Fig 4.7A). However, even in the absence of leptomycin B, nuclear 
localization of GFP-leupaxin was evident in approximately 30% of the FAK-null SMC that 
were cultured under the same conditions (Fig 4.7A, right panel).  To determine whether FAK 
regulates the rate of leupaxin translocation, we identified FAK-containing and FAK-null 
SMC in which GFP-leupaxin was predominantly cytoplasmic and performed time-lapse 
imaging following LMB treatment.  As shown in Fig 4.7C and 4.7D, LMB-induced leupaxin 
nuclear accumulation was evident much earlier in FAK-null SMC (90% of cells exhibited 
nuclear localization within 7.5 min) as compared to FAK-containing SMC (in which 
significant leupaxin accumulation required approximately 20 min).   
 We also used a pharmacological approach to confirm that leupaxin nuclear shuttling 
was regulated by FAK/Src activity.  To this end, we treated SMC with PP2 (10 μM), which 
reduced autophosphorylation of FAK on Y397 in HCSMC maintained in 10% serum (Fig 
4.7B; [154]). As shown in the bottom panel of Figure 4.7C, LMB-induced endogenous 
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leupaxin nuclear accumulation was much more rapid in PP2 treated cells than control cells.  
The use of the leupaxin antibody in LMB and PP2-treated HCSMC revealed similar effects 
on endogenous leupaxin localization (data not shown).  Further supporting the functional 
significance of FAK-regulated leupaxin shuttling, we found leupaxin was more effective in 
promoting SMa-actin transcription in Cre infected cells versus LacZ.  Additonally, we show 
that over-expression of a constitutively active FAK variant (termed SuperFAK; [150]) 
attenuated the leupaxin nuclear accumulation observed in FAK-null SMC (not shown) and 
partially reversed leupaxin-mediated SMC-marker gene up-regulation (Fig 4.7E).  
Collectively, these studies indicate that leupaxin nuclear translocation is regulated by 
changes in FAK activity and that sequestration of leupaxin to focal adhesion plaques is one 
mechanism by which activated FAK might limit SMC differentiation marker gene 
expression.  
 We hypothesized that leupaxin might regulate SMC-specific gene expression by 
interacting with SRF. As shown in Figure 4.8A, a GST-leupaxin fusion protein precipitated 
in vitro transcribed 35S-labeled SRF, and GFP-leupaxin and Flag-SRF were shown to co-
associate in Cos-7 lysates by reciprocal co-immunoprecipitations (Fig 4.8B). We next 
performed ChIP assays in HCSMC to determine whether endogenous leupaxin could be 
found associated with the CArG-containing regions of the SMC differentiation marker gene 
promoters. Our results show that leupaxin associated with the CArG-containing regions of 
the SM α-actin and SM-MHC promoters but not with the c-fos promoter in HCSMC 
maintained in 10% serum (Fig 4.8C). Furthermore, leupaxin did not associate with the SMα-
Actin promoter under serum-starved conditions, but could be induced by TGF-β (Fig 4.8D). 
When taken together with results from gel shift experiments demonstrating that leupaxin did 
 115
not associate directly with the SM α-Actin CArGs (data not shown), these results indicate 
that leupaxin likely associates with the SMC-specific promoters in an SRF-dependent fashion 
and that this interaction is facilitated by TGF-β.  Since TGF-β enhanced leupaxin association 
with the SM promoters, we wondered whether TGF-β treatment might negatively regulate 
FAK activity.  Recently Lim et al showed that FAK is negatively regulated by 
phosphorylation of Y407, an event likely due to stabilization of the closed inactive 
conformation of FAK [31].  Interestingly, we found that treatment with TGF-β led to rapid 
and prolonged phosphorylation of Y407-FAK in SMC (Fig 4.8E).  Thus, repression of FAK-
dependent signals may play a role in the promotion of SM marker gene expression following 
TGF-β treatment.    
The studies described above indicate that leupaxin and SRF can associate in cells and 
that leupaxin interacts with SRF-CArG binding elements on SM promoters.  To test whether 
activation of SMC-specific transcription by leupaxin required SRF, we co-expressed 
leupaxin with a SM α-actin promoter that contains mutations in all three CArG boxes.  As 
shown in Fig 4.9A, leupaxin activated the wild type SM α-actin promoter, but not the 
promoter containing the triple CArG mutation.  We also examined the ability of leupaxin to 
regulate SMC-specific transcription in SRF-/- ES cells.  Importantly, expression of leupaxin 
in SRF-/- ES cells did not enhance SM22 reporter gene expression, but this ability could be 
rescued by re-expression of SRF (Fig 4.9B).  These data strongly support the idea that 
leupaxin cooperates with SRF to stimulate SMC differentiation in a CArG-dependent 
manner.  We propose a model that leupaxin plays a dual role in SM function; aiding to 
coordinate multiprotein complexes in focal adhesions and in the nucleus and that leupaxin 
localization is regulated by FAK/Src activity. 
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Figure 4.6. Endogenous leupaxin is localized within focal adhesions. 
HCSMC were either untreated (top panel) or treated with Leptomycin B (LMB; 
5ng/ml): 30 min (bottom panel) prior to fixation. Leupaxin localization was 
determined by immunofluorescense using FITC-conjugated secondary antibodies 
(left panel, green).  Cells were co-stained with phalloidin (red) and DAPI (blue) to 
visualize the actin cytoskeleton and nuclei respectively (right panel). 
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Figure 4.7. FAK activity regulates leupaxin nuclear localization.  A. fakflox/flox  SMC 
were infected with LacZ or Cre adenovirus as described previously. 24hrs following 
infection, cells were transfected with GFP-leupaxin for 48hrs.  B. HCSMC were treated 
with vehicle (-) or PP2 (+) for 15 min and Western blotting was performed with anti-Y397 
FAK and anti-FAK antibodies. C. LacZ or Cre infected fakflox/flox SMC adenovirus were 
transfected with GFP-leupaxin and serum starved for 24 hrs prior to treatment.  Cells were 
imaged at time 0 and then at 1 min increments following LMB treatment (top and middle 
panel) or LMB and PP2 treatment (bottom panel).  Images captured at 0, 5, 10, 15, 20 
minutes are shown. D.  LacZ and Cre fakflox/flox SMC were transfected with GFP-leupaxin 
for 48 hrs (vehicle) and then treated with LMB for 7.5 min.  Cells were  counted to score 
percentage nuclear localization  Bar graph represents the % of cells with visible nuclear 
localization (n=150-200 cells/treatment).  E. 10T1/2 cells were co-transfected with the 
SM22-luciferase promoter and either empty Flag vector (Control), leupaxin (0.25μg) or 
leupaxin and Flag-SuperFAK (SFAK; 0.25μg each).  Luciferase activity was measured 48 
hr following transfection.  Data are representative of three individual experiments. 
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 Figure 4.8.  Leupaxin interacts with SRF in vitro and with SRF-bound CArG 
elements on SM promoters.  A. 30μg of either GST or GST-leupaxin was incubated 
with S-35 labeled in vitro translated SRF for an hour.  Complexes were washed  and 
electrophoresed. 2% of total S-35 labeled SRF incubated was run for a loading control.  
B. COS7 cells were transfected with equal concentrations of GFP-leupaxin and Flag-
SRF for 48 hrs.  Cells were lysed and immunoprecipitation was performed with either 
anti-GFP or anti-SRF antibodies.  Western blotting was performed with anti-Flag (left 
panel) and anti-GFP (right panel) antibodies.  C. Chromatin immunoprecipitation assays 
(ChIP) were performed by incubating anti-leupaxin (leu) or anti-H3 antibodies or rabbit 
IgG (NI, negative control) with sheared HCSMC DNA-protein complexes.  Complexes 
were reverse-cross-linked and RT- PCR was performed on extracted DNA using primers 
specific for CArG-containing regions of the SMα-actin, SM-MHC, and c-fos promoters.  
D. HCMSC were serum starved for 24 hrs prior to TGF-β treatment for 24 hrs.  ChIP 
assays were performed as described above.  E. SMC were serum starved for 24 hrs prior 
to TGF-β treatment (1ng/ml) for times indicated.  Western blotting was performed using 
anti-phosphospecific FAKY407 and anti-FAK antibodies. 
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Figure 4.9.  Leupaxin regulation of SMC gene transcription is SRF and 
CArG-dependent. A. 10T1/2 cells were transfected with the SMα-Actin promoter 
(left panel) or a triple CArG mutant SM α-actin promoter (ABI Mutant, right 
panel) along with either empty vector (C) or leupaxin (Leu; 0.4μg).  48 hrs 
following transfection luciferase activity was measured.  B. SRF-/- ES cells were 
co-transfected with the SM22-luciferase construct along with empty vector (C), 
leupaxin (leu), SRF or SRF plus leupaxin.  Luciferase activity was measured 24 hrs 
following transfection.  Data are representative of three individual experiments. 
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DISCUSSION 
 
 We found that deletion of FAK in SMC enhanced TGF-β-stimulated SM marker gene 
expression, but did not affect PDGF-BB or EGF-stimulated proliferation.  These data suggest 
that enhanced FAK activity limits SM differentiation and that tight regulation of FAK 
activity is likely important for proper SMC phenotypic modulation during development and 
following vascular injury.  We identified leupaxin as a binding partner for FAK in SMC and 
show that leupaxin associates with SRF and enhances SRF-dependent expression of SM 
marker genes and that FAK regulates the nuclear-cytoplasmic shuttling of this LIM domain 
containing SRF co-factor.  Thus, these studies indicate that leupaxin nuclear translocation is 
regulated by changes in FAK activity and that sequestration of leupaxin to focal adhesion 
plaques is one mechanism by which activated FAK might limit SMC marker gene 
expression.  
The cell culture model we have described herein, provides a direct comparison of 
SMC with or without FAK.  The well spread phenotype of our FAK-null SMC differs from 
previously described embryonic FAK-null fibroblasts which were more round and less 
spread than wild type fibroblasts, possibly due to enhanced Rho A activation [51, 81].   
However, recent studies that utilized a similar Cre/LoxP approach as ours (or siRNA) to 
knock down FAK expression in fibroblasts also did not reveal morphological changes 
following FAK depletion [155].  Collectively, these data suggest that the conventional FAK-
/- cells may have acquired mutations that regulate cell morphology.  Interestingly, the 
conventional FAK-/- cells express high levels of Pyk2, while Pyk2 levels are comparable in 
our Cre or LacZ treated SMC cultures and were also reported to be similar in the previously 
described Cre and LacZ treated fakflox/flox fibroblasts [155].  We did however observe a 
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consistent increase in vinculin protein levels in the absence of FAK, similar to what was 
observed in FAK-null mouse embryo fibroblasts (31).  Since vinculin is expressed in an 
SRF-dependent fashion, this finding supports our hypothesis that SRF-dependent gene 
transcription is elevated in FAK-null cells [156]. 
In support of the idea that FAK plays an active role in regulating smooth muscle cell 
phenotypes, FAK-null mouse embryonic fibroblasts were recently reported to exhibit a myo-
fibroblast appearance as assessed by high levels of SM α-actin containing stress fibers 
relative to control fibroblasts [157]. In addition, recent studies have provided evidence for a 
role of FAK in promoting striated muscle cell differentiation.  Clemente et. al. showed that 
the induction of differentiation of C2C12 cells into myotubes is accompanied by a transient 
inhibition of FAK activity from 0-2 hrs followed by later increase in FAK activity that lasted 
up to 5 days.  Interestingly, ectopic expression of a FAKY397F variant that reduced FAK 
activity in C2C12 cells lead to enhanced skeletal muscle marker gene expression, although 
FAK inactivation ultimately blocked myotube formation [158].  Thus, the dynamic 
regulation of FAK activity is essential for differentiation of C2C12 myoblasts into myotubes.  
A role for FAK in the promotion of cardiogenesis was suggested by studies in which stable 
expression of FRNK in ES cells was shown to induce cardiac α-myosin heavy chain and 
sarcomeric myosin expression [154].  Previous studies from FAK-null ES cells revealed that 
the absence of FAK did not preclude hematopoetic differentiation or differentiation of cells 
into all three germ layers [159], but no mention was made of the relative contributions of 
FAK-null cells to mesenchymal compared to non-mesenchymal lineages.  Since numerous 
reports suggest that FAK activity is required for osteoblast differentiation [160] it is possible 
that limiting FAK activity might enhance SRF-dependent muscle cell differentiation at the 
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expense of cartilaginous cell differentiation.  Further careful examination of the multi-lineage 
potential of FAK-/- ES cells using a combination of in vitro and chimeric approaches should 
aid in determining which cell types are restricted and which are promoted by FAK activation.  
Although FAK inactivation strongly enhanced TGF-β stimulated SM marker gene 
expression, TGF-β treated FAK-null and FAK-containing SMC had comparable activation of 
the canonical Smad pathway.  We postulate that FAK inactivation enhances SMC 
differentiation, at least in part, by promoting nuclear localization and subsequent SRF-
dependent transcriptional activation of SM marker genes by the LIM domain-containing 
protein leupaxin.  Since TGF-β inactivates FAK and stimulates leupaxin association with the 
CArG, the regulation of leupaxin could be one mechanism by which FAK and TGF-β -
induced signals converge.  However, we cannot rule out the possibility that FAK activity 
limits TGF-β SM gene transcription by altering alternative signaling pathways such as the 
RhoA/PKN/pp38 MAPK and Pi3K/Akt pathways that have been implicated in mediating 
TGF-b stimulated SM marker gene expression[105-107].  
Leupaxin is an understudied 43 kDa protein that is structurally similar to the focal 
adhesion adapter proteins paxillin and Hic-5.  Although originally reported as having a 
lymphoid-restricted expression pattern [144], we show that leupaxin is also highly expressed 
in aorta and in cultured smooth muscle cells.  In addition, the NCBI Gene Expression 
Omnibus Database shows that while 134 leupaxin EST transcripts per million (TPI) were 
found in human lymph node, 78 TPI were found in aorta, in support of our findings that 
leupaxin expression is enriched in smooth muscle cells.  
Although little is known regarding leupaxin’s cellular function, some parallels can be 
drawn from studies on its family members paxillin and Hic-5, since leupaxin shares 
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considerable structural homology with these proteins.  Paxillin, Hic-5, and leupaxin are each 
comprised of four N-terminal LD motifs and four C-terminal LIM domains that mediate 
protein-protein interactions [123, 140]. The most widely studied family member, paxillin, 
was originally identified as a major tyrosine phosphorylated protein in vSrc transformed cells 
[129], and was subsequently shown to be an adapter protein involved in the regulation of 
integrin-mediated signal transduction and cell migration [161].  Paxillin associates with the 
cytoskeletal proteins, vinculin, and tubulin and numerous signaling molecules such as the 
tyrosine kinases FAK, Pyk2, and Src, the tyrosine phosphatase, PTP-PEST, and the adapter 
protein Crk that can lead to activation of the small GTPases Rac1, Rap1A, and Ras and 
activation of Map Kinase signaling pathways [123].  In spite of the ability of Hic 5 to also 
localize to focal adhesions and associate with many of the same binding partners as paxillin, 
Nishiya et. al. showed that Hic-5 expression inhibits integrin-dependent growth and cell 
spreading by competing with paxillin for FAK binding (35).  This competitive function is 
thought to result from the known lack of integrin-dependent tyrosine phosphorylation of Hic-
5 and consequent lack of association of Hic-5 with the SH2-containing protein Crk that links 
FAK activation to downstream GTPases and MapKinases  [139].  Leupaxin was previously 
shown to bind to Pyk2 and co-localize with cortical F-actin in JY8 lymphoblasts and to bind 
to FAK and localize within podosomes of osteoclasts [144, 145].  Herein we show for the 
first time that leupaxin localizes within nascent focal contacts and mature focal adhesions in 
smooth muscle cells.  Although the binding sites for FAK and Pyk2 within leupaxin have not 
yet been determined, the interaction is likely mediated through one of the conserved LD 
structures that direct paxillin-FAK interactions.  Leupaxin does contain the critical YXXP 
Crk binding site in it’s amino terminus (present in paxillin) but whether leupaxin is tyrosine 
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phosphorylated at this site following integrin ligation and whether leupaxin associates with 
Crk (or other paxillin binding partners) are questions for future studies.   
Paxillin and Hic-5 were previously shown to undergo nucleocytoplasmic shuttling 
and to affect gene expression.  Similar to our findings with leupaxin, treatment with the 
nuclear export inhibitor, leptomycin B causes retention of paxillin and Hic-5 in the nucleus, 
providing evidence that these proteins normally cycle between focal adhesions and the 
nucleus [162, 163].  Although the precise mechanisms whereby the paxillin family members 
traffic into and out of the nucleus remains unclear, the conserved LD motifs in these proteins 
resemble conserved leucine-rich nuclear export sequences.  Both paxillin and Hic-5 bind to 
steroid receptors and have been shown to co-activate androgen, glucocorticoid, and 
progesterone response genes [164, 165].  Whether leupaxin can also regulate these 
transcriptional targets in addition to the SMC promoters is not yet known.  However, in spite 
of their ability to regulate steroid hormone induced gene expression, we found that forced 
expression of Hic-5 or paxillin (unpublished observations) did not influence SM marker gene 
expression, while leupaxin promoted a consistent increase in SM-MHC, SM α-actin, and 
SM22 promoter activity.  These data indicate that the nuclear functions of the paxillin family 
members are unique.  Interestingly several other LIM domain proteins including CRP1/2, 
LPP, and FHL2 also cycle between focal adhesions and the nucleus and these proteins like 
leupaxin influence SRF-mediated gene transcription [89, 90, 122].  We showed that leupaxin 
nuclear localization was enhanced following FAK inactivation and that FAK expression 
limits leupaxin-mediated transcription of SRF-dependent target genes.  It remains to be 
determined whether FAK activity may also regulate SM differentiation through cytoplasmic 
retention of other LIM containing SRF co-factors. 
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Several questions remain regarding the function of LIM proteins in the nucleus.  The 
fact that so many LIM domain proteins undergo nuclear-cytoplasmic shuttling and that 
several of these proteins regulate SM marker gene expression suggests that there might be 
some redundancy in function.  Selective expression of the varying LIM domain proteins may 
impose one means of divergent regulation.  For example, LPP is expressed in synthetic but 
not highly differentiated SMC expressing smoothelin [122] whereas CRP2 is expressed in 
differentiated SMC and has been shown to be down regulated when SMC exhibit a synthetic 
proliferative phenotype [166].  Thus, it is likely that different LIM proteins can facilitate 
coordinated transcriptional regulation at different stages of development.  Since each LIM 
domain has the capacity to binding to select partners it is also tempting to speculate that these 
adapter proteins might recruit a different set of co-activators to the transcriptional machinery 
to impart tight regulatory control.  In support of this idea, the N-terminal LIM domain of 
CRP directs binding to SRF, while the C-terminal LIM domain interacts with GATA 4 [90]. 
Herein we present evidence that leupaxin interacts directly with SRF and can associate with 
SRF-bound CArG elements within SM promoters.  We have not observed a functional 
interaction between GATA4, SRF, and leupaxin in our studies (data not shown), but it is 
possible that leupaxin associates with additional SRF-cofactors.  Since TGF-β stimulates 
leupaxin association with CArG regions of the SM promoters, it will be of particular interest 
in the future to determine whether leupaxin associates with Smad 2 or 3.  
Although reported to affect a wide variety of cellular processes a principal function 
for FAK in numerous cell types is its ability to modulate integrin and growth factor receptor 
stimulated cellular migration [155].  Direct evidence for the role of FAK in modulating 
fibronectin-dependent motility was previously shown using FAK-/- fibroblasts [167].  We 
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have also shown that FAK activity in SMC is essential for PDGF and FN-stimulated 
migration [147].  Taken together with our studies presented herein that reveal FAK activity 
also affects SMC phenotypic modulation, we postulate that tight regulation of SMC 
phenotype, by modulating FAK activity (or the intrinsic shifting of FAK/FRNK expression) 
could mediate a balance between SMC migratory and contractile capacities necessary for 
proper vasculogenesis during development and following vascular injury.  Indeed, our recent 
data indicates that SM marker genes are markedly down-regulated in FRNK-/- vessels 
following injury, indicating that endogenous FRNK expression (and FAK inactivation) is 
required for appropriate re-differentiation of neointimal SMC (manuscript in preparation).  
Interestingly, FAK is aberrantly active in many solid tissue cancers and enhanced FAK 
activity correlates with poor prognosis, an event thought to be a result of enhanced metastatic 
potential in cells with unchecked FAK activity [168].  Our data suggest that FAK could be 
playing an additional role in this setting, perhaps by modulating the differentiation state of 
cells to a phenotype that might make them more responsive to migratory signals.  
 127
  
 
CHAPTER V 
CONCLUSIONS 
 Smooth muscle cells (SMC) are involved various vascular disease, such as 
atherosclerosis, restenosis following balloon angioplasty and vein bypass grafts.  During 
these vascular diseases and also during normal vascular development, numerous changes 
occur within the vessel environment that enables SMC to dedifferentiate from a contractile 
phenotype to a synthetic proliferative phenotype.  The remodeling  of the extracellular 
matrix, an increase in growth factors and contractile agonists have all been shown to initiate 
signaling pathways leading to an increase in SMC proliferation, migration, and 
differentiation.  The tyrosine kinase, Focal Adhesion Kinase (FAK) plays a major role in the 
integration of the signals transmitted from these extracellular cues.  Our laboratory has 
previously shown that integrin- and growth factor-mediated SMC proliferation and migration 
are dependent on FAK activity.  Very little is understood about the role of FAK in embryonic 
development for FAK knockout embryos died between day E8.5 and E10.5 due to general 
cardiovascular defects [52].   Since extensive hemorrhage was observed, the vascular defect 
in FAK -/- embryos may be due in part to defective SMC recruitment or maturation.  There is 
very little is known about the role of FAK in SMC development and how the absence of 
FAK that could result in the observed cardiovascular phenotype.  The overall aim of this 
dissertation was to determine the role FAK in SMC vascular signaling by identifying the 
downstream targets of FAK that lead to SMC migration, proliferation, and differentiation 
through the utilization of in vitro and in vivo models. 
 FAK has been established as an important signaling conduit for integrin-, G-protein 
couple receptor-, and growth factor-stimulated cell migration and proliferation.  The 
signaling pathways responsible for transmitting the proliferative or migratory cues have been 
conflicting in the literature and appear to vary depending on the cell model system in which 
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the studies were performed.  Since FRNK, a dominant negative inhibitor of FAK is 
endogenously and selectively expressed in SMC, we hypothesized that tight regulation of 
FAK activity and downstream signaling is essential in SMC and that this signaling pathway 
may be distinct.  We showed that FRNK expression attenuated PDGF-stimulated migration 
and proliferation by dampening the Rac/JNK pathway.  Additionally, we were able to show 
that FAK inactivation by FRNK overexpression lead to a more differentiated phenotype 
characterized by an increased expression in the contractile genes, SM22, SM-MHC and SM 
α-actin.   
To better understand the role of FAK in SMC cellular processes we next generated a 
primary cell line that allowed us to examine SMC-specific deletion of FAK by utilizing 
Cre/loxP technology.  This system has highlighted several differences between SMC specific 
FAK responses and those documented in FAK-null fibroblasts and FAK-null endothelial 
cells.  Overall, FAK is essential for cell migration, regardless of the cell system.  FAK may 
function within focal adhesions as an important integrator of extracellular cues and as a 
signal transducer responsible for recruiting the necessary proteins for focal adhesion 
assembly and disassembly powering cell motility.  Studies are underway to identify the 
downstream signaling targets of FAK that are required for proper SMC migration.   
While we have previously shown by FRNK overexpression, that FAK activity is 
necessary for SMC proliferation, we found that in FAK-null SMC the proliferative response 
was unadulterated.  These data indicate that proliferation may be regulated at the level of 
FRNK.  Previous studies by Taylor et al have shown that FRNK expression is dynamically 
regulated during development and following vascular injury and its expression tightly 
correlates with SMC phenotypic modulation to a more contractile state [41].  Even though 
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we have shown that FAK-ablation results in increased SM marker gene transcription, we also 
found that FRNK expression induced SM marker gene expression.  However, the 
upregulation we observed in the absence of FAK was dependent on TGF-β stimulation 
whereas FRNK expression alone was sufficient to increase gene transcription.  The precise 
mechanism by which FRNK regulates SMC phenotypic modulation, by the promotion of 
differentiation and repression of proliferation still needs to be deciphered.  There are several 
putative mechanisms.  One, FRNK expression may regulate the localization of SMC specific 
transcription factors, including the myocardin family member, MRTF-A.  It is easy to 
hypothesize that FRNK expression might increase the propensity of MRTF-A nuclear 
localization and increase MRTF-A/SRF dependent SM gene transcription.  Additionally, 
FRNK may function to inhibit PDGF-dependent SM marker gene repression, by activating 
the Pi3K/Akt pathway diminishing the FOXO4/myocardin complex and enabling myocardin 
to bind SRF and activate the SM marker genes.   Further studies are required to determine 
how FRNK may function within SMC.  Utilizing inducible FRNK expression/repression 
SMC model systems in FAK- containing and FAK-null SMC may aid determining FRNK 
signaling in vivo. 
Herein, we have shown that the expression of the FAK binding partner, leupaxin can 
generate an increase SM marker gene transcription.  Like other LIM containing proteins, we 
found that leupaxin can translocate from focal adhesions to the nucleus where it can regulate 
gene transcription.  We show that leupaxin can bind to SRF and transactivate SM marker 
genes when it is localized within the nucleus.  While leupaxin nuclear localization was 
increased in the absence of FAK, we found that FRNK expression had no effect on leupaxin 
cytoplasmic/nuclear shuttling (unpublished observations).  The possibility of FRNK 
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expression regulating leupaxin protein levels was not tested.  Very little is known regarding 
leupaxin expression.  However, based on initial observations, where Lipsky et al noted that 
leupaxin expression was increased in mature leukocytes compared to undifferentiated bone 
marrow cells [144].  Leupaxin expression could be limited to differentiated SMC.  Antibody 
limitations have prevented studies to determine endogenous leupaxin expression during 
murine development.  Future studies using in situ hybridization or the generation of a 
leupaxin-LacZ transgenic mouse model might provide insight into leupaxin expression.   
As mentioned above we found the FAK activity diminished the ability of leupaxin to 
induce SM marker gene transcription.  We hypothesized that active FAK may sequester 
leupaxin within focal adhesions preventing nuclear translocation.  Based on leupaxin binding 
partners identified so far, such as FAK and PTP-PEST [145], focal adhesion localized 
leupaxin may play a role in cell migration.  Studies to address this possibility are necessary.   
A better understanding of the role of FAK/FRNK signaling within the vasculature 
remains to be elucidated.  The utilization of a SMC-specific model system will help in our 
understanding and aid in the development of therapeutic targets to treat and prevent various 
vascular diseases. 
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Figure 5.1  Model for FAK/FRNK signaling in vessel development.  During vascular 
development, the surrounding microenvironment is enriched with FN and secreted PDGF.  We 
postulate that this environment induces high levels of FAK activity and an increase in FAK-
dependent Rac1activation that contributes to the highly motile phenotype.  TGF-β is induced 
during vessel maturity leading to an upregulation of FRNK expression.  This leads to 
diminished FAK activity and the subsequent translocation of LIM containing proteins, such as 
leupaxin, from focal adhesions to the nucleus where they can promote differentiation.  The 
ECM within the medial layer  of the adult vasculature is rich in collagen, maintaining SMC in a 
quiescent state.  Vascular injury increases FN expression and PDGF secretion resulting in SMC 
dedifferentiation and the reactivation of FAK-dependent signaling pathways. 
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APPENDIX I 
FRNK expression induces smooth muscle differentiation 
   
ABSTRACT 
Adult medial vasculature SMC have the unique ability to phenotypically modulate from the 
usual differentiated contractile state to a dedifferentiated synthetic state.  This synthetic state 
allows for an increased proliferation and migration capacity generally needed for repair of 
vascular injury.  However, SMC differentiation is a dynamic process that must be tightly 
regulated to thwart the onset of vascular disease.  Our lab previously reported that a specific 
focal adhesion kinase (FAK) inhibitor termed FRNK (FAK related non-kinase) is selectively 
expressed in large arterioles when SMC are transitioning from a synthetic to contractile 
phenotype during vascular development and during vascular remodeling following vascular 
injury and that FRNK inhibits FAK-dependent SMC proliferation and migration.  Herein, we 
sought to determine if modulation of FAK activity by FRNK influenced the differentiation 
state of SMC.  Ectopic expression of FRNK increased the expression of SM marker genes.  
In addition, FRNK increased TGF-β -stimulated transcription of SM marker gene promoters.  
By utilizing SMC isolated from a Myc-FRNK transgenic mouse line, we were able to show 
that FRNK promotes SM marker gene transcription in vivo.  These data indicate that dynamic 
regulation of FRNK expression during development and following vascular injury functions 
to mediate SMC phenotypic modulation required for proper vasculogenesis. 
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INTRODUCTION 
The microenvironment within the vessel during vasculogeneis and various vascular 
pathologies is constantly shifting to maintain vessel integrity and tensile strength.  Vascular 
SMC retain an innate plasticity that enables them to respond to the fluctuation in circulating 
autocrine factors and remodeling extracellular matrix.  This plasticity enables SMC to 
dedifferentiate from a contractile phenotype to a synthetic proliferative phenotype.  Various 
autocrine factors and extracellular matrix cues have been shown to play a role in regulating 
SMC phenotype.  Focal Adhesion Kinase (FAK) has been shown to be an important 
regulator SMC proliferation and migration and I recently showed that FAK expression 
regulates SMC differentiation ([41], Chapter IV).   
Although a direct role for FAK in vascular smooth muscle growth and development 
in vivo has yet to be examined, germline deletion of FAK results in general mesodermal 
defects and embryonic lethality between E8.5-10 (similar to both fibronectin-/-, and α5-/- 
mice) [52].  Interestingly, our lab recently showed that FAK activity is regulated in a unique 
fashion in SMC, whereby a separate protein comprising the carboxyterminus of FAK, termed 
FRNK (FAK Related Non Kinase) that is selectively expressed in SMC with very high levels 
found in the large arterioles.  FRNK transcription results from the utilization of an alternative 
start site within the FAK gene and FRNK expression is independently regulated by a distinct 
promoter embedded within FAK intronic sequences [147, 169].  Whereas FAK protein levels 
remain relatively constant during vascular development, FRNK protein levels are 
dynamically regulated.  Arterial FRNK expression is greatly increased after birth and from 
two to three weeks following vessel injury [147].  The timing of FRNK expression indicates 
that FAK activity is tightly controlled when SMC are transitioning from a synthetic to 
 136
contractile phenotype.  Additionally, data has shown that FRNK can function as a dominant-
interfering mutant for FAK.  The aim of this study was to determine whether modulation of 
FRNK protein levels plays a direct role in the phenotypic state of SMC.  Herein we present 
evidence that ectopic expression of FRNK and overexpression of FRNK in SMC in vivo 
enhances TGF-β-stimulated differentiation.  
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MATERIALS AND METHODS 
 
Constructs and Reagents 
The promoter reporter constructs: SM α-actin (from -2560 to +2784), SM22 (from -450 to 
+88) and SM-MHC (from -4200 to +11600) and SMα-Actin mutant luciferase constructs 
used have been previously described [148 1568].  GFP and GFP-FRNK adenovirus were 
generated as previously described [147].  Flag-FAK, Flag- FAKY397F and Flag-FRNK were 
a generous gift from Dr. Tom Parsons (University of Virginia) and were previously described 
[149].  The anti –Myc and anti-total FAK antibodies were purchased from Upstate.  The anti-
Flag (M2) antibody was from Sigma. 
 
Cell Culture and Agonist Treatment  
Aortic smooth muscle cells were isolated from either Wistar Rats or fakflox/flox mice or 
MycFRNK transgenic mice.  In brief, thoracic aortas were stripped of the endothelial and 
adventitial layers by microdissection.  The SMC in the media were isolated by enzymatic 
digestion in buffer containing trypsin and collagenase as previously described [152].  Each of 
our preparations are routinely tested for expression of smooth muscle-specific markers (by 
immunohistochemistry) and the ability to drive smooth muscle specific expression of 
reporter constructs.  Only the cell lines that are deemed at least 85% pure by these 
measurements are utilized for further experimentation.  Cells are grown in DMEM: F12 (1:1) 
supplemented with 10% FBS and 1% penicillin-streptomycin and are used between passages 
5 and 18.  10T1/2 cells (ATCC) were maintained in DMEM plus 10% fetal bovine serum and 
1% penicillin-streptomycin.  
 138
 Promoter Assays 
Cells were transfected using Trans-IT (Mirus) transfection reagents according to 
manufacturer’s protocol.  Luciferase activity was detected by the Steady-Glo luciferase assay 
reagent (Promega). 
 
Western Blotting 
Western blots were performed using the appropriate antibodies at a 1/1000 dilution.  Blots 
were washed in TBST (TBS plus 0.05% Triton-X), followed by incubation with either horse-
radish peroxidase conjugated- rabbit anti-mouse antibody or - Protein A sepharose 
(Amersham) at a 1/2000 dilution.  Blots were visualized after incubation with 
chemiluminscence reagents (ECL, Amersham). 
Immunocytochemistry 
Cells were processed for immunocytochemistry using previously published methods [147]. 
In brief, cells were fixed with 4% paraformaldehyde, permeabilized with 4% Triton X-100 in 
PBS, incubated with an anti-Myc antibody (1:250) for 1 hr.  After washing with PBS, slides 
were incubated for 1 hour with Texas Red-conjugated donkey anti-mouse antibodies 
(2μg/ml). 
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RESULTS 
Since the timing of FRNK expression during development and following vascular 
injury correlates with the conversion of SMC from a synthetic to contractile phenotype, we 
asked whether FRNK expression altered SMC differentiation.  We utilized a well-
characterized SMC promoter-reporter assay in 10T1/2 cells using constructs containing the 
CArG-region of SMC promoters.  As shown in figure A1.1A, the ectopic expression of 
FRNK by adenoviral infection, resulted in a two to four-fold increase in serum- induced 
SM22, SM α−actin and SM-MHC promoter activity.  Since our previous data showed FAK 
deletion in SMC resulted in increased SM marker gene transcription, we reasoned that FRNK 
expression likely promotes SMC differentiation by attenuating FAK activity and relieving 
FAK-dependent repressive signals (Fig A1.1C). 
Previous data published from our lab demonstrate a role for FAK in regulating 
vascular SMC migration and proliferation and we recently determined that SMC depleted of 
FAK display an increase in SM marker genes compared to FAK-containing SMC (Chapter 
IV).  Therefore, we hypothesized that FAK activity might regulate SM marker gene 
transcription.  To determine if FAK activation limits SM marker gene expression we 
ectopically expressed a constitutively active FAK variant (termed SuperFAK; ref. [150]).  
This variant has enhanced FAK activity as assessed by autophosphorylation of FAK Y397 
(Western blot, Fig A1.1C).  We performed promoter assays experiments examining 
SuperFAK expression in 10T1/2 cells.  SuperFAK significantly reduced SM22- and SM-
αActin reporter gene expression, in support of the hypothesis that FAK activity may 
attenuate SM marker gene transcription (Fig A1.1B).  We performed additional SMC 
promoter-reporter assay in primary SMC and found that the ability of FAK variants to 
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stimulate SMC marker gene transcription is related to their efficacy to inhibit endogenous 
FAK activity (FRNK>autophosphorylation-deficient Y397FFAK>FAK>SuperFAK; Fig 
A1.1C).  Thus, we have determined that there is an inverse correlation between FAK activity 
and SMC differentiation.   
Selected agonists, such as TGF-β [170] and S1P [148], are potent stimulators SMC 
differentiation and have been shown to be sufficient to induce SMC differentiation in non-
committed fibroblast like cells, 10T1/2.  To determine if FAK/FRNK signaling regulated 
SMC differentiation in an agonist-dependent manner, we performed promoter assays in 
10T1/2 cells that were infected with GFP or GFP-FRNK adenovirus.  As shown in figure 
A1.2A, FRNK overexpression resulted in a 9 and 2-fold increase in SM22 and SM α-actin 
promoter activity, respectively, over GFP adenoviral controls.  However, TGF-β but not S1P 
treatment further enhanced FRNK-dependent SM gene transcription.  Since, FRNK 
attenuates FAK activation; we then asked if FAK activity had an effect on agonist-dependent 
stimulation.  Transient expression of a constitutively active FAK variant inhibited TGF-β-
dependent SM22 transcription markedly, but did not inhibit S1P-induced transcription (Fig 
A1.2B).  These data indicate that FRNK expression alone can induce SMC marker gene 
expression in SM precursor cells and that TGF-β stimulated SM marker gene transcription is 
negatively regulated by FAK activation. 
We created a transgenic mouse model that would allow us to determine the 
effectiveness of FRNK as a regulator of SM phenotype in vivo.  In these mice, the Myc-
FRNK transgene is under control of the SMα-Actin promoter.  Aortic SMC isolated from 
these mice show that Myc-FRNK is properly localized within focal adhesions (Fig A1.3A, 
left panel) and that Myc-FRNK is expressed three-fold compared to endogenous FRNK 
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levels (Fig A1.3A, right panel: courtesy of Rebecca L. Thompson).  Since transient FRNK 
overexpression in SM precursor cells exhibited an increase in SM marker gene transcription, 
we aimed to determine if Myc-FRNK SMC exhibited a more differentiated phenotype 
characterized by increased SM marker gene expression.  SM promoter-luciferase assays 
showed an increase in TGF-β stimulated SM marker gene transcription in Myc-FRNK SMC 
compared to Wt (fakflox/flox ) cells (FigA1.3B).  These data indicate that FRNK may function 
to inhibit FAK activity enabling the transition to a more differentiated phenotype. 
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DISCUSSION 
 
FAK activity is tightly regulated in SMC by selective and dynamic expression of 
FRNK, a dominant interfering mutant that attenuates FAK activity.  We previously reported 
that FRNK attenuates SMC proliferation and migration by regulating Rac1-dependent 
signaling [153].  Herein we have found an additional function for FAK/FRNK signaling in 
SMC.  We found that forced expression of FRNK enhanced SM marker gene expression in 
cultured cells.  We also created a mouse model where FRNK is constitutively but moderately 
overexpressed (2-3 fold over endogenous) in SMC in order to determine the role FRNK in 
vivo.  SMC isolated from these mice corroborate our in vitro findings and displayed a 
significant increase in SM marker gene expression compared to WT cells.  These data 
suggest that tight regulation of FAK activity by FRNK is likely important for proper SMC 
phenotypic modulation during development and following vascular injury.   
Data presented here shows that FAK/FRNK regulation of SMC differentiation 
appears to be specific for TGF-β-dependent signaling and not S1P. S1P-stimulated SM22 
transcription was not affected by FAK activity or FAK inactivity by FRNK overexpression.  
Lockman et al have shown that S1P-stimulated SMC differentiation is mediated through the 
RhoA signaling cascade [148].  While conventional FAK-null displayed a rounded 
phenotype attributed to increased RhoA activity, our FAK-null SMC show no defects in cell 
spreading indicating that RhoA activity might not be enhanced in our cells.  Therefore, S1P-
dependent RhoA activation and subsequent SM marker gene transcription appears to be 
independent of FAK/FRNK signaling.   
Interestingly, both ectopic expression of FRNK and deletion of FAK in SMC led to 
synergistic induction of SM marker genes following TGF-β treatment.  However, when we 
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expressed FRNK in 10T1/2 cells, while FRNK expression alone enhanced SM gene 
expression, no difference was observed between FRNK expressing and control cells in the 
fold induction of the marker genes by TGF-β.  There are two possible explanations.  One, 
there may be a difference in ectopic FRNK expression levels compared to that in vivo, where 
overexpression by adenoviral infection may result in maximal FRNK expression that is 
beyond that observed following vascular injury or during development.  Gross FRNK 
expression may sequester proteins away from active sites of focal adhesions and alter focal 
adhesion dynamics.  Alternatively, since recent data from our lab indicates that TGF-β 
induces FRNK protein levels in SMC, TGF-β upregulation of FRNK expression could intiate 
a positive feedback loop to regulate the phenotype of SMC.  This positive feedback loop may 
explain the observed increase in both TGF-β treated FAK-null SMC and Myc-FRNK SMCs 
but not in 10T1/2 cells.  TGF-β may directly regulate FRNK expression resulting in FAK 
inactivation and SMC differentiation (FigA1.3).  Studies to determine the mechanism of 
FRNK regulation are currently underway.   
Additional studies are also required to delineate the precise signaling pathway 
governed by FAK/FRNK during SM phenotypic modulation.  For example, FRNK 
expression may potentiate differentiation by activating the Pi3K/AKT pathway.  In support 
for this possibility, Liu et al have demonstrated the role of this pathway in regulating SM 
marker gene expression.  They found activation releases FOXO4 from the nucleus freeing 
myocardin to bind the transcriptional machinery. Taken together with our studies presented 
herein that reveal FAK activity also affects SMC phenotypic modulation, we postulate that 
tight regulation of SMC phenotype, by intrinsic shifting of FAK/FRNK expression could 
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mediate a balance between SMC migratory and contractile capacities necessary for proper 
vasculogenesis during development and following vascular injury.   
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Figure A1.1 SM marker gene expression is modulated by FAK/FRNK signaling.  A. 
10T1/2 cells were transfected with SM22, SM-MHC or SM α-actin-luciferase reporter 
plasmids.  Cells were transfected 24 hrs following transfection with either GFP or GFP-
FRNK adenovirus for 24 hrs prior to luciferase.  B. 10T1/2 cells were co-transfected 
with SM22 or SMα-Actin luciferase reporter and either empty vector (control) or Flag-
SuperFAK.  Luciferase activity was measured 48 hrs following transfection.  C. Rat 
Aortic SMC were co-transfected with SM22-luciferase reporter construct and with either 
empty vector (C), Flag-SuperFAK (SFAK), FAK, Y397FAK or FRNK in the presence of 
serum.  Luciferase activity was measured 48 hrs following transfection.  Cells not 
transfected (NT) or transfected with FAK (WT), Flag-SFAK, Flag-FRNK or Y397FAK 
were lysed and subjected to Western analysis using anti-Flag or an activation state-
specific FAK Y397 Ab.  Data are representative of at least three separate experiments.  
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Figure A1.2  FAK/FRNK signaling regulates TGF-β stimulated SM marker genes.  A.  
Cells were infected 24 hrs following transfection (SM22 or SM α-actin promoters) with 
either GFP or GFP-FRNK adenovirus for 24 hrs prior to luciferase detection or serum 
starved for 6 hrs and treatment with TGF-β overnight prior to detection. Data displayed as 
fold GFP-FRNK/GFP.  B. 10T1/2 cells were co-transfected with SM22, or SM α-actin-
luciferase reporter plasmids with either empty vector (Flag) or Flag-SuperFAK (SFAK).  
Cells were serum starved (SF) for 24hrs prior to treatment with either TGF-β (T) or S1P for 
24hrs.  Data are representative of at least three (A) or two (B) separate experiments. 
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 Figure A1.3.  Characterization of an in vivo model to study the role of FRNK in 
SMC differentiation.  A.  SMC were isolated from the thoracic aorta of SMα-Actin-
MycFRNK transgenic mice.  Cells were stained with anti-myc antibodies to determine 
proper FRNK localization (left panel).  Tissues from these mice (aged 6 weeks) were 
lysed and Western blotting was performed using a total FAK antibody to detect FAK, 
endogenous FRNK and myc-FRNK expression (Ao, aorta; Bl, bladder; St, stomach; Lu, 
lung; H, heart; Sk, skeletal muscle; K, kidney; SMC, rat aortic SMC).  Tissue blot 
courtesy of Rebecca L. Thompson.  B. fakflox/flox (FF) and Myc-FRNK SMC were 
transfected with the SM22-luciferase promoter reporter construct for 24 hrs.  Cells were 
serum starved 24 hrs prior to TGF-β treatment.  Luciferase activity was determined 24 
hrs following agonist treatment. 
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Figure A1.4  Proposed Model of FAK/FRNK regulation of SMC differentiation 
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Appendix II 
Structural analysis of the LIM domain protein Leupaxin 
ABSTRACT 
LIM containing proteins are characterized by the presence of double zinc-finger like 
structures that facilitate protein-protein interactions.  A subset of LIM proteins have been 
shown to localize within both focal adhesions and to undergo cytonuclear shuttling.  The 
paxillin family of LIM proteins includes paxillin, hic-5 and leupaxin.  We have previously 
shown that leupaxin is able to translocate to the nucleus where can stimulate SM marker gene 
transcription through interaction the transcriptional cofactor SRF.  However, very little is 
known regarding the function of the multiple C-terminal LIM domain and N-terminal LD 
protein binding motifs contained with leupaxin.  Therefore, we aimed to perform a structure-
function analysis to determine the importance of each leupaxin binding motif.  By generating 
proteins containing various non-functional LIM domains we found that LIM3 is necessary 
for leupaxin focal adhesion localization, while deletion of LD3 is dispensable for leupaxin 
localization.  Additionally, we identified a putative NES sequence in the extreme N-terminus.  
Leucine to alanine mutations in the identified NES consensus motif resulted in a 50% 
increase in leupaxin nuclear localization.  Collectively, these structure studies have provided 
insight towards understanding the function of this complex adapter protein. 
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INTRODUCTION 
LIM domain containing families of proteins play a role in signal transduction from 
focal adhesions to the nucleus.  These proteins are characterized by double zinc-finger like 
structures that mediate protein-protein interactions.  These modules were termed LIM 
domains based on homeodomain commonality observed in LIN-11, Isl1 and MEC-3 proteins 
[114].  Over 58 genes encoding LIM containing proteins have been identified and segregated 
into protein families based on the number of LIM domains, for example, the CRP family has 
2, the Zyxin family has 3 domains, and the Paxillin family has 4 domains [114].  
The paxillin family members include paxillin, Hic-5 and leupaxin.  Hic-5 and 
leupaxin share 57% and 37% homology with paxillin, respectively [140].  In addition to 4 C-
terminal LIM domains, paxillin, Hic5 and leupaxin contain several N-terminal LD motifs, 
that are also important for facilitating protein-protein interactions.  As previously observed 
with paxillin and Hic-5, we have recently shown that leupaxin is able to undergo cytoplasmic 
to nuclear translocation (Chapter IV).  While the importance of paxillin in regulating cell 
migration and the role of Hic-5 in gene transcription have been delineated, very little is 
known about the role of leupaxin.  We have previously shown that once in the nucleus 
leupaxin binds to the transcription factor SRF, and coactivates SM marker gene transcription 
(Chapter IV).  Herein, I have sought to dissect the mechanism of leupaxin function by 
analyzing the importance of both the LD motifs and LIM domains.  By determining the 
consequence of the loss of function of each protein-protein interaction domain, may help 
identify putative leupaxin binding partners and an understanding of leupaxin function within 
the cell.  
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MATERIALS AND METHODS 
Constructs and Reagents 
The GFP antibody was purchased from Clontech and Leptomycin B was from Sigma.  The 
SU6656 Src inhibitor was from Calbiochem.  GFP-leupaxin was constructed as previously 
described (Chapter IV).  LDD mutations and mLIM C/H to A mutations and Y to E/F point 
mutations were made by PCR mutagenesis using the primers detailed in Table A.1.  To 
generate GST-leupaxin, GFP-Leupaxin was cut with EcoRI and SmaI and directionally 
cloned into the GST vector.  GST-leupaxin mutations were made using the same primers as 
the GFP mutations. The promoter reporter constructs: SMα-Actin (from -2560 to +2784), 
SM22 (from -450 to +88) and SM-MHC (from -4200 to +11600) and SMα-Actin mutant 
luciferase constructs used have been previously described [148 1568].  Flag-FAK, Flag- 
FAKY397F and Flag-FRNK were a generous gift from Dr. Tom Parsons (University of 
Virginia) and were previously described [149]. PBSK-SuperFAK was a generous gift from 
Dr. Michael Schaller (University of North Carolina, ref 15).  To generate Flag-SuperFAK, 
PBSK-SuperFAK was cut with BamHI and Xho1 and directionally cloned into the Flag 
vector.  
 
Cell Culture and Agonist Treatment  
Aortic smooth muscle cells were isolated from either Wistar Rats or fakflox/flox mice, a 
generous gift from Dr. Louis Reichardt and Dr. Hilary Beggs, UCSF.  In brief, thoracic 
aortas were stripped of the endothelial and adventitial layers by microdissection.  The SMC 
in the media were isolated by enzymatic digestion in buffer containing trypsin and 
collagenase as previously described [152].  Each of our preparations are routinely tested for 
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expression of smooth muscle-specific markers (by immunohistochemistry) and the ability to 
drive smooth muscle specific expression of reporter constructs.  Only the cell lines that are 
deemed at least 85% pure by these measurements are utilized for further experimentation.  
Cells are grown in DMEM: F12 (1:1) supplemented with 10% FBS and 1% penicillin-
streptomycin and are used between passages 5 and 18.   10T1/2 cells (ATCC) were 
maintained in DMEM plus 10% fetal bovine serum and 1% penicillin-streptomycin. 
 
Promoter Assays 
Cells were transfected using Trans-IT (Mirus) transfection reagents according to 
manufacturer’s protocol.  Luciferase activity was detected by the Steady-Glo luciferase assay 
reagent (Promega). 
 
Western Blotting 
Western blots were performed using the appropriate antibodies at a 1/1000 dilution. Blots 
were washed in TBST (TBS plus 0.05% Triton-X), followed by incubation with either horse-
radish peroxidase conjugated- rabbit anti-mouse antibody or - Protein A sepharose 
(Amersham) at a 1/2000 dilution.  Blots were visualized after incubation with 
chemiluminscence reagents (ECL, Amersham). 
Immunocytochemistry 
Cells were processed for immunocychemistry using previously published methods [147]. In 
brief, cells were fixed with 4% paraformaldehyde. 
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In Vitro Kinase Assay 
To detect leupaxin phosphorylation: Flag-SuperFAK was transiently expressed in COS7 
cells. 48 hrs following transfection, cells were lysed in RIPA plus inhibitors (SU6656 was 
added 45 min prior to lysing).  Flag-SuperFAK was immunoprecipitated from cell lysates 
with 5 μg of anti-Flag (M2) antibody for 2 hrs followed a 2 hr incubation with pre-coupled 
Rabbit-αMouse Protein-A Sepharose beads.  Beads were washed twice with RIPA and 
resuspended in 2x Kinase buffer (50mM Hepes pH 7.3, 10mM MgCl2, 1mM MnCl2, 5mM 
NaF, 0.25% Triton 100-X,). GST, GST-leupaxin, and GST-leupaxin Y22F were prepped as 
previously described for GST-PAK beads.  Freshly purified GST constructs  (5μg)  were 
incubated with 5 μl of immunoprecipitated SuperFAK and 10μCi of γP-32 ATP in Kinase 
Buffer plus 25μM cold ATP for 10min at 30 oC.  Samples were resolved by SDS-PAGE.  
The radioactive gels were fixed in 50% methanol, 10% acetic acid and 20% glycerol for 
20min and then rehydrated for 90min in 7% acetic acid 5% methanol and 20% glycerol and 
then incubated in Amplify reagent (Amersham) for 30 min prior to exposure to film.   
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Figure A2.1.  Leupaxin focal adhesion localization is mediated through LIM domain 
3.  A. Schematic of WT and mutant LIM (mLIM) constructs created.  GFP- tagged 
constructs were transfected into 10T1/2 cells and focal adhesion (FA) localization was 
scored: strongest (++++)  moderate (++) and minimal to none (+).  B.  Rat Aortic SMC 
were co-transfected with SM22-luciferase promoter construct and either empty vector (C), 
GFP-leupaxin (WT), GFP-mLIM1, GFP-mLIM3 or GFP-mLIM4.  Luciferase activity was 
measured 48 hrs following transfection.  Data represents the average of three separate 
experiments. 
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 Figure A2.2   Leupaxin LD3 is not essential for focal adhesion localization or nuclear 
shuttling.  A.  Schematic of LD mutations.  GFP-leupaxin and GFP-LDΔ3 were 
expressed in 10T1/2 cells and focal adhesion (FA) localization was scored.  B.  SMC were 
transfected with either GFP-leupaxin or GFP-LDΔ3 for 24 hrs.  Cells were serum starved 
for 24 hrs prior to treatment with leptomycin B (LMB) for 20 min.    
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Figure A2.3   Leupaxin Y22 is a target of FAK phosphorylation.  A.  An in vitro 
kinase was performed by incubating immunoprecipitated SuperFAK (no treatment, left 
panel or treatment with SU6656)  with either  GST, GST-leupaxin or GST-
leupaxinY22F and 32p-ATP.  The rest of the IP complex was electrophoresed and 
western blotting was performed to determine Src activity in the immune complex.  B. 
SMC were co-transfected with SM22-luciferase promoter report construct and with 
either empty vector (C), GFP-leupaxin (WT), GFP-Y22E, or GFP-Y22F.  Luciferase 
activity was measured 48 hrs following transfection.  Data represent 2 (A) and 3 (B) 
 159
Figure A2.4   Leupaxin contains a putative NES motif.  A. Alignment of 
assumptive leupaxin NES with other known NES sequences within the LIM domain 
containing proteins, TRIP6, Zxyin, LPP and Hic-5.  Highlighted leucines are required 
for conserved NES and were mutated to alanines (mNES).  B. GFP-leupaxin (WT) and 
GFP-mNES were transfected into 10T1/2 cells to determine nuclear localization.  
Over 50% of mNES transfected cells showed nuclear localization compared to WT 
(graph).  C.  SMC were co-transfected with SM22- luciferase reporter and either 
empty vector (C) or GFP-leupaxin (WT) and GFP-mNES.  Luciferase activity was 
measured 48 hrs following transfection.  Western blot probed with an anti-GFP 
antibody shows equal expression of both constructs (inset).  Luciferase data is an 
average of three separate experiments.  
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RESULTS 
 
Like its other family members, paxillin and Hic-5, leupaxin localizes to focal 
adhesions.  Brown et al have shown that LIM3 of paxillin is essential for mediating paxillin 
focal adhesion localization.  We aimed to determine which of the four C-terminal LIM 
domains of leupaxin might facilitate leupaxin localization.  Each LIM domain of leupaxin 
was individually disrupted by mutating the four central cysteine or histine residues 
responsible for Zn+ binding.  Each mutated LIM construct was expressed in 10T1/2 cells to 
determine localization.  As shown in figure A2.1A WT leupaxin is highly localization within 
focal adhesions.  Disruption of LIM1 (mLIM1) shows a reduced expression within focal 
adhesions while mLIM4 expression localized as well as WT leupaxin.  As observed in 
paxillin, mutation of LIM3 dramatically impaired leupaxin focal adhesion targeting.  Next, 
we determined if LIM domain mutations had an effect on leupaxin-dependent SM marker 
gene transcription.  Promoter assays were performed in SMC (Fig A2.1B).  As anticipated, 
mLIM4 transactivated the SM22 promoter as well as WT leupaxin.  Even though mLIM3 
was unable to localize to focal adhesions, it was able to induce SM22 transcription, 
suggesting that binding partners regulating cytoplasmic localization differ from those 
responsible for nuclear localization.  While mLIM1displayed reduced focal adhesion 
localization it also exhibited a slight fold decrease in SM22 activation, however, it was still 
able to activate nearly 3-fold over empty vector.  These data indicate that while LIM3 
facilitates focal adhesion localization none of the LIM domains examined are singularly 
required for mediating transcriptional coactivation.   
 The greatest disparity in structure homology between the paxillin family 
members is within the N-terminus [123].  Therefore, we aimed to determine the importance 
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of the four LD motifs within the N-terminus of leupaxin.  LD motifs are classified by the 
consensus sequence, LDXLLXXL.  Primers were designed to individually delete each LD 
motif.  As shown in Fig A2.2A, deleting LD3 did not disrupt leupaxin localization within 
focal adhesions.  Therefore, we hypothesized that LD3 might be important for nuclear 
localization.  However, treatment with the CRM1-dependent inhibitor, leptomycin B, 
induced nuclear accumulation of both WT leupaxin and LDΔ3 leupaxin.  These data indicate 
that LD3 does facilitate the cellular localization of leupaxin. 
Leupaxin shares several binding partners with the other paxillin family members, 
including Pyk2, PTP-PEST, and FAK [144, 145].  Additionally, we have previously shown 
that FAK can regulate leupaxin cytoplasmic/nuclear shuttling for inactivation of FAK or loss 
of FAK resulted in an increase in leupaxin nuclear translocation (Chapter IV).  We 
hypothesized that FAK might regulate leupaxin localization through direct phosphorylation.  
To address this question, we ectopically expressed a constitutively active FAK mutant 
(SuperFAK), immunoprecipitated the kinase and then incubated with purified GST- leupaxin 
and γ32P-ATP to perform an in vitro kinase assay.  As shown in Figure A2.3A, purified GST-
leupaxin, but not GST alone, was efficiently phosphorylated by FAK in vitro.  We identified 
a tyrosine kinase phosphorylation target consensus YXXP site in the N-terminus of leupaxin 
and based on this observation, we mutated the tyrosine amino acid to phenylalanine to 
determine if this site was the target of FAK phosphorylation.  As shown in Figure A2.3A, the 
Y22F mutation inhibited FAK-dependent leupaxin phosphorylation.  Since SuperFAK was 
immunoprecipitated from whole cell lysates, we wanted to make sure that FAK was directly 
phosphorylating leupaxin and that phosphorylation was not induced by the FAK binding 
partner Src (which could be present in the FAK IP).  To eliminate the possibility of Src-
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dependent phosphorylation, cells were pretreated with the Src-specific inhibitor, SU6656, 
prior to SuperFAK immunoprecipitation.  In this case, we found that Src inhibition had no 
effect on leupaxin phosphorylation in vitro (Fig A2.3A, right panel), indicating that Y22 was 
likely a specific target for FAK.  Since we hypothesized that FAK phosphorylation may be 
one mechanism by which FAK regulates leupaxin localization, we asked if leupaxin Y22 
phosphorylation would affect leupaxin nuclear localization and subsequent SM marker gene 
transcription.  To this end, we generated a phospho-mimetic mutant (Y22E) leupaxin.  This 
mutant did not differ from WT leupaxin in its ability to enhance SM22 promoter activation 
(Fig A2.3B) or translocate to the nucleus (unpublished observations). 
We have previously shown that leupaxin can undergo cytoplasmic/nuclear shuttling 
through treatment with the CRM1-dependent inhibitor, leptomycin B. CRM1 is a nuclear 
export protein that binds to leucine-rich nuclear export sequences (NES).  Several LIM 
domain containing proteins have identified NES sequences, such as Hic-5, LPP and Trip6 
[121, 162, 171].  Therefore, we examined the leupaxin sequence for the presence of a 
leucine-rich NES and found a putative sequence in the extreme N-terminus, aa4-11.  In 
comparison to other known NES sequences, we found that these amino acids contain the 
three highly conserved leucines required for a functional NES (Fig A2.4A, bold).  To 
determine if this sequence was indeed a functional NES, we mutated the leucines to alanines 
(mNES).  We observed an increase in nuclear localization in mNES leupaxin compared to 
WT leupaxin expression, where over 50% of the cells showed some nuclear accumulation of 
mNES leupaxin (Fig A2.4B).  Since mNES showed an increased nuclear accumulation, we 
asked if this increase translated to an upregulation in SM marker gene transcription.  
Leupaxin mNES did exhibit a significant (albeit moderate) increase in SM22 gene 
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transcription compared to WT (FigA2.4C).  These data indicate that the ability of leupaxin to 
enhance SM marker gene expression correlates with its nuclear localization.  
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DISCUSSION 
 Leupaxin is one of three members of the paxillin family of LIM domain containing 
proteins.  We have previously shown that leupaxin can effectively shuttle from focal 
adhesions to the nucleus where it can interact with the transcriptional coactivator, SRF and 
induce SM marker gene transcription (Chapter IV).  Other labs have identified a few binding 
partners, including, FAK, Pyk2 and PTP-PEST [144, 145].  However, very little is known 
regarding the function of the four LD motifs and four LIM protein-protein interaction 
domains that comprise leupaxin.  Herein, we have shown that LIM3 is important for 
facilitating leupaxin localization to focal adhesions.  We also show that leupaxin is directly 
phosphorylated by FAK on tyrosine 22 and lastly, we have identified a putative CRM1-
dependent NES sequence within the N-terminus.  Collectively, these data may aid in our 
understanding of leupaxin-dependent mechanisms. 
 The three paxillin family members, paxillin, hic-5, and leupaxin, all contain four C-
terminal LIM domains.  The leupaxin LIM3 shares a 71% sequence identity with paxillin, 
therefore it is not surprising that like paxillin, that we found that LIM3 is important for 
facilitating leupaxin focal adhesion localization [126, 140].  However, it is still unknown how 
paxillin is targeted to focal adhesions, and it could be hypothesized that leupaxin and paxillin 
are targeted through similar interactions.  In addition, even though disruption of the 
individual LIM domains, 1,3 and 4, did not alter leupaxin stimulated gene transcription it 
does not eliminate the potential of these LIM domains to mediate an interaction with the 
transcriptional machinery.  Since leupaxin has four C-terminal LIM domains, individual 
mutations may not be sufficient to disrupt leupaxin’s association with transcriptional 
coactivators, such as SRF.  Therefore, different LIM mutation combinations might be 
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required to effectively determine the role of leupaxin in regulating SM marker gene 
transcription. 
 The disparity between paxillin and leupaxin N-terminal sequence suggests divergent 
roles within the cell.  The sequence coding LD2 and 3 of leupaxin only share 19% homology 
with paxillin [140].  We showed that the loss LD3 has no effect on focal adhesion localization 
or nuclear translocation of leupaxin.  These data indicate that LD3 is dispensable for both 
focal adhesion localization and nuclear shuttling.  However, this does not preclude the 
importance of an interaction between LD3 and an unknown binding partner that could 
regulate another undetermined function of leupaxin. 
 Leupaxin does contain a consensus YXXP Crk binding site in its amino terminus 
(present in paxillin) that is tyrosine phosphorylated by active FAK, indicating that leupaxin 
may be regulated in an adhesion-dependent fashion.  However, if phosphorylated leupaxin 
associates with Crk (or other paxillin binding partners) are questions for future studies.  
Other LIM domain proteins have been implicated in regulating cell migration, therefore, it 
could be hypothesized that leupaxin localization within focal adhesions might play a role in 
propagating migratory signals.  We had originally hypothesized that FAK-dependent 
leupaxin phosphorylation would sequester leupaxin within focal adhesions based on our 
previous studies showing that FAK activation diminished the ability of leupaxin to stimulate 
SM22 gene transcription.  However, we found that leupaxin Y22 phosphorylation was able to 
properly translocate to the nucleus where it could induce SM marker gene expression.  Our 
phosphorylation studies were determined through in vitro kinase assays and the consequence 
of leupaxin phosphorylation may be agonist-dependent or cell-type specific, so further 
studies are necessary to decipher FAK-dependent leupaxin responses. 
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 Like paxillin and Hic-5, we have previously shown leupaxin can undergo 
nucleocytocplasmic shuttling and affect gene expression.  We found that treatment with the 
nuclear export inhibitor, leptomycin B causes retention of leupaxin in the nucleus, providing 
evidence that leupaxin normally cycles between focal adhesions and the nucleus (Chapter 
IV).  Leptomycin B inhibits CRM1-dependent export by blocking CRM1 binding to leucine-
rich nuclear export sequences (NES) on target proteins.  We identified a putative NES 
sequence in the extreme N-terminus of leupaxin.  While mutations to this sequence resulted 
in a robust increase in leupaxin nuclear entrapment, it was not observed throughout the cell 
population.  NES studies have created a hierarchy of conserved NESs based on rate of 
nuclear export [173] and subsequent experiments revealed that the strongest NES shuttles at 
the greatest rate with the protein localization being almost exclusively cytoplasmic.  
However, nuclear localization of constructs containing strong NESs was induced following 
agonist treatment [172].  These reports may suggest that leupaxin nuclear localization might 
be agonist-driven.  Similar findings were shown for Hic-5, where mutation of the NES did 
not result in 100% Hic-5 localization, only following treatment with H202 was Hic-5 100% 
nuclear.  One might predict that a SM differentiation agonist, such as TGF-β would induce 
leupaxin nuclear shuttling.  Additionally, leupaxin nuclear export may be regulated by 
another mechanism, such as a KNS shuttling element, which is not regulated by CRM1 and 
therefore not inhibited by leptomycin treatment [173].  The presence of another shuttling 
motif may explain why leupaxin can still be observed within focal adhesions following 
leptomycin treatment.  Further analysis of leupaxin sequence is required to determine the 
presence of other consensus export sequences.  
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 Many questions remain to be answered.  Hic-5 has been shown to activate various 
gene promoters, including c-fos [142] and interactions with various coactivators may dictate 
gene-specific activation.  The SM marker genes, SM22, SM-MHC, SM α-actin, and the 
growth gene c-fos all contain CArG-dependent promoters requiring transactivation by SRF.  
We have previously shown through ChIP assays, that leupaxin can associate through SRF 
with the CArG elements of SM-MHC and SM α-actin but not c-fos.  The underlying 
mechanisms regulating the discrepancy between SRF-dependent activation of the contractile 
SM marker genes and SRF-dependent growth genes are poorly understood.  However, it 
could be postulated that LIM containing proteins, such as leupaxin, may function as a 
scaffold and regulate gene activation through the binding of various coactivators specific for 
each promoter.  Further work identifying leupaxin binding partners may assist in our studies 
aimed to determine the processes regulating SMC phenotypic modulation. 
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